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1. THE P53 PROTEIN AND ITS REGULATORS MDM2 AND MDMX
1.1 p53
The p53 protein was originally discovered in 1979 as a target of the SV40 oncogenic 
DNA virus Large T-antigen [1, 2]. More than 3 decades later and over 92.000 scientific 
papers published mentioning p53, the p53 protein is recognized as a central node in 
cellular stress responses. The p53 protein functions as a transcription factor, which 
upon activation and stabilization controls the expression of many genes involved in 
multiple pathways including cell cycle, metabolism, apoptosis and angiogenesis [3-
5]. Despite its central role in cellular responses to stress, p53-deficient mice develop 
almost normal, but are prone to develop malignancies of which lymphomas are most 
frequent [6, 7]. Mutations in the p53 gene are found in proximally 50% of all human 
cancers, emphasizing the importance of the tumor suppressor function of p53 [8, 9]. 
A more detailed analysis shows that 95% of p53 mutations are found in the exons 
encoding DNA binding domain, underlining its tumor suppressor function as tran-
scription factor [10]. A mutation in the DNA binding domain renders p53 incapable 
of binding to its consensus DNA recognition sequence, losing its transcription regula-
tory function, rendering a cell sensitive for a malignant transformation and relatively 
resistant to stress induced apoptosis, cell cycle arrest or senescence, e.g. induced by 
chemotherapeutics, radiation or hypoxia.
Despite this high mutation frequency, incidence of p53 mutations differs considerably 
between cancer types. P53 mutations are found rarely (<1%) in, for example, uveal 
melanoma (UM) and thyroid cancer, while mutations are found commonly (>90%) in 
ovarian cancer and lung squamous cell carcinoma (Figure 1) [11]. It is believed that 
in tumors expressing wild-type p53 the tumor suppressor pathway of p53 is inhibited 
either upstream or downstream, implicating that all cancers have an attenuated p53 
pathway [4].
1.2 Regulation of p53 by MDM2 and MDMX
The central and important functions of p53 in cell-fate determination imply that p53 
activity should be tightly controlled, in which ubiquitin ligase mouse double minute 
(MDM) 2 and the structurally related MDMX play a pivotal role. The importance of 
the MDM2 and MDMX proteins for p53 regulation is best illustrated by the mouse 
KO models. Knockout of either MDM2 or MDMX is embryonic lethal in a fully p53-
dependent manner [12-14]. Whereas MDM2 transgenic mice can rescue the MDMX 
knockout phenotype, high MDMX levels in MDMX transgenic mice cannot rescue the 
MDM2 knockout [15, 16]. Although both MDM2 and MDMX are crucial for embry-







Figure 1. Genomic alterations affecting p53, MDM2 or MDMX in different cancers. Frequency 
of mutations (green), amplifications (red), deed deletions (blue) and multiple alterations (gray) 








MDMX loss can be compatible with life, probably because in most adult tissues MDMX 
protein is not or hardly detectable anyway [17-23]. MDM2 is an E3 ubiquitin ligase 
and has been shown to directly bind p53 [24]. MDM2 activity results in lysine-48 
poly-ubiquitination of p53, which is consequently degraded by the proteasome [25]. 
Thereby MDM2 effectively keeps the basal levels of p53 low and thus promotes cell 
proliferation and survival. Both the RING finger domain and the central acidic domain 
of MDM2 are essential for the p53 ubiquitination [26, 27]. Although MDM2 during 
animal development is mainly acting through the repression of p53, MDM2 has been 
reported to have p53-independent functions and ubiquitination targets [28-31].
The essential p53 inhibitor MDMX was initially discovered as a novel p53 interac-
tor with high sequence homology with MDM2 [32]. MDM2 and MDMX have great 
structural similarities of which the N-terminal hydrophobic pocket that binds the 
N-terminal alpha helix of p53, shielding the p53 transactivation domain, is best 
conserved [33, 34]. Despite the high conservation of the RING finger domain and 
the central acidic domain MDMX does not have any E3 ubiquitin ligase activity and 
its main p53 inhibitory function is shielding the p53 transactivation domain [26, 
27]. Despite the lack of intrinsic E3 ligase activity MDMX forms a heterodimer with 
MDM2 [35], which is thought to promote MDM2 E3 activity by providing a better 
scaffold for E2-enzyme binding, thus resulting in faster degradation of p53 [36, 37]. 
Considering that the levels of MDM2 and MDMX are crucial for cellular activity of 
p53, expression of these proteins should also be tightly controlled. P53 has to be 
liberated from MDM2 and MDMX to exert is function upon certain stress, for example 
in response to DNA damage. Several phosphorylation events on MDM2, mediated 
by serine/threonine kinase ATM, inhibit its ubiquitin ligase activity towards p53 [38]. 
Upon stresses, MDM2 both auto-ubiquitinates [38, 39] and ubiquitinates MDMX [40-
42] sending both for proteasomal degradation. This cellular depletion of inhibitory 
proteins results in a feed forward loop in which p53 is stabilized and activated. After 
cellular stress, for example induced by DNA damage, during the recovery phase a 
cell needs to re-constrain p53. It has been shown that both MDM2 and MDMX are 
transcriptional targets of p53 providing a negative feedback loop and thus re-establish 
p53 inhibition [43, 44].
1.3 Reactivating p53 in cancer
In order to become malignant cells need to lose or at least attenuate p53 activity, for 
example by direct gene mutation [8, 9]. Therefore, specifically targeting p53 mutated 
cancer cells would provide a very interesting therapeutic intervention, potentially 
benefitting half of all cancer patients. It was reasoned that cancer cells with mutated 
p53 would remain sensitive for p53-induced apoptosis, since the downstream path-
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way remains intact [45]. Therefore, various approaches were designed to reactivate 
mutant p53 [46]. One compound discovered to reactivate mutant p53 was named p53 
reactivation and induction of massive apoptosis (PRIMA) [45], which binds the core 
domain the DNA binding domain of p53 and changes the conformation from mutant 
to wild-type, resulting in the induction of apoptosis [47, 48]. This biological effect 
induced by PRIMA has been suggested to be specific for p53 mutant cell lines [49]. 
However, evidence is accumulating that PRIMA induces anti-cancer effects regardless 
of the presence of p53 mutations [50, 51]. This could be explained, at least in part, 
by the observation that PRIMA also targets other p53 family members such as p63 
and p73 [51-53]. Other approaches found to target p53 mutated cells include the 
cholesterol lowering drugs, the statins [54, 55]. Depletion of cells from mevalonate-
5-phosphate by treatment with statins resulted in impairment of the mutant-p53 
interaction with the chaperone protein DNAJA1/hsp40 which caused ubiquitin E3 
ligase CHIP-mediated degradation of mutant p53 [55]. These studies have provided 
new insights with potential new strategies to specifically target mutant p53 cells.
Despite the frequent occurrence of p53 mutations, the remaining half of human can-
cers had to find alternative mechanisms to attenuate p53 signaling [4]. Amplifications 
of the MDM2 gene are frequently found in sarcoma [56-58] and esophageal cancer 
[59] (Figure 1). Similarly to MDM2, MDMX amplifications and overexpression are 
found in various cancers including glioblastoma [60], retinoblastoma [61] and breast 
cancer [62], in most cases correlating with wild-type p53 status (Figure 1). The MDM2 
interaction with the p53 transactivation domain is well defined by crystal structures 
[63]. These structures show that the hydrophobic pocket of MDM2 interacts with 3 
side chains from a peptide derived from the p53 transactivation domain. This clearly 
defined pocket and interaction between MDM2 and p53 allowed for effective drug 
development. The first small molecule compound described to bind MDM2 in its 
p53-binding pocket was Nutlin-3 [64]. Antagonizing the MDM2-p53 interaction us-
ing Nutlin-3 resulted in stabilization of p53 in an MDM2-amplified osteosarcoma cell 
line, leading in cell cycle arrest and apoptosis, both in vitro and in vivo. Importantly, 
the p53 activation by Nutlin-3 was not due to DNA damage signaling [65, 66]. This 
mode of action resulted in the observation that mice treated with Nutlin-3 did not 
lose weight while p53 was being activated, indeed separating Nutlin-3 from DNA 
damaging agents and their associated adverse clinical effects [64]. This approach 
has spurred the development of various small molecule compounds targeting the 
MDM2-p53 interaction such as 1, 4-benzodiazepin-2, 5-dione [67], spiro-oxindoles 
[68] and RITA [69], all resulting in p53 stabilization and inducing cell cycle arrest and 
apoptosis. Although found in a screen to identify p53 re-activating compounds and 







response, rendering the anti-cancer effects not exclusive to the MDM2-p53 inhibition 
[70-72]. Furthermore, some evidence exists indicating that RITA does not block the 
MDM2-p53 interaction [73], implying that RITA targets cells expressing p53, but not 
by directly binding to p53.
Based on these promising results in vitro and in pre-clinical mouse models, a number 
of clinical trials were initiated using various compounds targeting the MDM2-p53 in-
teraction [74]. RG7112, a Nutlin-3 analog, was initially tested in liposarcoma patients 
with MDM2 amplifications. Of the 20 patients in this clinical trial 14 had stable disease 
and 1 patient had a partial response [75]. Besides its therapeutic potential RG7112 
treatment elicited severe neutropenia and thrombocytopenia in these patients. In 
a phase 1 clinical trial assessing RG7112 in 116 patients with various hematological 
malignancies, similar to the sarcoma trial, 22% of the patients showed severe neu-
tropenia [76]. Although MDM2 inhibition has a clinical benefit for these patients, the 
strong, on target, adverse effects need to be managed in order to continue long-term 
MDM2 inhibition [77]. In addition, resistance to MDM2 inhibition has been shown to 
occur via specific point mutations in p53 [78, 79].
Antagonists for the MDMX-p53 interaction have been in development since MDMX 
amplification and/or overexpression in p53 wildtype tumors was discovered. Despite 
the overall structural similarity between MDM2 and MDMX, some important differ-
ences were found in their p53 binding pocket [34, 80]. These slight changes in the 
p53-binding hydrophobic cleft reduce the binding capabilities of Nutlin-3 to MDMX 
approximately 40 fold, although Nutlin-3 can still clearly antagonize the interaction 
between MDMX and p53 [61]. The reduced efficacy of MDM2 inhibitors for MDMX 
suggested a window of specificity, which led to the pursue of an MDMX-specific in-
hibitor. SJ172550 was the first described small molecule specifically designed to block 
the MDMX-p53 interaction [81]. However, it has been described later that SJ172550 
is not a simple inhibitor between MDMX and p53, but locks MDMX in a conforma-
tional state by covalent interaction that is unable to bind p53 [82]. Unfortunately, this 
conformational state change is dependent on many factors including the reducing 
potential of the media, hindering the further clinical development of SJ172550 [82]. 
Another study described molecules inhibiting MDMX transcription, e.g. XI-006 and 
XI-011 [83]. These compounds resulted in the cellular depletion of MDMX promoting 
p53 activation, reportedly without induction of double strands DNA breaks, provid-
ing treatment options for various cancers [84-86]. However, this MDMX depletion 
effect by XI-011 was later shown to be partly due to increased DNA damage signaling 
resulting in MDMX degradation and subsequent p53 activation [86, 87] and apoptosis 
induced by XI-006 in Ewing Sarcoma was even shown to be p53 independent [85]. It 
16
General introduction
thus appears that the design of small molecules specifically targeting MDMX without 
inducing DNA damage signaling is a difficult task. It could be that dual inhibitors of 
MDM2 and MDMX provide a solution [88]. By simultaneously inhibiting MDM2 and 
MDMX p53 activation is boosted, meaning that less MDM2 inhibition (and therefore 
less adverse effects) might be needed to achieve functional p53 activation.
Alternative approaches to target MDMX could involve other pathways, which have 
shown to play a role in overexpression of MDMX. It has been demonstrated that the 
receptor tyrosine kinases Her4 (also known as Erbb4) and AXL are capable of stabiliz-
ing MDMX in order to suppress p53 [89, 90]. Targeting these signaling pathways might 
be a potent way to destabilize MDMX, thus releasing p53 activity, possibly without 
inducing DNA damage signaling. However, these kinases have multiple targets and 
downstream effects independently of MDMX, which will make the analysis of these 
inhibitors on MDMX function especially difficult.
Alternative splicing is yet another mechanism by which the abundance of MDMX is 
reduced upon DNA damage [91]. The short isoform of MDMX, missing exon 6, is a 
naturally occurring transcript, which results in a short protein due to an early stop 
[92]. Mice that are lacking exon 6 are embryonic lethal in a p53-dependent manner 
[93]. By promoting the skipping of exon 6 using anti-sense oligonucleotides the splic-
ing ratio could be altered favoring the short over the full length isoform, resulting in 
decreased MDMX protein levels [94]. MDMX has been shown to be a potent target 
in both melanoma [95] and wildtype p53 breast cancer [96]. Depletion of MDMX 
resulted in a cell cycle arrest and apoptosis in a partly p53-independent manner [87, 
95]. The p53-independent cell cycle arrest could be explained, at least in part, by 
the p53-independent upregulation of the cyclin dependent kinase (CDK)-inhibitor 
p27 upon MDMX depletion [87]. These results suggest that MDMX might not only 
to be a therapeutic target in wildtype p53 tumors, but also in p53 mutated tumor 
cells. Indeed, p53 mutated breast cancer cell lines expressing high levels of MDMX are 
dependent on continuous MDMX expression for proliferation [97].
2. MELANOMA
To study the functions of p53 and especially of MDMX, this thesis focusses on mela-
noma, a malignancy arising from melanocytes. In cutaneous melanoma p53 mutation 
frequency is low (10-20%) and UM cells essentially lack p53 mutations [98, 99]. Despite 
the absence of MDM2 or MDMX amplification, melanoma cells frequently overex-







patients with distant metastases respond poorly to classical chemotherapy and, there-
fore, have a short overall survival, studying melanoma with a focus on the MDMX/p53 
complex is highly clinically relevant [100]. Although melanoma encompasses only a 
low percentage of skin cancer, melanoma is a deadly form of cancer causing most of 
the skin cancer-associated deaths. The increased melanoma incidence found over the 
last decades emphasizes the importance of finding an effective cure for melanoma 
[101]. Due to advances in early detection of melanoma the primary tumors can be 
efficiently resected resulting in high survival rates. However, prognosis significantly 
worsens upon metastasis. Improvements have been made during the past decades in 
understanding melanoma and how to use this knowledge to target this malignancy. 
The main current treatments for melanoma are briefly discussed below.
2.1 Cutaneous melanoma
2.1.1 Targeted therapy
Previous studies have already reported that the MAPK signaling pathway is ac-
tivated in various cancer types including melanoma [102]. The most frequent and 
well described melanoma driver is an activating mutation in the serine/threonine 
kinase BRAF gene in up to 50% of melanomas. Most common mutation is the valine 
(V) substitution for glutamic acid (E) of codon 600 (V600E), feeding into the MAPK 
pathway and driving melanomagenesis [102]. Mutations upstream of BRAF, mainly 
in NRAS, are found in 10-25% of all cutaneous melanoma cases [103]. The most com-
mon activating NRAS mutation occurs at the codon for glutamine (Q) 61 [104]. These 
hotspot mutations in BRAF and NRAS rendering the proteins permanently active, and 
continuously stimulate the pro-proliferation MAPK pathway. Additionally, in 14% of 
cutaneous melanoma samples inactivating mutations are found in NF1, a GTPase-
activating protein. By losing NF1 expression RAS-GTP is much slower converted to its 
inactive GDP form, resulting in increased RAS activation and consequently an overac-
tive MAPK pathway. Therefore, loss of NF1 (14%), activating mutation in NRAS (28%) 
or in BRAF (52%) explains the activated MAPK signaling in 94% of all melanoma cases 
(Figure 2A) [104].
Recently, a novel classification was presented identifying four major subtypes of 
cutaneous melanoma; BRAF, NRAS, NF1 and the so called triple-negative [104]. In-
terestingly, mutations in the gene encoding the receptor tyrosine kinase (RTK) KIT are 
enriched in the triple-negative subgroup. Although only 3% of all melanoma have KIT 
mutations or amplifications, these mutations are more commonly found in melanoma 
originating from mucosal, acral a chronically sun-damaged surface [105]. Like BRAF 
and NRAS, mutations in KIT focus on a ‘hot-spot’ with 30% of KIT mutations showing 



















































Figure 2. Melanoma signaling and therapeuti c interventi ons. A) Cutaneous melanoma signal-
ing driven by acti vati ng mutati ons in BRAF/NRAS or inacti vati ng mutati ons in NF1. Therapeuti c 
interventi ons consist of BRAF and MEK inhibiti on via Vemurafi nib/Dabrafi nib and Binimeti nib/
Trameti nib respecti vely. B) Oncogenic mutati ons driving signaling in uveal melanoma. Acti vat-
ing mutati ons in PLB4, GNAQ/11 and CYSLTR2 drive the PI3K/AKT/MTOR, PKC/MEK and the YAP 
pathway. Therapeuti c interventi ons in uveal melanoma therefore consist of PI3K, AKT, MTOR, 







use of RTK inhibitors in these patients [106]. When patients carrying a KIT mutation 
were treated with RTK inhibitory molecules, these cancer patients develop therapy 
resistance by acquiring secondary NRAS mutations [107].
Knowledge about BRAF and NRAS mutations have led to the development of mutant 
specific BRAFV600E inhibitors and MEK inhibitors, blocking the oncogenic MAPK path-
way [108]. Despite single agent success to BRAF and MEK inhibition, most patients 
develop disease progression after 6 to 7 months and only a small portion remain 
disease free [109-112]. The major factor contributing to BRAF and MEK inhibitor 
resistance found was the reactivation of the same MEK/ERK pathway via alternative 
means, such as activation of other receptor tyrosine kinases or NRAS upregulation 
[113-119]. MEK inhibition and NRAS depletion both trigger an apoptotic program in 
NRAS mutated melanoma, whereas only NRAS depletion additionally resulted in a 
CDK inhibitory effect. Indeed combined MEK and CDK4 inhibition resulted in syner-
gistic therapeutic effect [120]. These results suggest that CDK4 inhibition might result 
in increased patient survival in combination with MEK inhibition, which is currently 
being investigated in an ongoing clinical trial (identifier: NCT01781572).
2.1.2 Immunotherapy
In addition to BRAF- and MEK inhibitors [109, 121, 122] the FDA has also approved 
immunotherapies for melanoma treatment [123, 124]. The first immune checkpoint 
which could be effectively targeted and inhibited was cytotoxic T-lymphocyte anti-
gen-4 (CTLA-4) [125]. The response of a T lymphocyte, upon binding of the T cell 
receptor to a peptide presenting MHC molecule, is the result of a balance of both 
stimulatory and inhibitory signals (reviewed by [126]). This balance consists of the 
stimulatory interaction between CD80/86 (on the antigen presenting cell) and CD28 
and the inhibitory signals residing from an interaction between CD80/86 and CTLA-4. 
Cancer cells take advantage of these inhibitory signals by hiding them from tumor 
antigen-specific T-lymphocytes. Tumor-specific antigens arise as a consequence of 
genomic mutations. By blocking the inhibitory signals with CTLA-4 with monoclonal 
antibody Ipilimumab the T-lymphocytes are unleashed and shows convincing clini-
cal efficacy [123, 127]. Moreover, Ipilimumab was the first treatment to prolong the 
survival of advanced melanoma patients, highlighting the clinical importance of these 
therapies [123, 127].
Another effective immunotherapeutic approach is by blocking PD-1 and/or PD-1L us-
ing monoclonal antibodies. PD1 is a receptor expressed on various activated immune 
cells such as T-, B-, natural killer- cells and T- regulatory cells [128]. When PD1 binds to 
its ligand PD-1L, presented by an antigen presenting cell, the efficacy of the activated 
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immune cell is attenuated [129]. Like CTLA-4, PD-1/PD-1L blocking results in increased 
progression free- and overall survival, with a manageable toxicity profile [130-133]. 
Interestingly, BRAF inhibition seems to enhance PD-1/PD-1L expression suggesting 
that down regulating the immune system is beneficial for the acquirement of BRAF 
resistance [134]. These data suggested already that combining BRAF inhibition with 
immunotherapy could boost the efficiency of each single therapy. And indeed, pre-
clinical data have shown that combining BRAF inhibition with immunotherapy has 
significant additive effects over the single treatments [135, 136].
2.2 Uveal melanoma
Uveal melanoma (UM) accounts for approximately 5 % of total melanoma incidence 
and originates from the choroid (85%), iris (5%) or ciliary body (10%) [137, 138]. Driver 
mutations in UM are found in the α subunits of G-proteins GNAQ (50%) or GNA11 
(43%), mainly resulting in a Q209L substitution locking GNAQ/11 in a GTP-bound, 
active state [139-141]. Due to the high frequency of these activating mutations in 
GNAQ/11, like BRAF in cutaneous melanoma, targeting the mutant protein(s) could 
potentially serve as an interesting therapeutic intervention. Although a number of 
cyclic depsipeptides have been reported to selectively inhibit GNAQ, it has not been 
investigated properly whether these compounds can still bind the mutant GNAQ [141, 
142]. UM without GNAQ or GNA11 have mutual exclusive mutations in the G-protein 
coupled receptor encoding Cysteinyl Leukotriene Receptor 2 (CYSLTR2) (4%) or the 
downstream effector Phospholipase C Beta 4 (PLCB4) (2.5%) [143, 144]. Together 
these data demonstrate that constitutively active G-protein signaling is an important 
early event in UM.
Like with cutaneous melanoma, the primary UM tumor can be treated efficiently. 
However, once UM patients develop metastasis, which happens in about half of the 
patients within 15 years after primary tumor detection, median survival is reduced 
to only several months since no effective treatment exists [145-147]. Frequent chro-
mosomal aberrations in UM are loss of one copy of chromosome 3, amplification of 
8q, 6p or both. Less frequently 8p gain or loss of 1p, 6q and 16q is observed [148, 
149]. Monosomy 3 strongly correlates with development of metastasis and therefore 
is a marker for poor prognosis [150, 151]. The BAP1 gene residing at chromosome 3 
frequently shows an inactivating mutation and the remaining wild type BAP1 allele 
is often lost due the monosomy 3 [152]. Mutations in BAP1 have a strong predictive 
power for the occurrence of metastasis in UM and 80-90% of the metastatic patients 
contain a BAP1 mutation [152, 153]. BAP1 functions as a de-ubiquitination enzyme 
and a regulator of cell cycle progression and DNA damage response [154-157]. It 







primary targets, histone 2A [158]. Depletion of BAP1 in vitro results in a stem cell-like 
phenotype of UM cells [159]. In addition to monosomy 3 and loss of BAP1 expression, 
gain of 8q is associated with poor survival rates [160, 161]. Multiple potentially inter-
esting genes residing on 8q could potentially explain the poor survival and/or provide 
interesting therapeutic targets, such as proto-oncogenes PTP4A3, c-MYC, PVT1, LYN 
and MOS.
In addition, mutations have been found in the EIF1AX gene, coding for Eukaryotic 
Translation Initiation Factor 1A X-linked, an essential component of translation initia-
tion [162-164]. Mutations in EIF1AX occur for 20% in N-terminal end of the protein, 
which do not include inactivating mutations, such as frame shifts suggesting activating 
mutations [163, 165]. Mutations in EIF1AX are associated with good prognosis and 
subsequently correlate with disomy 3 [163]. Interestingly, only the mutant allele is 
expressed suggesting an oncogenic selection advantage [163]. Depletion of EIF1AX 
in wild type and mutant cell lines result in reduced cell viability, suggesting EIF1AX 
to be an essential gene [165]. Another gene often found mutated in UM in which 
two copies of chromosome 3 are retained is encoding the splicing factor 3B subunit 
1 (SF3B1) and these mutations corrupt SF3B1 functioning and are associated with a 
favorable prognosis [162, 166]. However, it has recently been shown that, although 
SF3B1 mutations have a favorable prognosis compared to monosomy 3 tumors, these 
mutations are associated with metastasis development after 5 year [167], indicating 
that SF3B1 mutations are a long term poor prognosis marker. Mutations in SF3B1 are 
found in 10-21% of patients and mainly affect Arg625 [163, 166]. SF3B1 has been 
shown to be an essential part of the spliceosome [168]. It is, therefore, not surprising 
that mutations in SF3B1 resulted in alterations in the splicing of many genes [169, 
170]. It remains unclear how EIF1AX and SF3B1 mutations exactly contribute to mela-
noma formation and how their functions correlate with their respective prognostic 
implications. It could be hypothesized that due to the mutual exclusive pattern and 
functioning in RNA processing EIF1AX and SF3B1 have partly overlapping functions in 
driving UM.
Most novel therapeutic interventions employed for metastasized UM focus on mu-
tated G-protein signaling. G-protein coupled signaling feeds into the know oncogenic 
MAPK pathway via its important effector PLC-β, which hydrolyzes phosphatidylinosi-
tol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
(DAG) [171]. IP3, via the increase of intracellular Ca2++, and DAG act as second mes-
sengers to activate various protein kinase C (PKC) isoforms (Figure 2B) [172, 173]. 
Although multiple PKC isoforms are activated, PKC δ and ε were shown to be sufficient 
to activate MEK, mediated by RAS Guanyl Releasing Protein 3 (RASGRP3) activation, 
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which in turn promotes UM survival and proliferation [174]. Indicating that the growth 
inhibitory effects of other PKC isoforms is not mediated trough MAPK inhibition. The 
insights into PKC activation have spurred investigations on PKC inhibitors such as So-
trastaurin. Indeed, UM cells are highly dependent on PKC and MEK signaling and were 
found to be sensitive to either MEK or PKC inhibition by small molecule compounds 
[175, 176]. A phase I clinical trial with UM patients was initiated using Sotrastaurin 
as PKC inhibitor. Sotrastaurin treatment resulted in progression free survival of 15 
weeks in about 50% of the patients [177]. Interestingly, both MEK and PKC inhibition 
is required to completely abolish ERK phosphorylation and thereby cell proliferation 
and survival in vitro and in vivo [176]. Unfortunately, a clinical trial assessing the 
potency of dual MEK and PKC inhibition had to be terminated due to strong adverse 
effects [178]. Aside from the MAPK pathway the PI3K pathway is also activated by 
the continuous G-protein coupled signaling in UM (Figure 2B). Upon activation PI3K 
catalyzes the conversion of PIP2 into PIP3, which in turn mediates the activation of 
AKT [179]. Indeed, the inhibition of the PI3K/AKT pathway has been shown to reduce 
proliferation in vitro [180]. A downstream target of AKT in the PI3K pathway is MTOR, 
a kinase with downstream effectors 4E-BP1 and S6K1 regulating translation [181-185]. 
Although multiple effective MTOR inhibitors exist, the impact of mTOR inhibition on 
UM cell proliferation and survival appears to be far less potent when compared to 
BRAF mutant cells [180, 186, 187]. Mutated G-protein coupled signaling to cell prolif-
eration and survival also involves the transcription regulators YAP and TAZ (Figure 2B). 
Mutated GNAQ/11 has been demonstrated to increase YAP/TAZ activity via Trio and 
downstream G-proteins Rho and Rac [188, 189]. The requirement of the YAP pathway 
for UM proliferation and survival was best illustrated by the knockdown of YAP in UM 
cells. Additionally, small molecule inhibition of YAP using Verteporfin demonstrated 
the clinical potential of targeting this pathway downstream of mutated GNAQ/11 
[188-190]. Together these pathways provide a wide range of opportunities to find 
novel therapeutic interventions for patients with metastasized UM (Figure 2B).
3. AIM AND OUTLINE OF THIS THESIS
The focus of this thesis is uveal melanoma (UM), an ocular cancer which, once metas-
tasized, is lethal due to lack of effective treatment options. UM is driven by an onco-
genic activating mutation in the α subunit of G-proteins GNAQ or GNA11. Essentially 
no mutations are found in the tumor suppressor gene p53 in UM. To represses p53 
activity approximately 65% of UM tumors express high levels of the p53 inhibitory 
proteins MDMX or MDM2. MDMX is shown to act as p53 inhibitor by binding to its 







has been demonstrated that the oncogenic function of MDMX reaches beyond that 
of p53 inhibition. The aim of this thesis is to unravel the oncogenic function of MDMX 
and provide new treatment options for patients with metastasized UM.
Chapter 2 describes the regulation of the transcriptome by MDMX in UM. We dem-
onstrate here that MDMX affects the transcription of genes involved in cell cycle 
regulation or apoptosis. This chapter also describes novel p53-independent effects 
of MDMX in addition to p53 inhibition, i.e. FOXO inhibition. Furthermore, a novel p53 
back-up mechanism with a potential therapeutic target is proposed in this chapter.
In chapter 3 the opportunities of a combined targeting of two common signaling path-
ways, GNAQ/11 mutations and wildtype p53, as therapeutic intervention for metas-
tasized UM patients is investigated. Drugs targeting these pathways, PKC- and MDM2 
inhibitors, are already known to elicit strong adverse effects in patients. Genetic 
interference with either MDMX or PKC δ expression or activity showed that beneficial 
effects can already be achieved by a more specific targeting, which is presumable less 
toxic to the patient.
In chapter 4 it is described, opposed to what has been reported before, that enhancer 
of zeste homolog 2 (EZH2) inhibition poses a valuable novel therapeutic invention for 
UM. However, since EZH2 inhibition might take too long to exert a clinical beneficial 
effect, it was investigated whether EZH2 targeting would sensitize UM cells for other 
therapeutic strategies. Indeed, interfering with EZH2 activity synergized with HDAC 
inhibition, thus providing a novel treatment option for metastasized UM.
In chapter 5 it is shown that combining two clinically approved drugs, the pan-histone 
deacetylase (HDAC) inhibitor Quisinostat and the pan-CDK inhibitor Flavopiridol, 
could serve as an effective therapeutic intervention for UM patients. In addition, this 
combination of compounds, effectively causing apoptotic cell death in UM cells, could 
serve as alternative treatment option for cutaneous melanoma patients as well.
In chapter 6 the results from the preceding chapters are summarized and discussed 
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Abstract
Tumor suppressor p53 has an important role in cell-fate determination. In cancer cells 
p53 activity is frequently inhibited by high levels of MDMX and/or MDM2. MDM2 is 
an E3 ubiquitin ligase whose activity results in ubiquitin- and proteasome-dependent 
p53 degradation, while MDMX shields p53’s transactivation domain. Interestingly, the 
oncogenic functions of MDMX appear more wide-spread than exclusively the inhibition 
of p53. The present study sets out to elucidate the MDMX controlled transcriptome. 
Therefore, we depleted MDMX from a high MDMX expressing uveal melanoma cell 
line and determined the effect on the transcriptome by RNAseq. Biological function 
analyses indicate the inhibition of the cell cycle- and stimulation of cell death- regulat-
ing genes upon selective MDMX depletion. Although the inhibition of p53 activity 
clearly contributes to the transcription regulation controlled by MDMX, it appeared 
that the regulation of multiple genes did not fully rely on p53 expression. Analysis of 
gene regulatory networks suggests a role for Forkhead box (FOX) transcription factors. 
Indeed, an increased level of FOXO1 protein was observed upon MDMX depletion, 
independent of p53 expression. The mechanism of the p53-independent oncogenic 
functions of MDMX could be partially explained by these p53-independent effects on 
the transcriptome possibly regulated by FOXO1. As an example, we demonstrate that 
MXD4 (also named MAD4) expression is controlled by MDMX in a p53-independent 
manner. Interestingly, we found that MXD4 depletion activates p53 potentially 
suggesting a backup system in which MXD4 promotes MDM2 activity upon MDMX 
depletion. In order to enhance p53 activating strategies the MXD4 is proposed as a 
potential new therapeutic target.
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The p53 protein is considered to be a master regulator in a cell, mainly due to its 
central role in cellular stress sensing and its ability to regulate the transcription of a 
plethora of genes involved in multiple biological processes including cell cycle regu-
lation, apoptosis, metabolism and autophagy [1]. Upon various types of intra- and 
extracellular stress p53 is activated and stabilized, resulting in transcriptional regula-
tion inducing cell cycle arrest, senescence or apoptosis [2, 3]. Because of its central 
and important function in cell-fate, p53 activity needs to be under tight control. This 
stringent control of p53 is provided by many proteins including the ubiquitin E3 ligase 
MDM2 and the structurally related MDMX. This was best demonstrated in vivo were 
knock out of MDM2 or MDMX in mice resulted in embryonic lethality, which was 
shown to be p53-dependent [3-7]. Although both MDM2 and MDMX are crucial for 
mouse embryonic development, in adult tissue MDM2 loss is always lethal whereas 
MDMX often has more mild effects, indicative of the differences in expression and 
functions between the two proteins [8-14]. MDM2 is an E3 ubiquitin ligase and has 
been shown to directly bind with its N-terminal hydrophobic pocket to the N-terminal 
α helix of p53 and subsequently ubiquitinate p53, which consequently is sent for 
proteasomal degradation [15-18]. MDMX was initially discovered as a novel p53 
interactor with high sequence homology and great structural similarities with MDM2 
[19-21]. Despite the high conservation of the acidic domain and the RING domain 
MDMX does not have any E3 ubiquitin ligase activity. However, MDMX can, via its 
RING finger, form a heterodimer with MDM2, enhancing MDM2’s ubiquitin ligase 
activity [22-24]. MDMX directly inhibits transcriptional activation by p53 by tightly 
binding and thereby shielding its transactivation domain [17, 18]. Considering that 
the levels of MDM2 and MDMX are crucial for the level and/or activity of p53 in a cell, 
also the levels of MDM2 and MDMX are under stringent control. Upon certain stress, 
e.g. DNA damage, p53 has to be liberated from its inhibitors MDM2 and MDMX. One 
mechanism is the degradation of both proteins by increased MDM2-mediated ubiqui-
tination via decreased de-ubiquitination by ubiquitin specific protease (USP) 7 [5, 18, 
25]. Additionally, serine-threonine kinase ATM-mediated phosphorylation on MDM2 
inhibits its ubiquitin ligase activity towards p53 [26]. As a result the p53 protein is 
activated and stabilized and can perform its tumor suppressor function. During the 
recovery phase after an insult, a cell needs to re-constrain p53 activity by MDM2 and 
MDMX. It has been demonstrated that both MDM2 and MDMX are transcriptional 
targets of p53 providing a negative feedback loop [27, 28].
Approximately 50% of all human cancers contain a genetically altered p53 gene, either 
a point mutation or a deletion leading to loss of expression, to render cancer cells re-
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sistant to the tumor suppressor function of p53 [29, 30]. Despite the high frequency of 
p53 mutations the other half of the human cancers evolved alternative mechanisms 
to attenuate p53 signaling [31]. Amplifications of MDM2 or MDMX are frequently 
found in sarcoma, glioblastoma, retinoblastoma and breast cancer, providing an inter-
esting therapeutic target, i.e. re-activation of wild-type p53 by inhibition of MDM2/
MDMX-p53 interaction [32]. Nutlin-3 was the first small molecule compound reported 
to exploit MDM2 overexpression by disrupting the MDM2 and p53 interaction result-
ing in stabilization of p53, subsequently inducing cell cycle arrest and apoptosis [33]. 
Importantly, it has been demonstrated that this p53 activation by Nutlin-3 was not due 
to activation of the DNA damage response [34, 35]. Recently it has been shown that 
the abundance of a naturally occurring MDMX short transcript isoform (MDMX-S) can 
be promoted using anti-sense oligonucleotides resulting in a shift from the full length 
to the short RNA isoform leading to decreased MDMX protein levels [36]. MDMX has 
been shown to be a potent therapeutic target in retinoblastoma, melanoma [37] and 
wild-type p53 breast cancer [38]. MDMX depletion induced cell cycle arrest and apop-
tosis in cancer cells in a partly p53-independent manner [37, 39], which could imply 
that MDMX is not only a valuable therapeutic target in wild-type p53 cancer cells, but 
also in p53 mutated cells. Indeed in p53 mutated breast cancer cell lines expressing 
high levels of MDMX protein the expression of MDMX was shown to be essential 
for cell viability and tumor growth [40]. This could be, at least partly, explained by 
the p53-independent upregulation of CDK inhibitory protein p27 upon MDMX deple-
tion [39]. Furthermore, high levels of MDMX inhibit the early DNA damage response, 
independently of p53 and MDM2, resulting in genome instability [41]. However, the 
exact mechanisms leading to the p53 independent oncogenic functions of MDMX 
remain unspecified. Here we set out to elucidate to which extent the transcriptome is 
controlled by MDMX in a wild-type p53 cell line and how transcription regulation by 
MDMX might explain both its p53-dependent and -independent functions.
Results
Regulation of transcriptional activity by MDMX
The effect of p53 reactivation on the transcriptome has been studied extensively 
in previous studies (reviewed by: [42]). Here we studied the regulation of the tran-
scriptome by MDMX. For this purpose we used a wild-type p53 cell line (MEL202) 
derived from a primary uveal melanoma, a cancer which rarely has mutated p53 
and frequently highly express MDMX to constrain p53 activity [43]. We had shown 
before that this cell line is dependent on MDMX expression for proliferation [39]. 
We generated five MEL202-derived cell lines; one cell line containing a doxycycline-
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inducible control shRNA expression construct and four cell lines containing a distinct 
doxycycline-inducible MDMX targeting shRNA expression construct.
Efficiency and kinetics of knockdown was tested by incubating the cells with doxycy-
cline for 24, 48 and 72 hrs and harvesting both RNA and protein. These initial experi-
ments show that the depletion of MDMX was efficient from 24 hours onwards with 
all shRNA constructs used (Figure 1A). Based on known p53 targets p21 and MAD2L1 
we determined the transcriptional kinetics upon MDMX depletion (Figure 1B). The 
increase of CDK inhibitor p21 expression was already present at 24 hours and did 
not increase dramatically in the later time points. Mitotic arrest deficient 2 like 1 
(MAD2L1), a component of the mitotic spindle assembly checkpoint, repression was 
only modest at 24, but reached plateau at 48 hours.
Based on these results we have performed transcriptional profiling by RNA sequencing 
upon doxycycline-inducible MDMX knockdown using 4 different shRNAs and 1 induc-
ible control shRNA incubated with doxycycline for 48 hours. Thorough analysis of the 
data resulted in the identification of 176 genes which were significantly upregulated at 
least 0.7log2 fold upon MDMX depletion (Supplementary Table 1). Besides induction 
of expression, 70 genes were significantly down regulated with at least -0.7log2 fold 
upon MDMX depletion (Supplementary Table 2.). Gene ontology (GO) terms pathway 
analysis clearly showed that the upregulated genes promote cell death and apoptosis, 
while the down regulated genes are associated with genes involved in controlling the 
cell cycle (Supplementary Table 3).
To determine whether these effects are mediated via a specific transcription factor 
we employed the computational method iRegulon [44]. It turned out that of the 176 
upregulated genes 66 have a p53 binding motive in their promotor regions (Supple-
mentary Figure 1 and Supplementary Table 1) indicating that, despite the limited log 
fold changes, 37.5% of the upregulated genes could be explained by the p53 activation 
upon MDMX depletion. It appeared also from these analysis that the majority (114 
of the 176, 65%) of the upregulated genes have a Forkhead Box (FOX) DNA binding 
motive, recognized by multiple FOX transcription factors. Interestingly, the genes 
containing a p53 DNA binding motive contained also a FOX motive in 89% of the cases. 
Analysis of the downregulated genes indicated enrichment for two known repressive 
transcription regulators, E2F4 and SIN3A. In total 61 of the 70 (87%) downregu-
lated genes contained one or both repressive transcription regulators binding sites 
(Supplementary Figure 1 and Supplementary Table 2). We verified the transcriptional 
regulation of a number of these genes using qPCR (Figure 2A). Not only at the RNA 
level but also at protein level the upregulation of p21 (CDKN1A) and p53 upregulated 
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Figure 1. Kinetics of MDMX depletion in MEL202 cells upon doxycycline treatment. A) Protein 
expression analysis of i-shCtrl and i-shMDMX MEL202 cells harvested after different incubation 
periods with doxycycline. The cells containing the distinct MDMX targeting shRNA constructs (#1, 
2, 3 and 4) show a clear reduction of MDMX protein upon doxycycline treatment (10 ng/ml). Si-
multaneously with MDMX depletion p53 levels slightly increase and also p21 levels rise, mostly at 
the later time points. B) Relative mRNA expression of p21 and MAD2L1 in i-shCtrl and i-shMDMX 
MEL202 cells harvested after different incubation periods with doxycycline (10 ng/ml). Expression 
of p21 is markedly increased upon MDMX depletion already after 24 hrs and only slightly increas-
es at later time points. Repression of MAD2L1 upon MDMX depletion takes approximately 48 
hours before reaching a plateau. Significant differences between the ish-Control and ish-MDMX 
knockdowns are indicated with an asterisk (*).
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modulator of apoptosis (PUMA or BBC3) and downregulation of MAD2L1 could be 
confirmed (Figure 2B). Importantly, not only the sequence data was confirmed but 
also the expression of the transcription factors binding to the motives identified by 
iRegulon (p53 and FOXO1) were slightly increased upon MDMX depletion (Figure 2B). 
Importantly, both p53 and FOXO1 were found to interact with MDMX in MEL202 cells 
(Figure 2C). This interaction could be stabilized by the inhibition of the proteasome 
using MG132. Furthermore, the transcriptional regulation of the same down- and up-
regulated MDMX target genes were also tested in a second uveal melanoma cell line 
(92.1) upon MDMX knockdown. In this cell line similar changes were observed as upon 
MDMX knockdown in MEL202 (Supplementary Figure 2A). These results indicate that 
the effects observed in the RNA sequencing are reliable and not cell line dependent.
p53-dependent and -independent effects
We and others have previously shown that depletion of MDMX can result in a p53-
independent growth arrest. We, therefore, determined to what extend the observed 
MDMX induced effects on the transcriptome are p53-dependent. As an initial step 
we investigated whether non-genotoxic activation of p53 by Nutlin-3 would affect 
the expression of the same genes as observed upon MDMX depletion. As expected, 
we observed that the mRNA level of the known p53 target gene p21 (CDKN1A) is 
strongly induced upon Nutlin-3 treatment (Figure 2D). Similar effects were observed 
for cytoplasmic FMR1 interacting protein 2 (CYFIP2) and patched domain containing 
4 (PTCHD4) (Figure 2C). Max dimerizing protein 4 (MXD4) and phosphoinositide-3-
kinase interacting protein 1 (PIK3IP1) expression was also increased upon Nutlin-3 
treatment, although the induction was much less compared to p21, CYFIP2 or 
PTCHD4. The mRNA levels of all genes downregulated upon MDMX knockdown that 
were tested (exonuclease 1 (EXO1), hyaluronan synthase 2(HAS2), kinesin family 
member 23 (KIF23), MAD2L1 and minichromosome maintenance 10 replication initia-
tion factor (MCM10)) were also repressed upon incubation with Nutlin-3 (Figure 2D). 
To investigate a putative cell line dependency of the regulation of these genes by p53 
we investigated the effect of Nutlin-3 treatment in another uveal and in four cutane-
ous melanoma cell lines, of which 94.07 contain a p53-inactivating mutation. Nutlin-3 
treatment of the uveal melanoma cell line 92.1 showed transcriptional regulation of 
these genes similar to the results in MEL202 (Supplementary Figure 3). p53 wild type 
cutaneous melanoma cell lines 04.01 and 06.24 showed upon Nutlin-3 treatment that 
p21, CYFIP1 and PTCHD4 are potent p53 targets, whereas PIK3IP1 and MXD4 expres-
sion levels hardly, if anything, changed (Supplementary Figure 3). It can be noted that, 
although p21, CYFIP1, PTCHD4 responded in every cell line, the levels of increase 
vary significantly per cell line. Nutlin-3 treatment of both cutaneous melanoma lines 
resulted in a strong decrease of mRNA levels of genes downregulated upon MDMX 
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Figure 2. Verification of MDMX target genes. A) Relative Expression of MAD2L1, KIF23, p21 and 
PTCHD4 genes after 48 hours of doxycycline treatment of indicated cell lines. MAD2L1 and KIF23 
are downregulated and p21 and PTCHD4 are upregulated upon MDMX knockdown. Significant 
differences in expression between doxycycline treated ish-Control cells and ish-MDMX cells is 
indicated with an asterisk (*). B) Analysis of protein expression after 48 hours doxycycline treat-
ment shows a consistent repression of MAD2L1 level and an increase in p53, FOXO1, p21 and 
PUMA levels upon MDMX depletion. C) Pull-down of MDMX shows that both p53 and FOXO1 
interact with MDMX. By inhibiting the proteasome, using MG132, this interaction is stabilized. 
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Figure 2. Verification of MDMX target genes. D) Relative mRNA expression of MDMX target 
genes in MEL202 cells upon 24 hour incubation with 4 µM Nutlin-3. Significant differences in 
gene expression between vehicle and Nutlin-3 are indicted with an asterisk (*). E) Relative mRNA 
expression of MDMX target genes upon MDMX depletion (48 hrs doxycycline, 10 ng/ml) in both 
MEL202 wild-type and MEL202 p53 knockout cells. Gene expression which was significantly up-
regulated upon MDMX depletion is indicated with an asterisk (*).
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depletion, except for HAS2; some transcriptional repression of HAS2 could only be 
found 06.24 (Supplementary Figure 3). Cutaneous melanoma cell line 94.07 has an 
inactivating mutation in p53, which indeed coincides with limited observed changes 
in the mRNA levels of the analysed genes upon Nutlin-3 treatment (Supplementary 
Figure 3). Together these results demonstrate that the p53 targets found upon MDMX 
knockdown are indeed bona fide p53 targets in melanoma in general.
As a second step to study the p53-dependency of the changes in the transcriptome 
upon MDMX depletion, we created MEL202 cells deficient of p53 using CRISPR/CAS9 
technology) [45, 46]. We selected two clones which fully lack any detectable p53 
protein as a consequence of an adenine insertion (after nucleotide position 143 of 
the coding sequence) resulting in the mutation of ASP48 to GLU and simultaneously 
introducing an alternative reading frame resulting in an early translation stop after 
amino acid position 50 (Supplementary Figure 4A and B). This lack of p53 protein 
renders the cells, as expected, resistant for Nutlin-3 induced growth arrest (Supple-
mentary Figure 4C). The p53 KO cells did not show any aberrations in their karyotype 
at chromosomal level compared with the parental cell line as determined by com-
bined binary ratio fluorescence in situ hybridization (COBRA FISH) (Supplementary 
Figure 4D). From these cells doxycycline-inducible shMDMX or -inducible shCtrl cell 
lines were generated. With the use of these cell lines we could clearly demonstrate 
that the increased expression of p21, PTCHD4 and CYFIP2 upon MDMX depletion is 
fully p53-dependent (Figure 2E). Interestingly, also the basal levels of these genes 
are largely p53-dependent, indicating that there is some basal p53 activity in these 
cells. Although both PIK3IP1 and MXD4 were found to be direct p53 targets genes 
according to our iRegulon analysis, upon MDMX depletion the expression of both 
genes was increased independently of p53 expression (Figure 2E). Although the 
MDMX depletion triggered induction of these genes is p53-independent, the Nutlin-3 
mediated increase of both MXD4 and PIK3IP1 expression occurred p53-dependent 
(Supplementary figure 5A), even though the basal levels of both PIK3IP1 and MXD4 
were not affected by p53 knockout. We again analysed 92.1 cells to confirm these 
data, albeit with shp53/mediated p53 depletion instead of knock out. Also in these 
cells the expression of p21, PTCHD4 and CYFIP2 was found to be p53-dependently 
upregulated upon MDMX depletion, but increased expression of PIK3IP1 and MXD4 
is p53-independent (Supplementary Figure 2A and B). IRegulon network analysis fur-
ther indicated the involvement of FOXOs in the transcriptional changes upon MDMX 
depletion. The previous mentioned upregulation of FOXO1 was indeed found to be 
p53-independent (supplementary figure 5B). These data show that not all upregu-
lated genes upon MDMX depletion are p53 target genes in these cell lines, possibly 
explaining the p53-independent growth stimulatory functions of MDMX.
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Similarly, we found that in both MEL202 and 92.1 cell lines the transcriptional repres-
sion of genes upon MDMX knockdown in many cases is partially, but not fully depen-
dent on p53 expression (Supplementary Figure 2A and Supplementary Figure 6).
MXD4 in uveal melanoma
To study the p53-independent functions of MDMX in greater detail we focussed on 
MXD4, which according to previous studies forms a transcription repressive complex 
with SIN3A. It has also previously been shown that SIN3A can interact with and protect 
p53 from MDM2 mediated ubiquitination and degradation [47, 48]. We hypothesized 
that upregulation of MXD4 upon MDMX depletion could function as a ‘rescue’ mecha-
nism for the tumor cell to counteract the p53 activation. We propose a model in which 
the increased MXD4 levels sequester a proportion of SIN3A and thereby partly liber-
ate p53 for MDM2-mediated ubiquitination resulting in its degradation. Supporting 
this model is our finding that MXD4 knockdown in MEL202 induced a p53-dependent 
growth arrest, indicating a p53 activating effect (Figure 3A and B). This suggestion is 
strengthened by the observation that the p53 target gene p21 is upregulated in MXD4 
knockdown cells. Similarly, the p53 repressed genes MAD2L1 and KIF23 are slightly 
downregulated in MXD4 knockdown cells (Figure 3A). Interestingly, these effects on 
p53 target genes could be further enhanced by MDMX knockdown. As expected, 
these enhanced transcriptional effects correlated with a stronger growth reduction in 
a long term cell proliferation assay (Figure 3C).
To investigate whether MXD4 knockdown also boosts other p53 stabilizing and/or 
activating approaches, cells were treated with a low dose of Nutlin-3 (MDM2/X inhibi-
tor), doxorubicin (topoisomerase 2 inhibitor) or XI-011 (inducer of MDMX depletion). 
In a three day cell viability assay neither MXD4 knockdown nor drug treatments had 
a strong effect on cell survival. However, the combination of MXD4 knockdown with 
either Nutlin-3, doxorubicin or XI-011 showed a synergistic reduction in cell survival 
(Figure 4A). These effects mostly correlate with an enhanced cell cycle arrest upon 
doxorubicin or XI-011 treatment (G1 and G2/M, respectively) (Figure 4B and C). Nei-
ther MXD4 knockdown nor the low concentration drug treatment affected MDMX lev-
els, but did slightly increase p53 levels (Figure 4B). In accordance with the enhanced 
biological effects, the MXD4 knockdown increases the induction of PUMA by Nutlin-3 
and XI-011, and the p21 induction by doxorubicin and XI-011 treatment. Likewise, 
MAD2L1 repression seems to be slightly more prominent in the MXD4 knockdown 
cells.
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Figure 3. MXD4 knockdown activates p53, inhibits cell growth and enhances effect of MDMX 
knockdown in MEL202 cells. Relative mRNA expression of MXD4, p21, MAD2L1, PIK3IP1 and 
KIF23 upon MDMX knockdown in sh-Control and sh-MXD4 cells. Asterisk (*) indicates significant 
differences between vehicle and doxycycline treated cell line. Significant differences in normal-
ized expression between sh-Control and shMXD4 targeting constructs in cells expressing ish-
Control are indicated with a hashtag (#). B) Quantification of long term growth assay of MEL202 
MXD4 knockdown cells in p53 wildtype and p53 knockout cells and C) MEL202 cells with either 
MXD4, MDMX or combined knockdown. Significant differences in absorbance between Control 
and sh-MXD4 (B) and between vehicle and doxycycline treated (C) is indicated with an asterisk (*).
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Our studies presented here make it evident that MDMX is affecting the transcription 
of genes which are implicated in cell cycle regulation and apoptosis. Further analysis 
of the downregulated MDMX target genes indicate that E2F4- and SIN3A-mediated 
transcription repression is involved. To discriminate whether SIN3A or E2F4 is essential 
for the repression of these target genes will be essentially impossible. First, because it 
has been shown that in SIN3A knock out cells E2F target genes are regulated [49] and, 
secondly, because previous studies actually showed that SIN3A forms a repressive 
complex with E2F4 [50, 51]. Most likely a large repressive complex is formed, contain-
ing multiple transcription repressive factors like HDACs, to ensure proper target gene 
repression.
Based on large meta-analysis performed by Fisher and colleagues our results suggest 
that depletion of MDMX liberates p53, resulting in increased levels of p21 protein, 
which in turn leads to the activation of the DP, RB-like, E2F4 and Muvb (DREAM) com-
plex, resulting in the repression of target genes [52-54]. Of the 210 essential regula-
tors of G2 phase and mitosis assigned to be regulated by the p53-p21-DREAM axis 
[53], we identify 23 genes down regulated upon MDMX depletion. The identification 
of the p53-p21-E2F4/SIN3A axis for 87% of the repressed genes seems to indicate that 
MDMX controls the transcriptional activity of p53 to control cell cycle progression. 
However, MDMX clearly has (wt)-p53 independent oncogenic functions [37, 39-41]. 
Such a p53-independent biological function could correlate with our observation that 
in distinct cell lines the repression of target genes upon MDMX depletion is not fully 
p53 dependent. It suggests that MDMX depletion is triggering E2F4/SIN3A-mediated 
target gene repression that is in part independent of p53.
The list of upregulated genes upon MDMX knockdown contains 66 genes that are 
potentially regulated directly by p53 of which multiple genes are among the most 
commonly found p53 activated genes, namely CDKN1A, zinc finger matrin-type 3 
(ZMAT3), tumor protein p53 inducible nuclear protein 1 (TP53INP1), tetraspanin 11 
(TSPAN11), ectodysplasin a2 receptor (EDA2R) and CYFIP2 [42], indicating that p53 
transactivation is repressed by MDMX in our uveal melanoma cells as expected. 
Surprisingly, although the regulation of most verified genes identified as p53 targets 
upon MDMX depletion is highly dependent on p53 expression, the regulation of at 
least PIK3IP1 and MXD4 is not. Both genes were identified as p53-responsive genes in 
previous studies, but since a clear p53 DNA binding near the promoter region could 
not be found they were not assigned as true p53 target gene status [52]. Also in our 
hands the responsiveness of these genes to p53 activation upon Nutlin-3 treatment 
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Figure 4. MXD4 knockdown sensiti zes cells for p53 acti vati on. A) Relati ve survival of MEL202 sh-
Ctrl and shMXD4 cells treated for 72 hrs with 0.5 µM Nutlin-3 (N), 12.5 nM Doxorubicin (D), 125 nM 
XI-011 (X) or vehicle (V). Numbers indicate the Excess over Bliss scores of the combinati on treated 
samples. An asterisk (*) indicates signifi cant diff erences in relati ve survival comparing the combi-
nati on treatment with both single treatments. Scores above 2.0 indicate synergism. B) Protein ex-
pression analysis of the cells treated as menti oned in A. While MDMX and p53 protein levels hardly 
change upon combinati on treatments compared to single treatment, levels of downstream p53 
targets p21, PUMA and to a lesser extent MAD2L1 show a stronger response in the combinati on 
treated samples. Vinculine expression was assessed to show equal loading. C) Cell cycle profi les 
of cells treated as indicated at A. Doxorubicin-treated cells show an enhanced S-phase depleti on 
when combined with MXD4 knockdown, while the profi les of the combined MXD4 knockdown + 
Nutlin-3 treated samples show intermediate phenotype compared to single treatments. Cells with 
combined MXD4 knockdown and XI-011 showed a clearly enhanced G2/M arrest.
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is very weak. Interestingly, both PIK3IP1 and MXD4 contain, like 65% of all the up-
regulated genes upon MDMX depletion, FOX transcription factor DNA binding sites. 
PIK3IP1 has been demonstrated to be a direct FOXO3 target [55]. We could verify that 
FOXO1 is stabilized upon MDMX depletion in a p53-independent manner. It could be 
hypothesized that MDMX, by the demonstrated binding of FOXO1, inhibits FOXO1 
explaining, at least partly, the p53-independent oncogenic functions of MDMX.
The MXD4 (MAD4) protein has been described as an antagonist for c-MYC by compet-
ing with c-MYC for MAX dimerization [56-58]. Possibly relevant for our story is the 
observation that MXD4 is not only a c-MYC antagonist, but it can also form a tran-
scriptional repressor complex with SIN3A [59]. SIN3A has also been reported to bind 
p53 and thereby protect it from MDM2-mediated ubiquitination and degradation [47, 
48]. Since the reduced proliferation upon MXD4 knockdown is p53-dependent, we 
hypothesize that MXD4 can repress p53 activity by binding SIN3A, allowing enhanced 
MDM2-mediated degradation of p53. Indeed we observed a small increase in p53 
protein level upon MXD4 knockdown, suggesting that MXD4 is involved in p53 stabil-
ity. In addition, various p53 stabilizing and activating strategies could be enhanced 
upon MXD4 knockdown, i.e. upon MDMX depletion, MDM2/X inhibition via Nutlin-3, 
and treatment of the cells with doxorubicin or XI-011.
In conclusion, our data presented here suggest the existence a novel back-up loop 
in which a FOX transcription factor is released or activated upon MDMX depletion 
resulting in increased MXD4 expression. Subsequently, MXD4 competes with p53 for 
SIN3A binding, sensitizing p53 for MDM2-mediated degradation thereby blunting the 
p53 tumor suppressor response. Implicating that MXD4 is a potential novel target to 
boost current p53 activating strategies.
Acknowledgements
The authors like to acknowledge Prof S. van de Burg and Dr. E. Verdegaal for the kind 
donation of cell lines 94.07 04.01, 04.04 and 06.24. The authors like to acknowledge 
Dr. M. Goncalves for his assistance and the kind donation of the adenoviral expression 
vectors used during the establishment of p53 knockout cells.
52
MDMX regulates transcriptional activity of p53 and FOXO
References
 1. Bieging KT, Mello SS, Attardi LD. Unravelling mechanisms of p53-mediated tumour suppression. Nat 
Rev Cancer. 2014; 14: 359-70. doi: 10.1038/nrc3711.
 2. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol 
Cell Biol. 2008; 9: 402-12. doi: 10.1038/nrm2395.
 3. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by 
absence of p53. Nature. 1995; 378: 206-8. doi: 10.1038/378206a0.
 4. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient 
mice by deletion of p53. Nature. 1995; 378: 203-6. doi: 10.1038/378203a0.
 5. Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, 
Marine JC, Prives C, Shiloh Y, Jochemsen AG, et al. DNA damage-induced phosphorylation of MdmX at 
serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol Cell Biol. 2005; 
25: 9608-20. doi: 10.1128/MCB.25.21.9608-9620.2005.
 6. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, 
Sands AT, Zhang N. mdmx is a negative regulator of p53 activity in vivo. Cancer Res. 2002; 62: 3221-5. 
doi:
 7. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. Rescue of embryonic 
lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regu-
late p53. Nat Genet. 2001; 29: 92-5. doi: 10.1038/ng714.
 8. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC. Mdm4 
and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad 
Sci U S A. 2006; 103: 3232-7. doi: 10.1073/pnas.0508476103.
 9. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. Keeping p53 in check: essential 
and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 2006; 13: 927-34. doi: 10.1038/
sj.cdd.4401912.
 10. Valentin-Vega YA, Okano H, Lozano G. The intestinal epithelium compensates for p53-mediated 
cell death and guarantees organismal survival. Cell Death Differ. 2008; 15: 1772-81. doi: 10.1038/
cdd.2008.109.
 11. Valentin-Vega YA, Box N, Terzian T, Lozano G. Mdm4 loss in the intestinal epithelium leads to compart-
mentalized cell death but no tissue abnormalities. Differentiation. 2009; 77: 442-9. doi: 10.1016/j.
diff.2009.03.001.
 12. Grier JD, Xiong S, Elizondo-Fraire AC, Parant JM, Lozano G. Tissue-specific differences of p53 inhibition 
by Mdm2 and Mdm4. Mol Cell Biol. 2006; 26: 192-8. doi: 10.1128/MCB.26.1.192-198.2006.
 13. Ringshausen I, O’Shea CC, Finch AJ, Swigart LB, Evan GI. Mdm2 is critically and continuously required 
to suppress lethal p53 activity in vivo. Cancer Cell. 2006; 10: 501-14. doi: 10.1016/j.ccr.2006.10.010.
 14. Moyer SM, Larsson CA, Lozano G. Mdm proteins: critical regulators of embry ogenesis and homeosta-
sis. J Mol Cell Biol. 2017. doi: 10.1093/jmcb/mjx004.
 15. Barak Y, Oren M. Enhanced binding of a 95 kDa protein to p53 in cells undergoing p53-mediated 
growth arrest. EMBO J. 1992; 11: 2115-21. doi:
 16. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a com-
plex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992; 69: 1237-45. doi:
 17. Kawai H, Wiederschain D, Yuan ZM. Critical contribution of the MDM2 acidic domain to p53 ubiqui-
tination. Mol Cell Biol. 2003; 23: 4939-47. doi:
 18. Meulmeester E, Frenk R, Stad R, de Graaf P, Marine JC, Vousden KH, Jochemsen AG. Critical role for a 
central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol. 2003; 23: 4929-38. doi:
53





 19. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van 
Oordt W, Hateboer G, van der Eb AJ, Jochemsen AG. MDMX: a novel p53-binding protein with some 
functional properties of MDM2. EMBO J. 1996; 15: 5349-57. doi:
 20. Marine JC, Jochemsen AG. Mdmx and Mdm2: brothers in arms? Cell Cycle. 2004; 3: 900-4. doi:
 21. Bottger V, Bottger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, Jochemsen AG, Lane DP. Compara-
tive study of the p53-mdm2 and p53-MDMX interfaces. Oncogene. 1999; 18: 189-99. doi: 10.1038/
sj.onc.1202281.
 22. Sharp DA, Kratowicz SA, Sank MJ, George DL. Stabilization of the MDM2 oncoprotein by interaction 
with the structurally related MDMX protein. J Biol Chem. 1999; 274: 38189-96. doi:
 23. Gu J, Kawai H, Nie L, Kitao H, Wiederschain D, Jochemsen AG, Parant J, Lozano G, Yuan ZM. Mutual 
dependence of MDM2 and MDMX in their functional inactivation of p53. J Biol Chem. 2002; 277: 
19251-4. doi: 10.1074/jbc.C200150200.
 24. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. HdmX stimulates Hdm2-mediated 
ubiquitination and degradation of p53. Proc Natl Acad Sci U S A. 2003; 100: 12009-14. doi: 10.1073/
pnas.2030930100.
 25. Pereg Y, Shkedy D, de Graaf P, Meulmeester E, Edelson-Averbukh M, Salek M, Biton S, Teunisse AF, 
Lehmann WD, Jochemsen AG, Shiloh Y. Phosphorylation of Hdmx mediates its Hdm2- and ATM-
dependent degradation in response to DNA damage. Proc Natl Acad Sci U S A. 2005; 102: 5056-61. 
doi: 10.1073/pnas.0408595102.
 26. Stommel JM, Wahl GM. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is 
required for p53 activation. EMBO J. 2004; 23: 1547-56. doi: 10.1038/sj.emboj.7600145.
 27. Phillips A, Teunisse A, Lam S, Lodder K, Darley M, Emaduddin M, Wolf A, Richter J, de Lange J, Verlaan-
de Vries M, Lenos K, Bohnke A, Bartel F, et al. HDMX-L is expressed from a functional p53-responsive 
promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to 
control p53 activity. J Biol Chem. 2010; 285: 29111-27. doi: 10.1074/jbc.M110.129726.
 28. Pigolotti S, Krishna S, Jensen MH. Oscillation patterns in negative feedback loops. Proc Natl Acad Sci U 
S A. 2007; 104: 6533-7. doi: 10.1073/pnas.0610759104.
 29. Hollstein M, Hergenhahn M, Yang Q, Bartsch H, Wang ZQ, Hainaut P. New approaches to understand-
ing p53 gene tumor mutation spectra. Mutat Res. 1999; 431: 199-209. doi:
 30. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 
2000; 77: 81-137. doi:
 31. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408: 307-10. doi: 
10.1038/35042675.
 32. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, 
Cerami E, Sander C, Schultz N. Integrative analysis of complex cancer genomics and clinical profiles 
using the cBioPortal. Sci Signal. 2013; 6: pl1. doi: 10.1126/scisignal.2004088.
 33. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein 
C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. 
Science. 2004; 303: 844-8. doi: 10.1126/science.1092472.
 34. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007; 13: 23-31. doi: 10.1016/j.
molmed.2006.11.002.
 35. de Lange J, Ly LV, Lodder K, Verlaan-de Vries M, Teunisse AF, Jager MJ, Jochemsen AG. Synergistic 
growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma. 
Oncogene. 2012; 31: 1105-16. doi: 10.1038/onc.2011.309.
54
MDMX regulates transcriptional activity of p53 and FOXO
 36. Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, 
Radaelli E, Al-Haddawi M, Tan SY, et al. Antisense oligonucleotide-mediated MDM4 exon 6 skipping 
impairs tumor growth. J Clin Invest. 2016; 126: 68-84. doi: 10.1172/JCI82534.
 37. Gembarska A, Luciani F, Fedele C, Russell EA, Dewaele M, Villar S, Zwolinska A, Haupt S, de Lange J, Yip 
D, Goydos J, Haigh JJ, Haupt Y, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat 
Med. 2012; 18: 1239-47. doi: 10.1038/nm.2863.
 38. Haupt S, Buckley D, Pang JM, Panimaya J, Paul PJ, Gamell C, Takano EA, Lee YY, Hiddingh S, Rogers TM, 
Teunisse AF, Herold MJ, Marine JC, et al. Targeting Mdmx to treat breast cancers with wild-type p53. 
Cell Death Dis. 2015; 6: e1821. doi: 10.1038/cddis.2015.173.
 39. de Lange J, Teunisse AF, Vries MV, Lodder K, Lam S, Luyten GP, Bernal F, Jager MJ, Jochemsen AG. 
High levels of Hdmx promote cell growth in a subset of uveal melanomas. Am J Cancer Res. 2012; 2: 
492-507. doi:
 40. Jeffreena Miranda P, Buckley D, Raghu D, Pang JB, Takano EA, Vijayakumaran R, Teunisse AF, Posner A, 
Procter T, Herold MJ, Gamell C, Marine JC, Fox SB, et al. MDM4 is a rational target for treating breast 
cancers with mutant p53. J Pathol. 2017. doi: 10.1002/path.4877.
 41. Carrillo AM, Bouska A, Arrate MP, Eischen CM. Mdmx promotes genomic instability independent of 
p53 and Mdm2. Oncogene. 2015; 34: 846-56. doi: 10.1038/onc.2014.27.
 42. Fischer M. Census and evaluation of p53 target genes. Oncogene. 2017; 36: 3943-56. doi: 10.1038/
onc.2016.502.
 43. Jochemsen AG. Reactivation of p53 as therapeutic intervention for malignant melanoma. Curr Opin 
Oncol. 2014; 26: 114-9. doi: 10.1097/CCO.0000000000000033.
 44. Janky R, Verfaillie A, Imrichova H, Van de Sande B, Standaert L, Christiaens V, Hulselmans G, Herten 
K, Naval Sanchez M, Potier D, Svetlichnyy D, Kalender Atak Z, Fiers M, et al. iRegulon: from a gene list 
to a gene regulatory network using large motif and track collections. PLoS Comput Biol. 2014; 10: 
e1003731. doi: 10.1371/journal.pcbi.1003731.
 45. Maggio I, Stefanucci L, Janssen JM, Liu J, Chen X, Mouly V, Goncalves MA. Selection-free gene repair 
after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD 
muscle cell populations. Nucleic Acids Res. 2016; 44: 1449-70. doi: 10.1093/nar/gkv1540.
 46. Holkers M, Maggio I, Henriques SF, Janssen JM, Cathomen T, Goncalves MA. Adenoviral vector DNA for 
accurate genome editing with engineered nucleases. Nat Methods. 2014; 11: 1051-7. doi: 10.1038/
nmeth.3075.
 47. Murphy M, Ahn J, Walker KK, Hoffman WH, Evans RM, Levine AJ, George DL. Transcriptional repres-
sion by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 
1999; 13: 2490-501. doi:
 48. Zilfou JT, Hoffman WH, Sank M, George DL, Murphy M. The corepressor mSin3a interacts with the 
proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol Cell Biol. 
2001; 21: 3974-85. doi: 10.1128/MCB.21.12.3974-3985.2001.
 49. McDonel P, Demmers J, Tan DW, Watt F, Hendrich BD. Sin3a is essential for the genome integrity and 
viability of pluripotent cells. Dev Biol. 2012; 363: 62-73. doi: 10.1016/j.ydbio.2011.12.019.
 50. Dannenberg JH, David G, Zhong S, van der Torre J, Wong WH, Depinho RA. mSin3A corepressor regu-
lates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes 
Dev. 2005; 19: 1581-95. doi: 10.1101/gad.1286905.
 51. Li H, Collado M, Villasante A, Matheu A, Lynch CJ, Canamero M, Rizzoti K, Carneiro C, Martinez G, 
Vidal A, Lovell-Badge R, Serrano M. p27(Kip1) directly represses Sox2 during embryonic stem cell 
differentiation. Cell Stem Cell. 2012; 11: 845-52. doi: 10.1016/j.stem.2012.09.014.
55





 52. Fischer M, Grossmann P, Padi M, DeCaprio JA. Integration of TP53, DREAM, MMB-FOXM1 and RB-E2F 
target gene analyses identifies cell cycle gene regulatory networks. Nucleic Acids Res. 2016; 44: 6070-
86. doi: 10.1093/nar/gkw523.
 53. Fischer M, Quaas M, Steiner L, Engeland K. The p53-p21-DREAM-CDE/CHR pathway regulates G2/M 
cell cycle genes. Nucleic Acids Res. 2016; 44: 164-74. doi: 10.1093/nar/gkv927.
 54. Fischer M, Steiner L, Engeland K. The transcription factor p53: not a repressor, solely an activator. Cell 
Cycle. 2014; 13: 3037-58. doi: 10.4161/15384101.2014.949083.
 55. Schmidt-Strassburger U, Schips TG, Maier HJ, Kloiber K, Mannella F, Braunstein KE, Holzmann K, Ush-
morov A, Liebau S, Boeckers TM, Wirth T. Expression of constitutively active FoxO3 in murine forebrain 
leads to a loss of neural progenitors. FASEB J. 2012; 26: 4990-5001. doi: 10.1096/fj.12-208587.
 56. Grinberg AV, Hu CD, Kerppola TK. Visualization of Myc/Max/Mad family dimers and the competition 
for dimerization in living cells. Mol Cell Biol. 2004; 24: 4294-308. doi:
 57. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN. 
Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent 
transformation and are expressed during neural and epidermal differentiation. EMBO J. 1996; 15: 
2030. doi:
 58. Rottmann S, Luscher B. The Mad side of the Max network: antagonizing the function of Myc and more. 
Curr Top Microbiol Immunol. 2006; 302: 63-122. doi:
 59. Yang W, Yang X, David G, Dorsey JF. Dissecting the complex regulation of Mad4 in glioblastoma multi-
forme cells. Cancer Biol Ther. 2012; 13: 1339-48. doi: 10.4161/cbt.21814.
 60. Chen PW, Murray TG, Uno T, Salgaller ML, Reddy R, Ksander BR. Expression of MAGE genes in ocular 
melanoma during progression from primary to metastatic disease. Clin Exp Metastasis. 1997; 15: 509-
18. doi:
 61. De Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, Danen EH, Jager 
MJ. Establishment and characterization of an uveal-melanoma cell line. Int J Cancer. 1995; 62: 155-61. 
doi:
 62. Amirouchene-Angelozzi N, Frisch-Dit-Leitz E, Carita G, Dahmani A, Raymondie C, Liot G, Gentien D, 
Nemati F, Decaudin D, Roman-Roman S, Schoumacher M. The mTOR inhibitor Everolimus synergizes 
with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma. Oncotarget. 
2016; 7: 23633-46. doi: 10.18632/oncotarget.8054.
 63. Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Inducible and reversible gene silencing by stable 
integration of an shRNA-encoding lentivirus in transgenic rats. Proc Natl Acad Sci U S A. 2008; 105: 
18507-12. doi: 10.1073/pnas.0806213105.
 64. Carlotti F, Bazuine M, Kekarainen T, Seppen J, Pognonec P, Maassen JA, Hoeben RC. Lentiviral vectors 
efficiently transduce quiescent mature 3T3-L1 adipocytes. Mol Ther. 2004; 9: 209-17. doi: 10.1016/j.
ymthe.2003.11.021.
 65. Chen X, Rinsma M, Janssen JM, Liu J, Maggio I, Goncalves MA. Probing the impact of chromatin con-
formation on genome editing tools. Nucleic Acids Res. 2016; 44: 6482-92. doi: 10.1093/nar/gkw524.
 66. Szuhai K, Bezrookove V, Wiegant J, Vrolijk J, Dirks RW, Rosenberg C, Raap AK, Tanke HJ. Simultaneous 
molecular karyotyping and mapping of viral DNA integration sites by 25-color COBRA-FISH. Genes 
Chromosomes Cancer. 2000; 28: 92-7. doi:
 67. Szuhai K, Tanke HJ. COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluo-
rescence in situ hybridization karyotyping. Nat Protoc. 2006; 1: 264-75. doi: 10.1038/nprot.2006.41.
 68. Hof PV, Arindrarto W, Bollen S, Kielbasa S, Laros J, Mei H. (2017). BIOPET: Towards Scalable, Maintain-
able, User-Friendly, Robust and Flexible NGS Data Analysis Pipelines. 2017 17th IEEE/ACM Interna-
tional Symposium on Cluster, Cloud and Grid Computing (CCGRID), pp. 823-9.
56
MDMX regulates transcriptional activity of p53 and FOXO
Methods
Cell culture and viability assays
The UM cell lines MEL202 [60] and 92.1 [61] were cultured in a mixture of RPMI and 
DMEM-F12 (1:1 ratio), supplemented with 10% fetal calf serum (FCS) and antibiotics. 
Cutaneous melanoma lines 94.07 04.01, 04.04 and 06.24 were cultured in DMEM 
medium, supplemented with 10% FCS and antibiotics.
For short term growth assay the cells were seeded in triplicate, in 96-well format and 
incubated for 3 days with drugs as indicated. Cell survival was determined via the 
Cell Titre-Blue Cell Viability assay (Promega, Fitchburg, WI, USA); fluorescence was 
measured in a microplate reader (Victor, Perkin Elmer, San Jose, CA, USA). Excess over 
Bliss values were calculated to determine the synergism between two conditions as 
described by Amirouchene-Angelozzi N et al.[62].
For colony assays the cells were seeded in triplicate in 12-well plates and were 
incubated for 8 days. Cells were fixed for 5 minutes in 4% paraformaldehyde. DNA 
was stained using 30-minute incubation with 0.05% crystal violet. After washing and 
drying the relative number of cells was quantified by solubilizing the crystal violet in 
methanol and measuring absorbance at 545nM using a microplate reader (Victor3, 
Perkin Elmer).
Manipulation of cell lines
1. Establishment of inducible MDMX knockdown cell lines
Inducible shRNA knockdown lentiviral vectors were constructed as described previ-
ously [38, 63]. Production of lentivirus stocks by transfections into HEK293T cells 
essentially as described, but calcium phosphate was replaced with PEI [64]. Virus was 
quantitated by antigen capture ELISA measuring HIV p24 levels (ZeptoMetrix Corp., 
New York, NY, USA). Cells were transduced using MOI 2 in medium containing 8 μg/
ml polybrene. Target sequences of shRNA constructs to deplete MDMX are: #1: 5’- 
GTGCAGAGGAAAGTTCCAC, #2: 5’- GAATCTCTTGAAGCCATGT, #3: 5’- CAGTCCTTCAGC-
TATTTCAT and #4: 5’- AGTCAAGACCAACTGAAGC. As a control shRNA the construct 
targeting 5’-GAATCTTGTTACATCAGCT was used.
2. Generation of p53 knockout MEL202-derived cells
MEL202 cells were transduced with puromycin-selectable lentiviral guideRNA expres-
sion construct (AA19_pLKO.1-puro.U6.sgRNA.Bvel-stuffer) [65], with targets the 
sequence: 5’-CCATTGTTCAATATCGTCCG-3’ in exon 4 of the p53 gene. After selection 
on puromycin, Cas9 was temporarily expressed upon transduction with adenoviral 
57





Cas9 expression construct (AdVD2P.Cas9.F50 [45]) or a control EGFP encoding adenovi-
ral vector (20 IUs/cell). The EGFP-encoding adenoviral vector used differs from AdV.
Δ2.donorS1/T-TS [46] in that it has FRT sites flanking an expression cassette consisting 
of the human PGK1 gene promoter, the EGFP ORF and the bovine growth hormone 
polyadenylation signal. Cells were selected for p53 inactivity by continuous presence 
of 4 µM of Nutlin-3 (Cayman Chemical, Ann Arbor, MI, USA) after which single cell 
derived clones were established and p53 protein expression was analyzed. To deter-
mine the exact mutation genomic DNA of these clones was isolated which was used 
as a template for PCR (Fw primer: GAGACCTGTGGGAAGCGAAA and Rv-primer: GCT-
GCCCTGGTAGGTTTTCT), followed by Sanger sequencing using the forward primer. To 
investigate chromosomal abnormalities upon CRISPR/Cas9-mediated p53 knockout, 
karyotyping of the cell lines was performed by COBRA-FISH as described earlier [66, 
67].
RNA sequencing
MEL202 cells with 4 MDMX targeting doxycycline inducible shRNA constructs and 1 
control shRNA construct were treated for 48 hours with 10 ng/ml doxycycline; the 
cell line containing the control shRNA construct was also mock treated to investigate 
doxycycline induced effects.
RNA was isolated from three independent biological replicates. RNA was isolated us-
ing miRNeasy (Qiagen, Hilden, Germany) and treated with DNAse (Qiagen) according 
to manufactures protocol. The quality of the samples was determined using a Bioana-
lyzer 6000 nanochip (Agilent), followed by ribosomalRNA depletion using Ribo-Zero 
(Epicentre, Madison, WI, USA) after which the libraries were constructed as described 
by the NEBNext Ultra Directional RNA Library Prep Kit for Illumina (NEB E7420S). 
Samples were pooled and sequenced on the HiSeq2500, run type paired-end 2x50bp 
+ dual index on v4 reagents and flowcells. Read counts were extracted from the BAM 
files with FeatureCounts (version 1.5.3).
All RNAseq files were processed using the BIOPET Gentrap pipeline version 0.7 de-
veloped at the LUMC [68]. This pipeline performs FASTQ pre-processing (including 
quality control, quality trimming and adapter clipping), RNAseq alignment, read and 
base quantification, and optionally transcript assembly. In this project, FastQC ver-
sion 0.11.2 was used for checking raw read QC. Low quality read trimming was done 
using Sickle version 1.33 with default settings. Adapter clipping was performed using 
Cutadapt version 1.9.1 with default settings. The RNAseq reads alignment was per-
formed using GSNAP version 2014-12-23 with setting “--npaths 1 --quiet-if-excessive”. 
The reference genome used was GRCh38 without the alternative contigs. The gene 
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read quantification was performed using HTSeq-count version 0.6.1p1 with setting 
“--stranded=reverse”. The gene annotations used for quantification were GENCODE 
version 23.
For statistical analysis of the read counts R (version 3.4.2) was used. Read counts 
were normalized using quantile normalization in the DeSeq package (Version 1.16.1). 
Differential expression analysis was performed with DeSeq. Gene regulatory network 
analysis was performed using iRegulon (44). Enriched biological processes (GO) were 
determined using String-DB version 10.5.
RNA isolation, cDNA synthesis and real-time quantitative PCR
RNA was isolated using the SV total RNA isolation kit (Promega), after which the re-
verse transcriptase reaction mixture as indicated by Promega was used to synthesize 
cDNA. qPCR was performed using SYBR green mix (Roche Diagnostics, Indianapolis, 
IN, USA) in a C1000 touch Thermal Cycler (Bio-Rad laboratories, Hercules, CA, USA). 
Relative expression of target genes was determined in three independent experi-
ments compared to housekeeping genes CAPNS1 and SRPR. Per experiment the aver-
age relative expression was compared to the untreated set at 1. For primer sequences 
see supplementary table 4.
Western blot analysis
After incubation with drugs as indicated cells were harvested in Laemmli sample buf-
fer. SDS-PAGE was used to separate equal amounts of protein which were blotted 
onto polyvinylidene fluoride transfer membranes (Millipore, Darmstadt, Germany). 
Followed by blocking in TBST (10 mM Tris-HCl pH8.0, 150 mM NaCl, 0.2% Tween 20) 
containing 10% milk. Membranes were incubated with the proper primary antibodies: 
USP7 (A300-033A, Bethyl Laboratories, Montgomery, TX, USA), MDMX (8C6, Milli-
pore, Burlington, MA, USA), p53 (DO1, Santa Cruz Biotechnology, Dallas, TX, USA), p21 
(CP74, Millipore), PUMA (G3, Santa Cruz Biotechnology), MDM2 (SMP14, Santa Cruz 
Biotechnology; 3G9, Millipore), MAD2L1 (C2C3, Genetex, Irving, CA, USA) or Vinculin 
(hVIN-1/V9131, Sigma-Aldrich, St Louis, MO, USA)) and appropriate HRP-conjugated 
secondary antibodies (Jackson Laboratories, Bar Harbor, ME, USA). Chemolumines-
cence was used to visualize bands by exposure to X-ray film.
Flow cytometry
Cells were harvested for cell cycle analysis by trypsinization, washed twice in PBS and 
fixed in ice cold 70% ethanol. Following fixation, cells were washed in PBS contain-
ing 2% FCS and stained using PBS containing 2% FCS, 50 µg/ml RNAse and 50 µg/ml 
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propidium iodide (PI). Flow cytometry analysis was performed using the BD LSR II 
system (BD Biosciences, San Diego, CA, USA).
Immuno-precipitations
MEL202 cells, 80-90% confluent, were incubated with 10 µM MG132 for 5 hours to 
establish inhibition of the proteasome. Cells were washed twice with cold PBS and 
subsequently lyzed in a low salt containing Giordano buffer (50mM Tris-HCl pH7.4, 
150 mM NaCl, 0.1% Triton X-100 and 5 mM EDTA; supplemented with phosphatase- 
and protease inhibitors and 15% glycerol). 500 µg of lysate was incubated with 30 µl 
of 50% bead suspension of HDMX or control beads (Chromotek, Planegg-Martinsried, 
Germany) in a final volume of 800 µl, tumbling for 16 hours at 4°C. After this incuba-
tion flow-through was collected. Beads were washed 3 times in lysis buffer according 
to manufactures instructions. Samples were eluted in 40 µl Laemmli buffer, incubated 
at 98°C for 5 minutes. Samples were span through a 0.2 µm nylon centrifugal filter 
(VWR, Radnor, PA, USA) to remove beads, elution’s and flow-through (30 µl with 15 
µl 3x Laemmli buffer incubated for 5 minutes at 98°C)were separated using SDS-PAGE 
and analysed as described above (Western blot analysis). Primary antibodies used 
for protein detection were C29H4 (Cell Signaling technology, Danvers, MA, USA) for 
FOXO1, a mix of SMP14 (Santa Cruz Biotechnology) and 3G9 (Millipore) was used for 
MDM2, DO1 (Santa Cruz Biotechnology) for p53, flow-through MDMX was detected 
using 8C6 (Millipore) and pull-down MDMX using MDMX-BL (Bethyl Laboratories). 
USP7 (A300-033A, Bethyl Laboratories) was detected to ensure equal loading of the 
flow-through.
Statistical analysis
Student’s t-test was used to calculate the significance between two groups. P-values 
of 0.05 or less were considered to be significant.
60
MDMX regulates transcriptional activity of p53 and FOXO
Supplementary table 1. Upregulated genes upon MDMX knockdown
Gene ID Log2FoldChange iRegulon motive  
PTCHD4 1.92   
PIK3IP1 1.59 FOX  
CYFIP2 1.58 FOX p53
ACTA2 1.57   
CDKN1A 1.48 FOX p53
EDA2R 1.47 FOX  
MIR34A 1.45   
C10orf10 1.35 FOX  
BTG2 1.35   
TSPAN11 1.34 FOX p53
PTGER4 1.23 FOX p53
C10orf54 1.14 FOX p53
ZMAT3 1.13 FOX p53
MXD4 1.09 FOX p53
FAM212B 1.09   
COL16A1 1.08 FOX p53
CCDC18-AS1 1.07   
PLN 1.05 FOX  
FOXN3-AS1 1.05   
DDIT4 1.04 FOX p53
p53INP1 1.04 FOX  
TCP11L2 1.02 FOX p53
TXNIP 1.01 FOX  
MYO15B 1.00   
DENND2A 1.00 FOX  
PNRC1 0.99 FOX  
MIR100HG 0.98   
DHX58 0.98   
SORBS2 0.97 FOX p53
ADAM19 0.95 FOX  
ADAMTS6 0.95 FOX p53
COL24A1 0.95 FOX  
TAP1 0.95   
ERBB4 0.94 FOX  
YPEL2 0.94 FOX p53
FOXP2 0.94 FOX p53
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Supplementary table 1. Upregulated genes upon MDMX knockdown (continued)
Gene ID Log2FoldChange iRegulon motive  
GAPDHP33 0.93   
RPS27L 0.93 FOX p53
ARRDC3 0.93 FOX p53
CASP4 0.93   
EFNA1 0.93 FOX p53
AP1G2 0.92 FOX p53
IL1RAPL1 0.92 FOX  
p53TG1 0.92   
PDGFC 0.92 FOX  
RASGRF2 0.92 FOX  
FILIP1 0.91 FOX p53
FZD4 0.91 FOX p53
SULF2 0.90 FOX p53
TM7SF2 0.90   
SYTL2 0.90 FOX  
CFAP70 0.90   
L1CAM 0.89   
PHLDA3 0.89 FOX p53
CFI 0.89   
LINC00518 0.89   
PLSCR4 0.88 FOX  
CTSO 0.88 FOX  
PPP1R9A 0.87 FOX  
S100B 0.87   
FEZ1 0.87 FOX  
NINJ1 0.86 FOX p53
CDC42EP5 0.86 FOX p53
P2RX6 0.86   
BTBD19 0.86   
JMY 0.85 FOX  
WDR66 0.85   
ADAMTS10 0.85 FOX  
LTBP4 0.85 FOX  
EPAS1 0.85   
GMPR 0.85 FOX  
KCNIP4-IT1 0.84   
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Supplementary table 1. Upregulated genes upon MDMX knockdown (continued)
Gene ID Log2FoldChange iRegulon motive  
ITGB8 0.84 FOX  
KLHL30 0.84 FOX  
ALDH3B1 0.84 FOX p53
DNASE1L1 0.84   
DRAM1 0.84   
FDXR 0.84 FOX  
JUN 0.84 FOX  
SATB1 0.84 FOX p53
OPRL1 0.84 FOX  
DMD 0.83 FOX p53
LACC1 0.83   
ABCA9 0.83 FOX  
RPS6KA2 0.82 FOX  
FSIP2 0.82   
FN1 0.82   
ABCA1 0.82 FOX  
RIMS2 0.82 FOX p53
HSPB7 0.81 FOX  
C15orf52 0.81  p53
PLA2G4C 0.81   
PLK3 0.81 FOX  
MAML3 0.81 FOX p53
ZNF630 0.81   
SFRP4 0.80   
PRSS23 0.80 FOX p53
TSC22D1 0.80 FOX  
BBC3 0.80 FOX p53
SESN1 0.80 FOX p53
RND3 0.80 FOX  
MCF2L 0.80 FOX p53
PCDHGA12 0.80   
SATB1-AS1 0.79   
SEMA3B 0.79 FOX p53
ICAM5 0.79   
SLC4A3 0.78  p53
MDM2 0.78 FOX p53
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Supplementary table 1. Upregulated genes upon MDMX knockdown (continued)
Gene ID Log2FoldChange iRegulon motive  
March2 0.78   
ADAMTS13 0.78 FOX  
GADD45A 0.78 FOX p53
ARSG 0.78 FOX p53
C1RL 0.78   
PSMG3-AS1 0.78   
CALCOCO1 0.78   
KLF9 0.78 FOX  
ZNF610 0.77 FOX  
FAM214A 0.77   
KIF26B 0.77 FOX  
C1orf101 0.77 FOX  
LRRTM4 0.76 FOX  
ICA1 0.76 FOX p53
GPR155 0.76 FOX p53
RAB7B 0.76   
CUBN 0.76 FOX  
FHDC1 0.75 FOX p53
DDB2 0.75  p53
LINC00346 0.75   
DOCK8 0.75   
JAG1 0.75 FOX p53
ZRANB2-AS2 0.75   
SEMA6C 0.75 FOX p53
ZNF536 0.75 FOX  
FBXO32 0.75 FOX p53
FAM43A 0.75 FOX  
KLHL7-AS1 0.74   
ACER2 0.74  p53
ETFBKMT 0.74   
CD226 0.74 FOX p53
PCDHA9 0.74   
DCLK1 0.74 FOX  
VPS37D 0.74  p53
DOK6 0.74 FOX p53
EPHA2 0.74  p53
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Supplementary table 1. Upregulated genes upon MDMX knockdown (continued)
Gene ID Log2FoldChange iRegulon motive  
NPAS3 0.73 FOX  
RHOJ 0.73 FOX p53
LCA5L 0.73 FOX  
PBX1 0.73 FOX  
C1S 0.73   
CA8 0.73 FOX  
ITGAX 0.73   
PARD3B 0.73 FOX p53
PBXIP1 0.72 FOX  
CNTN1 0.72 FOX p53
NDRG1 0.72 FOX  
ASTN2 0.72 FOX p53
HTR2B 0.72 FOX p53
PLD1 0.72 FOX p53
LRRC37A3 0.72 FOX  
PLK2 0.72  p53
LAMA4 0.72 FOX  
PQLC3 0.72   
ITGA3 0.71 FOX p53
COL4A5 0.71 FOX  
GDPD1 0.71   
SV2B 0.71   
FAM227A 0.71   
C1orf116 0.71 FOX p53
RCAN2 0.71 FOX  
EHHADH 0.71 FOX p53
ZNF528 0.71   
FAP 0.71 FOX p53
CRIM1 0.71 FOX p53
LIMA1 0.70 FOX p53
IGFBP7 0.70 FOX p53
RRM2B 0.70 FOX p53
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Supplementary table 2. Downregulated genes upon MDMX knockdown
Gene ID Log2FoldChange iRegulon motive  
CEP128 -1.54   
LMNB1 -0.93 E2F4 SIN3A
KIF14 -0.93 E2F4 SIN3A
HLX -0.92 E2F4  
IDH1 -0.90 E2F4 SIN3A
DTL -0.88 E2F4 SIN3A
ANP32E -0.87 E2F4 SIN3A
KIF4B -0.87   
HAS2 -0.87 E2F4  
MTFR2 -0.87   
SCML1 -0.87 E2F4  
AURKB -0.86 E2F4 SIN3A
CENPI -0.85 E2F4 SIN3A
DCLRE1A -0.85 E2F4 SIN3A
MDM4 -0.83 E2F4  
CDC25A -0.83  SIN3A
AUNIP -0.82   
SKA3 -0.81 E2F4 SIN3A
SPAG5 -0.80  SIN3A
KIF23 -0.80  SIN3A
SUV39H1 -0.79 E2F4 SIN3A
CHAF1A -0.79 E2F4 SIN3A
ERCC6L -0.79 E2F4 SIN3A
BRCA1 -0.78 E2F4 SIN3A
MCM7 -0.78 E2F4 SIN3A
MAD2L1 -0.78  SIN3A
MCM10 -0.78 E2F4 SIN3A
NUF2 -0.77 E2F4 SIN3A
WDR62 -0.77 E2F4 SIN3A
NMRK2 -0.77   
PBK -0.77 E2F4 SIN3A
MCM3 -0.77  SIN3A
WDR76 -0.77 E2F4 SIN3A
SASS6 -0.76 E2F4 SIN3A
GSG2 -0.76  SIN3A
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Supplementary table 2. Downregulated genes upon MDMX knockdown (continued)
Gene ID Log2FoldChange iRegulon motive  
CHAF1B -0.76 E2F4  
ZNF114 -0.75   
CLSPN -0.75 E2F4 SIN3A
FKBP5 -0.75 E2F4 SIN3A
MCM4 -0.75 E2F4 SIN3A
SKA1 -0.75  SIN3A
SKA2 -0.75 E2F4 SIN3A
GTSE1 -0.75  SIN3A
DBF4 -0.74  SIN3A
SMC4 -0.74 E2F4 SIN3A
KIF4A -0.74 E2F4 SIN3A
SGO1 -0.73   
CCNB1 -0.73  SIN3A
RBM47 -0.73 E2F4 SIN3A
PSMC3IP -0.73 E2F4 SIN3A
HIST1H2AM -0.73 E2F4 SIN3A
PRR5L -0.72 E2F4 SIN3A
MIS18A -0.72   
E2F8 -0.72 E2F4 SIN3A
DEPDC1B -0.72 E2F4 SIN3A
ERI1 -0.72 E2F4 SIN3A
SLC43A3 -0.72 E2F4  
ATAD5 -0.71 E2F4 SIN3A
CDT1 -0.71 E2F4 SIN3A
MCM5 -0.71 E2F4 SIN3A
HIST1H1E -0.71 E2F4 SIN3A
SFXN1 -0.71 E2F4  
C1orf112 -0.71 E2F4 SIN3A
INCENP -0.71 E2F4 SIN3A
RACGAP1 -0.71 E2F4 SIN3A
TRAIP -0.71 E2F4 SIN3A
DBF4B -0.70  SIN3A
CEP72 -0.70   
GINS2 -0.70 E2F4  
ORC6 -0.70 E2F4 SIN3A
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Up-regulated genes top 5 GO biological processes
pathway ID pathway description




GO:0007155 cell adhesion 24 0.000647
GO:0010942 positive regulation of cell death 19 0.000647
GO:0043068
positive regulation of programmed cell 
death 18 0.000647
GO:0043065 positive regulation of apoptotic process 17 0.0023
GO:0042981 regulation of apoptotic process 27 0.0048
Down-regulated genes top 5 GO biological processes
pathway ID pathway description count in gene set false discovery rate
GO:0007049 cell cycle 44 2.24E-32
GO:0000278 mitotic cell cycle 36 5.08E-29
GO:1903047 mitotic cell cycle process 34 6.14E-28
GO:0022402 cell cycle process 37 2.68E-27
GO:0007067 mitotic nuclear division 22 1.77E-19
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CAPNS1 F ATGGTTTTGGCATTGACACATG 
CAPNS1 R GCTTGCCTGTGGTGTCGC 
SRPR F CATTGCTTTTGCACGTAACCAA 
SRPR R ATTGTCTTGCATGCGGCC 
69

















































































































































































Supplementary fi gure 1. Gene regulatory network of genes transcripti onally aff ected upon 
MDMX knockdown. A) Gene regulatory network of genes downregulated upon MDMX deple-
ti on identi fying the two major regulators E2F4 and SIN3A. B) Gene regulatory network of genes 
upregulated upon MDMX depleti on identi fying the two major regulators p53 and Forkhead box 
(FOX) transcripti on regulators.
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Supplementary figure 2. Transcriptional effects upon MDMX depletion in 92.1 cells. A) Relative 
mRNA expression of the downregulated genes EXO1 and KIF23, and the upregulated genes p21 
and PTCHD4 upon MDMX depletion in 92.1/shCtrl and 92.1/shp53 cells. B) Relative mRNA expres-
sion of PIK3IP1 and MXD4 in 92.1 cells under conditions described in A. Significant differences in 
expression between vehicle and doxycycline treated cells are indicated with an asterisk (*).
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Supplementary figure 3. Effects of Nutlin-3 treatment on expression of ‘MDMX target genes’ 
in uveal and cutaneous melanoma cell lines. Relative mRNA expression of CYFIP2, p21, PIK3IP1, 
PTCHD4, MXD4, EXO1, HAS2, KIF23, MAD2L1 and MCM10 upon 24 hours of Nutlin-3 treatment 
in uveal melanoma cell line 92.1 and cutaneous melanoma cell lines 04.01, 06.24 and 94.07. 
Differences in expression between vehicle and Nultin-3 treated cells found to be significant are 
indicated with an asterisk (*).
72



































M            N            N N







Supplementary figure 4. Generation of p53 knock-out MEL202 cells. A) Analysis of protein ex-
pression of MEL202 control cells and two distinct MEL202 p53 knockout cells treated for 24 hrs 
with DMSO (D) or 4 µM Nutlin-3 (N). The p53 protein levels increased in the GFP control cells 
upon Nutlin-3 treatment, but remained undetectable in the p53 knockout cells. MDMX levels 
showed minor differences between clones. MDM2 levels increased upon Nutlin-3 treatment in 
the p53 knockout cells but remained undetectable in the p53 KO cells. B) Sanger sequencing of 
control and p53 knockout clones. Shown are the guide RNA sequence and the insertion of one 
adenine, highlighted by the asterisk (*). C) Relative survival of MEL202 control- and MEL202 p53 
KO cells upon 4 µM Nutlin-3 treatment for 72 hrs. Significant differences in relative survival be-
tween vehicle and Nutlin-3 treatment are indicated with an asterisk (*). D) COBRA-FISH analysis 
of chromosomal content of MEL202 control - and two distinct p53 knockout clones.
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Supplementary figure 5. Effects of Nutlin-3 treatment on expression of ‘MDMX target genes’ in 
MEL202 control- and p53 knockout cells. A) Relative expression of EXO1, HAS2, KIF23, MAD2L1, 
MCM10, CYFIP2, p21, PTCHD4, PIK3IP1 and MXD4 in MEL202 control- and p53 knockout cells 
upon 24 hours of 4 µM Nutlin-3. Significant differences in expression between vehicle and Nut-
lin-3 treated cells are indicated with an asterisk (*). B) Protein expression analysis upon MDMX 
knockdown (48 hrs doxycycline, 10 ng/ml) in MEL202 control- and p53 knockout cells. The cells 
containing the distinct MDMX targeting shRNA constructs show a clear reduction of MDMX pro-
tein upon doxycycline treatment. MDMX depletion results in a slight increase of p53 and FOXO1 
protein levels. USP7 was analysed to show equal loading.
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Supplementary figure 6. Repressing of transcription upon MDMX depletion is partly p53-inde-
pendent. Relative mRNA expression of KIF23, MCM10 and EXO1 upon MDMX depletion (48 hour 
of 20 ng/ml doxycycline), in MEL202 control cells and MEL202 p53 knockout cells. Significant 





Targeting MDMX and PKCδ to improve current uveal 
melanoma therapeutic strategies
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Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, 
the Netherlands.
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Abstract
Uveal melanoma (UM) is the most frequent ocular cancer in adults, accounting for 
~5% of the total melanoma incidence. Although the primary tumour is well treatable, 
patients frequently develop metastases for which no curative therapy exists. Highly 
activated protein kinase C (PKC) is a common feature of UM and has shown potential 
as therapeutic intervention for UM patients. Unfortunately, PKC inhibition as single 
treatment appears to have only limited clinical benefit. Combining PKC inhibition with 
activation of p53, which is rarely mutated in UM, by MDM2 inhibitors has shown 
promising results in vitro and in vivo. However, clinical studies have shown strong ad-
verse effects of MDM2 inhibition. Therefore, we investigated alternative approaches 
to achieve similar anti-cancer effects, but with potentially less adverse effects.
We studied the potential of targeting MDMX, an essential p53 inhibitor during 
embryonal development but less universally expressed in adult tissues compared 
to MDM2. Therefore, targeting MDMX is predicted to have less adverse effects in 
patients. Depletion of MDMX, like the pharmacological activation of p53, inhibits the 
survival of UM cells, which is enhanced in combination with PKC inhibition.
Also pan-PKC inhibitors elicit adverse effects in patients. Since the PKC family consists 
of 10 different isoforms it could be hypothesized that targeting a single PKC isoform 
would have less adverse effects compared to a pan-PKC inhibitor. Here we show that 
specifically depleting PKCδ inhibits UM cell growth, which can be further enhanced 
by p53 reactivation.
In conclusion, our data show that the synergistic effects of p53-activation by MDM2 
inhibition and broad spectrum PKC inhibition on survival of UM cells can also largely 
be achieved by the presumably less toxic combination of depletion of MDMX and 
targeting a specific PKC isoform, PKCδ.
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Uveal melanoma (UM) is a collective name for a cancer arising from the melanocytes 
originating from the choroid (85%), iris (5%) or ciliary body (10%).[1] Primary tumors 
can be treated effectively, but approximately half of the patients develop metastasis 
within 15 years after primary tumor detection.[2, 3] Thus far no therapeutic interven-
tion has been successful in treating metastatic UM. Due to the lack of effective therapy 
the median survival of patients with metastasized UM therefore ranges between 3 
and 12 months.
UM is most frequently driven by activating mutations in the alpha subunits of G-
proteins GNAQ (50%) or GNA11 (43%).[4-6] As a result, these G-proteins are locked in 
a GTP-bound state, continuously activating a number of signaling pathways, including 
the MAPK pathway. The latter is achieved via an important downstream effector of 
GNAQ and GNA11, Phospholipase C-β (PLC-β), which hydrolyzes phosphatidylinositol 
4,5-bisphosphate (PIP2) to generate inositol 1,4,5-trisphosphate (IP3) and diacylglyc-
erol (DAG).[7] These are both second messengers activating various protein kinase 
C (PKC) isoforms, which in turn fuel the continuous activation of the MAPK pathway. 
These findings have spurred studies to investigate the potential of PKC and MEK in-
hibitors in treating UM patients. UM cells containing a GNAQ or GNA11 mutation are 
indeed dependent on MAPK signaling and were shown to be sensitive to both MEK 
and PKC inhibition.[8, 9] However, preclinical in vivo studies showed that both MEK 
and PKC inhibition is needed to completely abolish MAPK signaling and thereby tumor 
growth.[9] Confirming these pre-clinical studies, phase I clinical trials show promising 
results, but only modest clinical benefit, for both PKC and MEK inhibitors as single 
agents.[10] Based on the pre-clinical studies a phase II clinical trial was conducted to 
assess combined PKC and MEK inhibition. This phase II clinical trial was terminated 
premature due to strong adverse effects [11]. Based on the clinical activity of PKC 
inhibitor Sotrastaurin/AEB071, progression free survival of 15 weeks in half of the pa-
tients[10], has encouraged us and others to explore whether the effect of Sotrastau-
rin can be boosted by interfering with additional oncogenic or tumor suppressor 
pathways. New insights into UM has stimulated studies combing PKC inhibition with 
CDK inhibition or targeting the PI3K/mTOR pathway.[11] An alternative interesting 
approach could be the activation of p53, which is essentially never mutated in UM. 
We have previously shown that UM frequently overexpress the p53 inhibitors MDM2 
and/or MDMX.[12] Furthermore, we found that pharmacological activation of p53 or 
depletion of MDMX results in diminished UM cell growth and synergistically enhances 
DNA damage induced cell death.[13] Recently, it has been shown that the combina-
tion of an inhibitor of the MDM2-p53 interaction (CGM097[14]) with the broad PKC 
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inhibitor Sotrastaurin did not achieve synergistic inhibition of cell growth in vitro.
[11] Even so, in vivo 4 out of 5 PDX models showed a significant additive effect when 
AEB071 was combined with the MDM2 inhibitor CGM097.
In this study we re-activated p53 by Nutlin-3 treatment and demonstrate that the 
combination of Nutlin-3 with Sotrastaurin does synergistically inhibit UM cell 
growth in vitro. Our data suggest these synergistic effects are due to a switch from 
a p53-induced cell cycle arrest to a pro-apoptotic response in combination with PKC 
inhibition. Detailed genetic studies showed that depletion of MDMX from UM cells 
enhances the efficacy of pan-PKC inhibition and, vice versa, PKCδ depletion sensitizes 
UM cells for p53 activation. Our results indicate that specifically targeting MDMX or 
PKCδ are potential new avenues for effectively treating UM patients in combination 
with PKC-inhibitor(s) or p53 reactivation, respectively.
Results
Synergistic growth inhibition upon PKC inhibition and p53 reactivation
We first examined whether p53 reactivation (Nutlin-3) in combination with PKC inhibi-
tion (Sotrastaurin) synergistically inhibits the growth of UM cells (Figure 1). In cell 
lines MEL270, MEL202, MM66, OMM2.5, OMM2.3 and MM28 combining Sotrastau-
rin with Nutlin-3 resulted in synergistic growth inhibition. So far the OMM1 cell line 
is the only exception of all GNAQ/11 mutated cell lines tested in which Sotrastaurin 
does not significantly enhance the Nutlin-3 effect. As expected, and shown before [9], 
MEL290 cells, lacking a GNAQ/11 mutation, are not responsive to Sotrastaurin and 
the combination of Nutlin-3 and Sotrastaurin is even antagonistic.
Combined Nutlin-3 and Sotrastaurin treatment promotes apoptosis
To assess target engagement of Sotrastaurin in the GNAQ/11 mutated UM cell lines 
we determined the levels of phosphorylated PKCδ/θ and phosphorylated MARCKS 
(Figure 2). The levels of these phosphorylated proteins almost disappeared or were 
significantly reduced upon Sotrastaurin treatment, confirming inhibition of the PKC 
activity. In GNAQ/11 wild-type cell line MEL290 neither phosphorylated PKCδ/θ nor 
could phospho-MARCKS not be detected, as has previously been reported.[9] Effectiv-
ity of Sotrastaurin was further confirmed by the reduced mRNA levels of CDC25A, 
Survivin and Cyclin D1 in the treated cells (Supplementary Figure 1S), as has been 
reported before [8, 15]. Interestingly, in most cell lines Sotrastaurin also increased 
the levels of the pro-apoptotic protein PUMA. Treating cells with Nutlin-3 resulted 
in increased levels of p53 protein in all cell lines, with a concomitant increase in 
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expression of known target genes/proteins (e.g. p21, MDM2 and PUMA; Figure 2, 
Supplementary figure 1S). Furthermore, p53 reactivation repressed the expression of 
the pro-survival gene Survivin (Supplementary Figure 1S).
Combined Sotrastaurin/Nutlin-3 treatment slightly further increased the levels of 
the pro-apoptotic PUMA protein compared to single treatments while, in contrast, 
CDC25A and Survivin mRNA levels and p21 protein were reduced in most cell lines 
compared to single treatments. The mRNA levels of p21 were not reduced upon com-
binatory treatment, suggesting that the p21 protein reduction is regulated at a post 
transcriptional level. These results suggest that the pro-apoptotic response remains 
the same or is slightly increased in the combination treatment, but that the cell cycle 
arrest and pro-survival response is reduced, indicative of a shift from a cell cycle arrest 
to apoptosis.
To study whether the observed shift in biochemical response results in increased 
apoptosis, we investigated PARP cleavage as a marker for apoptosis because upon 
induction of apoptosis the PARP protein gets cleaved by activated caspases. Clear 
increased levels of cleaved PARP were detected in cell lines MEL270, OMM2.3 and 
OMM2.5 when treated with Nutlin-3/Sotrastaurin (Figure 3a) and to a lesser extent 
in OMM1 and MEL202 cells. In MM66 and MM28 cells Sotrastaurin treatment alone 
already resulted in PARP cleavage, which was not further enhanced by addition of 
Nutlin-3 (Figure 3a). However, in MM66 and MM28 the full-length PARP levels in the 
combined treated cells decreased, indicating that the percentage of cleaved PARP 
compared to full length still increased in the Nutlin-3/Sotrastaurin treated cells. 
Additionally, cleaved caspase 3 was increased in MM66 and MM28 cells further indi-
cating the induction of apoptosis (Supplementary Figure 2a). No PARP cleavage was 
observed in MEL290 cells.
Since the main goal is to find better treatment for UM metastases, further experi-
ments have been performed with metastasis-derived cell lines only. Flow cytometry 
analysis was performed to examine the effects of the drugs on the cell cycle progres-
sion and a possible induction of a subG1 fraction, indicative of cell death. The MM66 
and OMM1 cells showed an arrest in the G1 phase upon p53 reactivation. This effect 
was not obvious in MM28 cells, possibly also because these cells grow very slowly and 
the population of untreated cells already contains 87% of cells in G1-phase (Figure 3b 
and Supplementary Figure 2Sb). Nutlin-3 treatment did slightly increase subG1 frac-
tion in MM28 cells. Cell cycle profiles of OMM2.3 and OMM2.5 cells were only slightly 
affected by treatment with Nutlin-3. Sotrastaurin treatment induced an accumulation 
of cells in G1 phase in all cell lines. In MM66 and MM28 cell lines Sotrastaurin also 
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 0.74  0.64   0.38  0.28 0.34 CI
 0.56  0.56   0.68  0.81 0.69 CI
3.9   8.7  19.1  45.5 107.9 CI
 0.55  0.47   0.37  0.38 0.31 CI
 0.03  0.03  0.05  0.05 0.02 CI
 0.04  0.05  0.06  0.06 0.03 CI
 0.78  0.97   1.03  0.97 1.17 CI




























Figure 1. Synergistic growth inhibition by Sotrastaurin and Nutlin-3 in GNAQ/11 mutated UM 
cells. Various UM cell lines were treated for 72 hours with indicated concentrations Sotrastaurin 
and Nutlin-3 alone or in combination to determine the effect on cell viability. Data plotted are the 
normalized averages with the standard deviation as error bars. To determine putative synergism 
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the combinati on index (CI) values were calculated with the Compusyn soft ware. CI values below 
0.9 were considered to be synergisti c, between 0.9 and 1.1 additi ve and above 1.1 to be antago-
nisti c. Combinati ons which survival signifi cantly diff ered compared to both single treatments are 
indicated with an asterisk (*).
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Figure 2. Biochemical response of uveal melanoma cell lines to Sotrastaurin and Nutlin-3. Cell 
lines OMM2.3, OMM2.5 and OMM1 and were treated with 8 µM Nutlin-3 and 4 µM Sotrastaurin. 
MEL290 was incubated with 2 µM Nutlin-3 and 4 µM Sotrastaurin, cell line MM28 with 8 µM Nut-
lin-3 and 1 µM Sotrastaurin, and cell lines MEL202, MEL270 and MM66 with 2 µM Nutlin-3 and 
0.5 µM Sotrastaurin. All cell lines were incubated for 24 hours aft er which cells were harvested. 
Protein lysates were analyzed for the expression levels of phosphorylated PCKδ/θ, phosphory-
lated MARCKS, p53, MDM2, PUMA, p21 by Western blot. Expression of vinculin was analyzed to 
control for equal loading.
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Figure 3. Inducti on of apoptosis upon combined p53 acti vati on with PKC inhibiti on. (a) Cell 
lines OMM2.3, OMM2.5 and OMM1 and were treated with 8 µM Nutlin-3 and 4 µM Sotrastaurin. 
MEL290 was incubated with 2 µM Nutlin-3 and 4 µM Sotrastaurin, cell line MM28 with 8 µM 
Nutlin-3 and 1 µM Sotrastaurin. and cell lines MEL202, MEL270 and MM66 with 2 µM Nutlin-3 
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increased cells in subG1 (14.6% and 21.0%, respectively), in concordance with the 
analysis of PARP cleavage. Combining Nutlin-3 and Sotrastaurin slightly increased 
number of G1 cells in OMM2.5 and OMM2.3, but not in the other cell lines. Impor-
tantly, simultaneous p53 reactivation and PKC inhibition significantly increased the 
fraction of subG1 cells in all cell lines, most strikingly in MM28, MM66 and OMM2.5 
cells. In conclusion, these results together with the PARP cleavage analysis indicate 
that the combination of Nutlin-3 and Sotrastaurin is more potent in the induction of 
apoptosis compared to the single treatments.
MDMX depletion enhances growth inhibitory effect of Sotrastaurin
Since ‘specific’ MDM2 inhibitors in the clinic have shown strong adverse effects [16], 
we determined whether specific targeting of MDMX could serve as an alternative for 
MDM2-inhibitor based therapies in UMs, especially in combination with Sotrastaurin. 
Therefore, we created OMM2.3- and MEL202- derived cell lines containing two dis-
tinct MDMX-targeting shRNAs (i-shMDMX) or control shRNA (i-shCtrl) under control 
of doxycycline inducible promoter. Inducing shRNA expression with doxycycline re-
sulted in depletion of MDMX protein in the i-shMDMX containing cells with no effect 
in the i-shCtrl cells (Figure 4a and c). Concomitantly, depletion of MDMX activated 
p53 signaling with up-regulation of mRNA levels of p53 target genes MDM2, CYFIP2, 
MAD2L1 and KIF23 in MEL202 and p21 in both OMM2.3 and MEL202 (Supplementary 
Figure 3Sa and b). Although OMM2.3 cells express rather low basal levels of MDMX 
protein, depletion of MDMX still resulted in growth inhibition (38-53% survival) in a 
long term growth assay (Figure 4b). Growth inhibition upon Sotrastaurin treatment 
was comparable in the OMM2.3-derived cell lines (~55% survival). Adding Sotrastaurin 
to MDMX-depleted cells further reduced cell survival to 21-28% (Figure 4b). MEL202 
cells showed a 45-47% survival upon MDMX depletion and a 46-60% survival upon 
PKC inhibition. Combining MDMX depletion with PKC inhibition resulted in a further 
reduction of survival of ~30%, a reduction of ~20% compared to Sotrastaurin (Figure 
4c and d). However, in both cell lines the Excess over Bliss scores did not suggest syn-
ergism. These results suggest that targeting MDMX could be further explored as an 
alternative for p53 activation by MDM2-inhibitors in obtaining enhanced UM growth 
inhibition by PKC inhibition with Sotrastaurin.
and 0.5 µM Sotrastaurin. All cell lines were incubated for 72 hours before harvesting. Protein 
lysates were analyzed for the expression levels of cleaved and full length PARP by Western blot. 
Expression of vinculin was analyzed to control for equal loading. (b) MM66 cells were incubated 
with 2 µM Nutlin-3 and 0.5 µM Sotrastaurin for 72 hours after which the cell cycle profiles were 
determined by flow cytometry after PI staining, showing an increase in the subG1 fraction upon 
combined treatment.
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r 3PKCδ depletion sensitizes UM cells for p53 activation
Previous studies have shown non-redundant and essential roles for various PKC iso-
forms in cancer cell growth. One of the PKC isoforms shown to be essential for UM 
cell growth and proliferation is PKCδ.[8, 17] To specifically target PKCδ in MEL202 
and OMM2.5 cells we introduced lentiviral constructs which inducible express PKCδ-
targeting shRNAs (i-shPKCδ; two distinct target sequences) or control shRNA (i-shCtrl). 
Incubating the cells with doxycycline strongly reduced PKCδ levels, without effecting 
PKC isoforms α, β, λ, and ξ, in the i-shPKCδ cells without effect in the i-shCtrl cells (Fig-
ure 5a and Supplementary Figure 4Sa and C). Depletion of PKCδ reduced OMM2.5 cell 
survival to 52-57% (Figure 5b). OMM2.5 cells expressing i-shCtrl or i-shPKCδ shRNAs 
showed similar sensitivity to Nutlin-3 treatment with a survival of 29-38%. Combining 
PKCδ depletion with Nutlin-3 reduced cell survival to 9 - 12%, a reduction of ~17% for 
both inducible shRNA’s compared to Nutlin-3 alone, which results in high synergistic 
Excess over Bliss values of 5.0 (Figure 5b). Interestingly, PARP cleavage could only 
be detected in the Nutlin-3 treated cells depleted for PKCδ, indicating the triggering 
of apoptosis (Figure 5a). Indeed, the induction of cell death was confirmed by flow 
cytometry analysis, which showed a strong increase in the fraction of subG1 cells in 
Doxycycline/Nutlin-3 treated i-shPKCδ cells, whereas single treatments mainly show 
a minor induction of subG1 and a G1 arrest (Figure 5c). Synergism was also observed 
in MEL202 cells when PKCδ depletion was combined with Nutlin-3 in a long term 
growth assay, with Excess over Bliss scores of 5.5 and 9.4 (Supplementary Figure 4b). 
Specificity of the PKCδ knockdown was demonstrated by the lack of change in PCK 
isoforms α, β, λ and ξ (Supplementary Figure 4c). Indicating PKCδ depletion alone is 
sufficient to replace pan-PKC inhibition for achieving synergist cell growth inhibitory 
effects in combination with p53 reactivation.
Figure 4. MDMX depletion inhibits UM cell growth and increases growth inhibition by So-
trastaurin treatment. (a, c) OMM2.3 and MEL202 i-shCtrl and i-shMDMX cells were incubated for 
72 hours with 10 ng/ml doxycycline, 0.5 µM Sotrastaurin or the combination before harvesting. 
The expression of MDMX and phosphorylated MARCKS was analyzed by Western blot. Vinculin 
expression was analyzed to control for equal loading). (b, d) OMM2.3 and MEL202 i-shCtrl and 
i-shMDMX cells were seeded in quadruplicate in 12-well plates and incubated for 8 days with in-
dicated compounds (OMM2.3: 20 ng/ml doxycycline and 0.5 µM Sotrastaurin; MEL202: 20 ng/ml 
doxycycline and 0.1 µM Sotrastaurin). Cell survival was determined using crystal violet staining. 
Data plotted are the normalized averages with the standard deviation as error bars. Combina-
tions which survival significantly differed compared to both single treatments are indicated with 
an asterisk (*).
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Figure 5. PKCδ depleti on and Nutlin-3 synergize to induce apoptosis in UM cells. (a) OMM2.5 
i-shCtrl and i-shPKCδ cells were incubated for 72 hours with 20 ng/ml doxycycline, 8 µM Nutlin-3 
or the combinati on of compounds. Expression of phosphorylated PKCδ, p53 and PARP was deter-
mined using Western blot. Expression of vinculin was assessed to control for equal loading. (b) 
OMM2.5 i-shCtrl and i-shPKCδ cells were seeded into 96 wells plates and incubated with 20 ng/
ml doxycycline and 4 µM Nutlin-3. Aft er 5 days of incubati on cell survival was determined by CTB 
measurement. Data plott ed are the normalized averages with the standard deviati on as error 
bars. Combinati ons which survival signifi cantly diff ered compared to both single treatments are 
indicated with an asterisk (*). (c) Cell cycle profi les of OMM2.5 i-shCtrl and i-shPKCδ cells were 
determined aft er 72 hours of treatment with indicated drugs by fl ow cytometry aft er PI staining, 
showing an increase in the subG1 fracti on upon combined treatment.
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UM is considered to be a rare disease with an incidence of approximately 6 per mil-
lion, accounting for 5% of all melanoma cases.[18] Melanomas originating from the 
uvea are most commonly driven by activating mutations in G-proteins GNAQ (50%) or 
GNA11 (43%).[4, 5] These distinct mutations, among additional effects, hyper-activate 
protein kinase C (PKC) isoforms, which in turn feed into the MAPK pathway. This insight 
has spurred the development of several (pan-) PKC inhibitors, including Sotrastaurin. 
Despite the effectivity of Sotrastaurin in vitro on the growth of UM cell lines, in a phase 
I clinical trial only modest effects as single therapy were observed.[10] To enhance the 
effect of the PKC inhibitor a trial was started with Sotrastaurin in combination with 
a MEK inhibitor. Unfortunately, this clinical trial had to be terminated prematurely 
due to toxicity issues. The urge for novel therapeutic interventions has spiked the 
interested to combine PKC inhibition with compounds inspired by other key features 
of UM. One of these features is the lack of p53 mutations. UMs frequently show high 
levels of MDM2 and/or MDMX to constrain p53 tumor suppressor activity, opening 
the possibility to use MDM2/X inhibitors such as Nutlin-3 to reactivate p53. Previous 
studies have already shown that MDM2/X inhibitors have the potential to be used as 
therapeutic intervention for UM.[12, 13, 19]
During the course of our studies it has been reported that inhibition of p53 regulation 
by MDM2 using CGM097 further constrained in vivo tumor growth in UM PDX models 
when combined with PKC inhibition, although this combination did not result in syn-
ergistic growth inhibition in vitro.[11] In contrast, our results clearly show synergistic 
effects when p53 reactivation is combined with PKC inhibition with the same PKC 
inhibitor and also with an alternative inhibitor GF109203X (data not shown). This ap-
parent controversy can possibly be explained by the use of distinct p53-reactivators. 
We have previously shown that Nutlin-3 not only prevents the MDM2/p53 complex, 
but also affects the MDMX/p53 interaction, which has not been investigated for the 
MDM2 inhibitor CGM097. It could suggest that only inhibiting the MDM2/p53 inter-
action might not be sufficient to fully unleash p53 and achieve a synergistic response, 
at least in vitro. Even so, functional MDM2 inhibition might be not be the optimal way 
to go in patients, due to the previous reported adverse effects.[16, 20, 21] Therefore, 
we focused our studies on targeting MDMX, because mouse studies have indicated 
that depletion of MDMX has much less detrimental effects on the well-being of the 
organism, most likely because MDMX is less universal expressed in adult tissues. We 
demonstrate here that depletion of MDMX also enhanced the growth inhibitory ef-
fects of PKC inhibition. Furthermore, we have shown previously that MDMX has onco-
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genic effects beyond inhibition of p53 [12, 19, 22, 23], so targeting MDMX might have 
more wide-ranging tumor growth inhibitory effects than merely p53 re-activation.
Unfortunately, to date, no small molecule compound specifically targeting MDMX is 
commercially available. It had been reported that the XI-011 compound decreases 
MDMX levels in tumor cells by blocking transcription of the MDMX gene.[24] However, 
we have shown previously that this compound not only affect MDMX levels but also 
clearly elicits a DNA damage response, making the mode-of-action of this compound 
rather complex.[12] Much more promising, Dewaele and colleagues recently showed 
the potential of stimulating the naturally occurring alternative splicing of MDMX by 
antisense oligonucleotides, thereby decreasing the amount of full length MDMX 
protein.[25] The depletion of MDMX resulted in inhibition of cutaneous melanoma 
growth, both in vitro and in PDX mouse models. These results combined with ours 
strongly suggest a potential therapeutic intervention to target metastasized UM.
Previous studies have demonstrated the non-redundant and often essential roles of 
different PKC isoforms in UM.[8, 17] We sought to determine whether an inhibition or 
depletion of a single PKC isoform could also be capable of enhancing MDM2/MDMX 
inhibition. Wu and colleagues showed in 2012 in two independent studies that PKC 
isoforms α, β, θ, ε and δ are essential for UM cell line viability.[8, 17] More recently 
it was reported that PKC ε and δ are responsible for the activation of RASGRP3 driv-
ing the RAS/MEK/ERK pathway. [26] In line with these studies we show that UM 
cell viability depends on PKCδ and therefore could provide a potential drug target, 
especially since PKCδ does not seem to be required for development and normal 
cell proliferation.[27, 28] Interestingly the depletion of a single PKC isoform not only 
reduced cell viability, but also synergistically enhanced the effects of Nutlin-3. Our 
data show that this reduced cell survival is due to the induction of cell death, most 
likely via apoptosis. The induction of cell death suggests an interesting therapeutic 
potential. Our study shows that combining an isoform-selective PKC inhibitor with 
MDMX-inhibition might be a new potent therapeutic intervention for UM metastases 
with limited adverse effects.
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Methods
Cell culture and lentiviral transduction
Cell lines MEL270, MEL202, OMM2.3, MEL290, OMM2.5 and OMM1 were cultured 
in a mixture of RPMI and DMEM F12 (1:1 ratio), supplemented with 10% FCS and 
antibiotics. MM66 and MM28 were cultured in IMDM containing 20% FCS and anti-
biotics. Inducible shRNA knockdown lentiviral vectors were constructed as described 
previously.[29, 30] Production of lentivirus stocks by transfections into 293T cells 
essentially as described, but calcium phosphate was replaced with PEI.[31] Virus was 
quantitated by antigen capture ELISA measuring HIV p24 levels (ZeptoMetrix Corp., 
New York, NY, USA). Cells were transduced using MOI 2 in medium containing 8 μg/
ml polybrene. Target sequences to deplete MDMX or PKCδ and control sequences are 
shown in Table 1.
Western blot analysis
Cells were washed twice in ice cold PBS and lysed in Giordano buffer (50mM Tris-
HCl pH7.4, 250 mM NaCl, 0.1% Triton X-100 and 5 mM EDTA; supplemented with 
phosphatase- and protease inhibitors). Equal protein amounts were separated using 
SDS-PAGE and blotted on polyvinylidene fluoride transfer membranes (Millipore, 
Darmstadt, Germany). After blocking the membranes in TBST (10 mM Tris-HCl pH8.0, 
150 mM NaCl, 0.2% Tween-20) containing 10% non-fat dry milk, membranes were 
incubated with the proper primary antibodies (listed in a Table 2) and appropriate 
HRP-conjugated secondary antibodies (Jackson Laboratories, Bar harbor, MA, USA). 
Bands were visualized using chemoluminescence and autoradiography.
RNA isolation, cDNA synthesis and real-time quantitative PCR
RNA was isolated from cells using the SV total RNA isolation kit (Promega, Fitchburg, 
WI, USA), from which cDNA was synthesized using the reverse transcriptase reaction 
mixture as indicated by Promega. QPCR was performed using SYBR green mix (Roche, 
Basel, Switzerland) in a C1000 touch Thermal Cycler (Bio-Rad laboratories, Hercules, 
CA, USA). Relative expression of CDC25A, cyclin D1, survivin, p21 and MDM2 was 
determined over three independent experiments, compared to housekeeping genes 
CAPNS1 and SRPR. Relative expressions per experiment were compared and the un-
treated samples average was set at 1. Primer sequences are listed in Table 3.
Flow cytometry analysis
To analyze cell cycle profiles, the cells were harvested using trypsinization, washed 
with ice-cold PBS and fixed in ice-cold 70% ethanol. Cells were washed in PBS contain-
ing 2% FCS and resuspended in PBS containing 2% FCS, 50 µg/ml RNAse and 50 µg/
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ml propidium iodide. Flow cytometry was performed using the BD LSR II system (BD 
Bioscience, San Diego, CA, USA). 10.000 cycling cells were analyzed and percentages 
G1, S and G2/M were determined and set to 100%. The subG1 population was deter-
mined as a percentage of the total population.
Cell growth and viability assays
Cells were seeded in triplicate, in 96-well format. Next day compounds were added 
and cells were incubated for 72 hours. Cell survival was determined using CellTitre-
Blue Cell Viability assay (Promega); fluorescence was measured in a microplate reader 
(Victor3, Perkin Elmer, San Jose, CA, USA). Synergism between Sotrastaurin and 
Nutlin-3 was calculated using Compusyn software (Paramus, NJ, USA). Sotrastaurin 
and Nutlin-3 were obtained from Selleck Chemicals (Houston, TX, USA) and Cayman 
Chemical (Ann Arbor, MI, USA), respectively.
Long term growth assay
Cells were seeded in triplicate in a 12-well plates and were incubated for 8 days. Cells 
were fixed for 5 minutes in 4% paraformaldehyde. DNA was stained using 30-minute 
incubation with 0.05% crystal violet. After washing and drying the relative number 
of cells was quantified by solubilizing the crystal violet in methanol and measuring 
absorbance at 545nM using a microplate reader (Victor3, Perkin Elmer).
Determining synergism
To determine the extent of synergism between Sotrastaurin and Nutlin-3 in UM cell 
lines Combination index (CI) values were calculated by comparing ranges of both 
single drugs (concentrations as indicated in the figure) to the combined treatment. 
Therefore, we used the CompuSyn program which uses the Chou-Talalay method.[32] 
CI values below 0.9 were considered to be synergistic, between 0.9 and 1.1 additive 
effects and above 1.1 to be antagonistic. Excess over Bliss (EoB) was used to deter-
mine the synergism between two conditions as described by Amirouchene-Angelozzi 
N et al.[33] when no two ranges of drugs were tested. EoB was used to determine the 
extent of synergism between MDMX depletion and Sotrastaurin and PKCδ depletion 
and Nutlin-3.
Statistical analysis
Differences between two groups were calculated using Student’s t-test; P-values of 
0.05 or less were considered to be significant.
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Supplementary Figure 1S. Analysis of gene transcription in response to Sotrastaurin and Nut-
lin-3. Cell lines OMM1, OMM2.5 (8 µM Nutlin-3 and 4 µM Sotrastaurin) and MM66 (2 µM Nut-
lin-3 and 0.5 µM Sotrastaurin) were incubated with Sotrastaurin and Nutlin-3 for 24 hours. Cells 
were harvested, RNA isolated, cDNA synthesized and expression of CDC25A, cyclin D1, Survivin, 
p21 and MDM2 was determined. Relative expression compared to untreated controls is plotted.
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Supplementary Figure 2S. Inducti on of cell cycle arrest and cell death upon p53 acti vati on and 
PKC inhibiti on. (a) MM66 and MM28 were incubated for 72 hours with Sotrastaurin (MM66: 4 
µM and MM28 1 µM), 8 µM Nutlin-3 or the combinati on. Expression of cleaved caspase 3 was 
determined by Western blot. Expression of UPS7 was assessed to control for equal loading. (b) 
Aft er treati ng OMM2.5, OMM1, OMM2.3 (8 μM Nutlin-3 and 4 μM Sotrastaurin) and MM28 (8 
μM Nutlin-3 and 1 μM Sotrastaurin) for 72 hours the cell cycle profi les were determined with fl ow 
cytometry using PI staining. Representati ve fi gures of three independent experiments with the 
percentage of each cell cycle phase (G1, S, G2/M and subG1) are shown.
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Supplementary Figure 3S. p21 expression in response to MDMX knockdown. (a) OMM2.3- and 
MEL202 i-shCtrl and i-shMDMX cells were incubated with 20 ng/ml doxycycline or solvent for 72 
hours. Cells were harvested, RNA isolated, cDNA synthesized and expression levels of p21 mRNA 
was determined by qPCR. Relative expression compared to untreated is plotted. (b) Expression 
levels of known p53 target genes (MDM2, CYFIP2, MAD2L1 and KIF23) upon MDMX depletion in 
MEL202.
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Supplementary Figure 4S. PKCδ depleti on sensiti zes MEL202 cells for Nutlin-3. (a) MEL202 i-
shCtrl and -i-shPKCδ cells were incubated for 72 hours with 20 ng/ml doxycycline, 1 µM Nutlin-3 
or the combinati on. Expression of phosphorylated PKCδ, p53 and PARP was determined by West-
ern blot. Expression of vinculin was assessed to control for equal loading. (b) MEL202 i-shCtrl and 
-i-shPKCδ cells were seeded in quadruplicate into 12-well plates and incubated for 8 days with 20 
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ng/ml doxycycline, 1 µM Nutlin-3 or the combination. Cell survival was determined using crystal 
violet staining. Data plotted are the normalized averages with the standard deviation as error 
bars. Combinations which survival significantly differed compared to both single treatments are 
indicated with an asterisk (*). (c) MEL202 i-shCtrl and -i-shPKCδ cells were incubated for 72 hours 
with 20 ng/ml doxycycline. Expression of PKCδ, phosphorylated PKC α, β, λ, and ξ was determined 
by Western blot. Expression of USP7 was assessed to control for equal loading.

CHAPTER 4
Combined EZH2 and HDAC inhibition as novel therapeutic 
intervention for metastasized uveal melanoma
R. C. Heijkants, A. F. A. S. Teunisse, A. G. Jochemsen
Department of Cell and Chemical Biology, Leiden University Medical Centre, Leiden, 
the Netherlands.
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Summary
Purpose: Currently there is no effective therapeutic intervention available for patients 
with metastasized uveal melanoma (UM) resulting in poor prognosis. Loss of the 
tumor suppressor BAP1 is frequently found (80-90%) in metastasized UM. Expres-
sion of enhancer of zeste homolog 2 (EZH2), a methyltransferase and an essential 
component of the polycomb repressive complex 2 (PRC2), is frequently dysregulated 
in cancer. Like UM, mesotheliomas frequently lack BAP1 expression and it was found 
that loss of BAP1 expression sensitize these cells for EZH2 inhibition. However, UM 
cell proliferation was reported not to be affected by EZH2 inhibition, independent 
of BAP1 expression. Here we continued studying the potential of EZH2 inhibition as 
therapeutic strategy for metastasised UM.
Methods: A panel of UM cell lines was used to determine the effects of EZH2 inhibi-
tion on both short and long term proliferation assays. Using the same cell lines the 
combination of EZH2 and histone deacetylase (HDAC) inhibition was assessed on cell 
proliferation, western blotting and flow cytometry.
Results: Here we demonstrate that UM cells are responsive to EZH2 inhibition in a 
long term growth assay. Furthermore, EZH2 inhibition sensitized UM cells for histone 
deacetylase inhibition even in a short term growth assay, correlating with increased 
induction of cell death.
Conclusions: EZH2 inhibition, opposed to what has been suggested previously, could 
still serve as a potential therapeutic intervention for metastasized UM when com-
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Introduction
Uveal melanoma (UM) is an ocular malignancy originating from melanocytes located 
in the choroid (85%), iris (5%) or ciliary body (10%) [1, 2]. Primary tumors can usually 
be treated efficiently, however, approximately half of the patients within 15 years 
after primary tumor detection will develop metastases, for which no effective treat-
ment exists to date [3, 4]. In addition to the driver mutations in the G-proteins GNAQ 
or GNA11, monosomy 3 and amplification of 8q are frequently observed genomic ab-
errations in UM [5, 6]. Particularly monosomy 3 strongly correlates with development 
of metastases and is, therefore, a robust marker for poor prognosis [7, 8]. The BAP1 
gene is located at chromosome 3 and in monosomy 3 tumors the remaining copy of 
BAP1 is often found mutated leading to complete loss of BAP1 protein expression 
[9]. Indeed, mutations in BAP1 have a strong predictive power for the occurrence of 
metastasis in UM and 80-90% of the UM metastases show loss of BAP1 expression [9, 
10]. Interestingly, a previous study reported upregulation of enhancer of zeste (EZH) 
2 expression in mesothelioma upon BAP1 loss [11].
EZH2 is frequently overexpressed and also mutated in various cancer types, including 
melanoma, and its high expression correlates with disease progression and aggres-
sion (Reviewed by [12]). EZH2 is an essential component of the polycomb repressive 
complex 2 (PRC2) and functions as a methyltransferase, catalysing the tri-methylation 
of histone H3 at lysine 27 (H3K27me3) [13, 14]. This repressive tri-methylation mark 
of histone H3 is recognized by the PRC1 complex resulting in gene silencing [15, 16]. 
In this way EZH2 controls the transcription of numerous genes [17]. In addition to 
the transcription repressive function of EZH2 in the PRC2 complex, it has been dem-
onstrated that EZH2 is capable of promoting transcription, independently of PRC2 
complex [18]. The switch from transcription repressor to activator appears to be me-
diated by the phosphorylation of serine 21. All in all, EZH2 emerges as an important 
regulator of transcription in cancer cells.
Transformation of BAP1 knockout myeloid cells was found to be EZH2-dependent and 
EZH2 inhibition was demonstrated to be an effective treatment for BAP1-negative 
mesothelioma in a pre-clinical in vivo model [11]. Based upon these results a clinical 
trial with the EZH2-inhibitor Tazemetostat on patients with BAP1-negative malignant 
mesothelioma is ongoing (NCT02860286). These observations in malignant mesothe-
lioma could be extrapolated to BAP1-negative metastasized UM, possibly providing 
an effective therapeutic intervention. However, a follow-up study addressing this 
matter reported that UM cell lines are insensitive to EZH2 inhibition regardless of 
BAP1 expression, disputing the generality of the observations made in malignant 
106
Combined EZH2 and HDAC inhibition as novel therapeutic
mesothelioma [19]. However, it was argued that UM cell lines might need a prolonged 
exposure to EZH2 inhibition to observe growth inhibitory effects, especially because 
BAP1-negative UM cell lines generally have a very long doubling time [20]. This study 
focuses on the long term effects of EZH2 inhibition on UM cells and addresses the 
combinatory use of EZH2 inhibitor with histone deacetylase (HDAC) inhibition as 
potential therapeutic strategy for metastasized UM.
Results
EZH2 inhibition slows down uveal melanoma cell growth.
First, the biochemical effect of EZH2 inhibition, namely the reduction of H3K27me3, 
was confirmed at different time points with all distinct EZH2 inhibitors tested in the 
current study (T: Tazemetostat, E: EPZ011989, G: GSK503 and U: UNC1999) compared 
to DMSO (D) treated cells (Fig. A). The reduction of H3K27me3 after 24 hours incuba-
tion with EZH2 inhibitors is modest, but strong effects could be observed after 48, 72 
and 96 hours. Although it must be noted that UNC1999 appears less potent since this 
drug is not able to completely abolish detectable H3K27me3 in time, in contrast to the 
other EZH2 inhibitors (Fig. 1A). To assess the long term effects of EZH2 inhibition on 
growth of UM cells, cells were seeded into 6-well plates and cultured with or without 
exposure to two distinct EZH2 inhibitors (EPZ011989 or Tazemetostat), each condition 
in duplicate. When control (DMSO)-treated cells reached 80-90% confluency the cells 
from all conditions were counted to determine the effect of EZH2 inhibition on the 
growth, and all conditions were re-seeded in the same density as before to ensure 
equal conditions during this long term assays. Only minimal or no growth inhibition 
was observed within 5-9 days of treatment matching previous reported data of EZH2 
inhibition in UM cells (Fig. 1B) [19]. Results of all cell counts show different dynamics 
per cell line upon EZH2 inhibition (Supplementary Fig. 1A). Interestingly, the BAP1-
positive cells (OMM1, OMM2.5 and MM66) could still be sub-cultured with continu-
ous EZH2 inhibition even though EZH2 inhibition resulted in clear growth retardation 
of OMM1 and MM66 cells. OMM2.5 was the only cell line tested whose growth was 
hardly affected by EZH2 inhibition, even after 40 days (Supplementary Fig. 1A).
Interestingly, two out of three BAP1-negative cells (MP38, MM28) completely stopped 
proliferating after 1 or 2 passages (Supplementary Fig. 1A). These data slightly hint 
towards a higher efficacy of EZH2 inhibition in BAP1-negative cells, although more 
BAP1-negative and positive cell lines need to be tested to confirm this result. However, 
supporting this possibility is that analysis of TCGA data indicates that EZH2 mRNA 
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Figure 1. Eff ects of EZH2 inhibiti on on long-term growth of BAP1-positi ve and -negati ve uveal 
melanoma cell lines. (A) Time-course of four disti nct EZH2 inhibitors (Tazemetostat (T; 6 µM), 
EZP011989 (E; 6 µM), GSK503 (G; 6 µM), UNC1999 (U; 4 µM) and control (DMSO-treated) to in-
vesti gate kineti cs of H3K27me3 reducti on; USP7 expression is analysed to show equal loading. (B) 
Early and last data points of proliferati on assay of BAP1-positi ve (OMM1, OMM2.5 and MM66) 
and BAP1-negati ve (MM28, MP38 and MP46) uveal melanoma (UM) cells cultured in duplicate in 
the conti nuous presence of EZH2 inhibitors (2 µM Tzms (Tazemetostat) or 3 µM EPZ (EZP011989)). 
When DMSO treated cells reached 80-90% confl uency the cells from all wells/conditi ons were 
trypsinized and counted and re-seeded with the same initi al density to conti nue the assay.
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(Supplementary Fig. 1B) [21]. No such upregulation was found for SUZ12 expression, 
another member of the PRC2 complex, showing that the EZH2 upregulation was 
Tzms GSK EPZ UNC
MP38 12.5 3.1 11.1 7.1
MP65 26.8 23.8 19.4 34.2
XMP46 17.6 20.1 7.7 12.4
OMM1 25.9 21.1 9.8 17.6
OMM2.5 32.3 24.0 27.0 9.6
MM66 3.3 7.3 4.3 3.3












































































































































































Figure 2. Synergistic effects of combined EZH2- and HDAC inhibition on uveal melanoma. (A) 
Indicated cell lines were treated with 4 distinct EZH2 inhibitors, Tazemetostat (Tzms; 4 µM), GSK 
(GSK503; 4 µM), EZP011989 (EPZ; 4 µM for MM28, MP65 and MM66; 6 µM for MP38, MP46, 
OMM1 and OMM2.5), UNC1999 (UNC; 1 µM for MM28, MP65, OMM1, OMM2.5 and MM66; 4 
µM for MP38 and MP46) or DMSO, the HDAC inhibitor Quisinostat or by a combination. Asterisk 
(*) indicates significant differences (p ≤ 0.05) between Quisinostat-treated and the combined 
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not due to a general increase of all members of PRC2. In accordance with previous 
observations for mesothelioma cells [11], our results are supporting the argument 
that BAP1-negative UM cells are more sensitive to EZH2 inhibition, although the dif-
ferences are clearly less dramatic in UM compared to mesothelioma.
Synergistic effects of concurrent HDAC and EZH2 inhibition.
Due to the lack of a rapid onset of growth arrest, EZH2 inhibition most likely will not 
be effective as single treatment for metastatic UM patients. It has previously been 
shown that dual inhibition of EZH2 and HDACs strongly reduced tumor cell survival 
and, therefore, has an interesting therapeutic potential [22-24]. For this reason we 
tested the broad spectrum HDAC inhibitor Quisinostat (JNJ-26481585), with known 
pre- and clinical effects in (uveal) melanoma cells and patients [25-27], in combination 
with four distinct EZH2 inhibitors. As mentioned before, EZH2 inhibition did not or 
hardly affect UM survival after an incubation of 5 days (Fig. 2A). Even so, all EZH2 
inhibitors clearly enhanced the growth inhibition by Quisinostat in a synergistic man-
ner in most cell lines (Excess over Bliss values >2) (Fig. 2A and B).
Combinatory inhibition of HDAC and EZH2 induces uveal melanoma cell 
death.
Analysis of protein lysates of tested cell lines showed a marked increase in H3K9/14-
acetylation and a decrease of K27 tri-methylation upon Quisinostat or Tazemetostat, 
respectively (Fig. 3A). These changes in epigenetic markers show that both compounds 
efficiently affect activity of their designated target proteins. In most cell lines the com-
bination stimulated cell death by apoptosis as indicated by increased PARP cleavage 
(Fig. 3A). Only MM66 did not show an increase in PARP cleavage in the combination 
compared to single Quisinostat treatment. MM28 hardly showed any PARP cleavage, 
suggesting resistance to apoptosis induction (Fig. 3A). Combination of Quisinostat 
with GSK503 yielded similar results in four cell lines tested (data not shown). Surpris-
ingly, in both MM28 and MM66 the changes in epigenetic markers clearly indicate 
EZH2 and HDAC inhibition upon drug treatment, rendering the lack of synergism not 
due to inefficient target inhibition but to not yet identified differences between these 
cell lines. To verify increased cell death by the combined treatment, flow cytometry 
analyses have been performed. As expected, both EZH2 inhibitors Tazemetostat and 
GSK503 hardly affected the cell cycle profile correlating with the lack of effect on cell 
proliferation (Fig. 3B). Quisinostat on the other hand elicited a clear G1 phase cell 
cycle arrest, in accordance with our earlier and previous studies with other HDAC 
inhibitors [27, 28]. Importantly, combined treatment increased the fraction of subG1 
cells in most cell lines (Fig. 3B), in agreement with the PARP cleavage analyses. As with 
the previous experiments hardly any differences were found between the single treat-
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Figure 3. Inducti on of cell death upon concurrent inhibiti on of EZH2 and HDAC. (A) Biochemical 
eff ects of EZH2 and HDAC inhibiti on on BAP1-positi ve and -negati ve UM cells were assessed aft er 
48 hours by Western blot. Tazemetostat (T; 4 µM) reduced tri-methylated lysine 27 of histone 3 
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ments and the combined-treated MM66 cells although a slightly increased subG1 
phase is found in the Quisinostat/GSK503 combination.
To find an explanation for the increased cell death upon combinatory treatment ex-
pression of a number of genes involved in apoptosis was investigated, i.e. BIM, NOXA 
and Survivin.
These genes were chosen because it had been shown that BIM expression is strongly 
increased by combined HDAC and EZH2 inhibition [29] and both NOXA and Survivin 
have been reported to be responsive to HDAC inhibition [30, 31]. Indeed, Quisinostat 
is strongly increasing the mRNA levels of BIM and NOXA and in combination with EZH2-
inhibition by Tazemetostat the levels are further enhanced, although this increase is 
not always statistically significant (Supplementary Fig 2). BIM protein levels were also 
investigated and indeed in most cell lines the combined Quisinostat/Tazemetostat 
treatment resulted in further increase in BIM levels (Figure 3A). As reported, HDAC 
inhibition strongly downregulates the expression of Survivin, which is not affected by 
addition of Tazemetostat. Since several reports that HDAC inhibition increases levels 
of FOXO proteins and the BIM gene is a known FOXO target, we investigated the ex-
pression of FOXO1, FOXO3 and FOXO4 mRNA. Also in these tested UM cell lines HDAC 
inhibition increased FOXO1 and FOXO3 mRNA levels and in 2/3 cell lines the increase 
is enhanced by concomitant EZH2 inhibition (Supplementary Fig 2). FOXO4 mRNA 
levels were also increased upon HDAC inhibition in all UM cell lines tested, although 
less prominent, and was not further enhanced when HDAC and EZH2 inhibition was 
combined.
Thus, EZH2 inhibitors do not affect UM cell proliferation or survival at early time 
points but they still might sensitize UM cells for other therapeutic interventions, as 
illustrated here by HDAC inhibition. These effects are likely to be mediated in part by 
the upregulation of FOXO transcription factors.
ac). Pro-apoptotic BIM protein levels and PARP cleavage were analysed as apoptotic markers 
and expression of vinculin was analysed to show equal loading. (B) Effects of EZH2 inhibition (T; 
Tazemetostat; 4 µM) and G; GSK503; 4 µM), HDAC inhibition (Q; Quisinostat; 40 nM) or combina-
tions on the cell cycle profiles of UM cells after 48 hours.
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Discussion
Despite ongoing developments with regard to novel therapeutic strategies to treat 
metastasized UM, no effective curative treatment is available. Typical for the onset of 
metastasis in UM is the loss of one chromosome 3 and inactivating mutations in the 
remaining BAP1 gene [10, 32]. These events result in the absence of BAP1 expression 
in 80-90% of the metastasized UM cases [10]. The observation that cells lacking BAP1 
expression would be more sensitive for EZH2 inhibition would, therefore, meet the 
need for a specific treatment of UM metastases. The data presented in this study 
suggest that UM cells are sensitive for EZH2 inhibition upon long-term treatment, 
seemingly in contrast to the conclusions drawn by Schoumacher et al.[19]. Same cell 
lines and partly the same compounds (Tazemetostat = EPZ6438) were used, but the 
apparent discrepancies can easily be explained by the long incubation time which 
EZH2 inhibitors need before affecting the cell growth. Furthermore, in general the 
BAP1-negative cells demonstrate a slightly more dramatic and faster response to 
EZH2 inhibition suggesting a potential enhancement of the treatment by BAP1 loss. 
This could be, at least partially, explained by the observation that BAP1-negative UM 
tumors tend to have higher EZH2 expression compared to BAP1-positive UM tumors.
Previous studies have already established the potency and interesting therapeutic 
potential of combined EZH2 and HDAC inhibition in various malignancies [22-24]. 
Moreover, HDAC inhibition as single treatment or in combination has already been 
demonstrated to be an interesting strategy for treating UM [27, 28, 33]. Although 
growth retardation by EZH2-inhibitors takes time, i.e. several replication rounds, at 
early time points EZH2-inhibition sensitizes the UM cells for HDAC inhibition. We 
show here for the first time that combined inhibition of EZH2 and HDAC results in a 
synergic reduction in UM cell growth. Underlying these synergistic effects most likely 
is the induction of cell death in the combinatory treated cells. In accordance with 
previous studies, results in this study show increased levels of pro-apoptotic BIM and 
NOXA upon dual inhibition of EZH2 and HDACs, correlating with increased FOXO1 and 
FOXO3 mRNA levels, potentially underlying the increase in cell death and the syner-
gism [29]. Although we cannot exclude additional pathways leading to the enhanced 
apoptosis, previous studies using HDAC inhibitors, including quisinostat, have shown 
that the increased cell death is at least partly dependent on the enhanced FOXO pro-
tein expression [34, 35]. Therefore, we propose that EZH2 inhibition in combination 
with other compounds, e.g. an HDAC inhibitor like Quisinostat, can provide a useful 
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Methods
Cell culture growth and viability assays
The UM cell lines MEL202, OMM2.5 and OMM1 were cultured in a mixture of RPMI 
and DMEM-F12 (1:1 ratio), supplemented with 10% fetal calf serum (FCS). Cell lines 
OMM2.5 and MEL202 were kindly provided by B Ksander [36]. OMM1 cells were kind-
ly provided by GPM Luyten [37]. Establishment of the UM cell lines MM28, MM66, 
MP38, XMP46 and MP65 has been described [38] and these cells were maintained 
in IMDM containing 20% FCS. All media were supplemented with 100 U/ml penicillin 
and 100 µg/ml streptomycin. All cells were cultured in a humidified incubator at 37 
°C and 5% CO2.
For short term growth assay the cells were seeded in triplicate, in 96-well format and 
incubated for 5 days. Cell survival was determined via the Cell Titre-Blue Cell Viability 
assay (Promega, Fitchburg, WI, USA); fluorescence was measured in a microplate 
reader (Victor, Perkin Elmer, San Jose, CA, USA).
Tazemetostat, EPZ011989, GSK503, UNC1999 (all purchased from Selleck Chemicals, 
Houston, TX USA) and Quisinostat (Johnson and Johnson, New Brunswick, NJ, USA) 
were used at concentrations indicated in the figure legends.
Six UM cell lines were cultured in the continuous presence of EZH2 inhibitors (2 µM 
Tzms (Tazemetostat) or 3 µM EPZ (EZP011989)). Cell were seeded sparsely in a 6-well 
format, ranging from 5x104 to 1.2x105 cells/well, depending on the cell line. When 
the confluency reached 80-90% in the DMSO treated cells all conditions were counted 
in duplicate, using a Bűrker chamber, and re-seeded with the same initial density to 
continue the assay. Cells were provided with fresh medium/drugs every 2-3 days.
Western blot analysis
After incubation with drugs as indicated cells were harvested in Laemmli sample buffer. 
Bradford Ultra (Expedeon, San Diego, Ca USA) was used according to manufacturer’s 
protocol to determine protein concentrations. Equal protein amounts were separated 
using SDS-PAGE and blotted onto polyvinylidene fluoride transfer membranes (Mil-
lipore, Darmstadt, Germany). After blocking in TBST (10 mM Tris-HCl pH8.0, 150 mM 
NaCl, 0.2% Tween 20) containing 10% milk, membranes were incubated with the fol-
lowing primary antibodies diluted in TBST/5% BSA (H3K27me3 (39155, Active Motif, 
Carlsbad, CA, USA), USP7 (A300-033A, Bethyl Laboratories, Montgomery, TX, USA), 
PARP (9542, Cell Signalling Technology, Beverly, MA, USA), Ac-H3 (06-599, Millipore), 
BIM (2819, Cell Signalling Technology, Beverly, MA, USA) or Vinculin (hVIN-1/V9131, 
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Sigma-Aldrich, St Louis, MO, USA)) and appropriate HRP-conjugated secondary an-
tibodies (Jackson Laboratories, Bar Harbor, ME, USA). Bands were visualized using 
chemoluminescence and visualized by exposure to X-ray film.
Flow cytometry
Cells were harvested for cell cycle analysis by trypsinization, washed twice in PBS 
and fixed in ice cold 70% ethanol. After fixation, cells were washed in PBS containing 
2% FCS and resuspended in PBS containing 2% FCS, 50 µg/ml RNAse and 50 µg/ml 
propidium iodide (PI). Flow cytometry analysis was performed using the BD LSR II 
system (BD Biosciences, San Diego, CA, USA).
Quantitative PCR
MM28, MP38 and MP46 cell were incubated for 48 hours with 4 µM Tazemetostat, 40 
nM Quisinostat or a combination. The SV total RNA isolation kit (Promega, Fitchburg, 
WI, USA) was used to extract and purify RNA, from which cDNA was synthesized us-
ing the reverse transcriptase reaction mixture as indicated by Promega. SYBR green 
mix (Roche Diagnostics, Indianapolis, IN, USA) was used to perform qPCR in a C1000 
touch Thermal Cycler (Bio-Rad laboratories, Hercules, CA, USA). Relative expression of 
target BIM (Fw: CATCGCGGTATTCGGTTC and Rv: GCTTGCCATTGGTCTTTTT), NOXA (Fw: 
ACTGTTCGTGTTCAGCTC and Rv: GTAGCACACTCGACTTCC), Survivin (Fw: AGCCCTTTCT-
CAAGGACCA and Rv: CAGCTCCTTGAAGCAGAAGAA), FOXO1 (Fw: ATGTGTTGCCCAAC-
CAAAGC and Rv: TGCTTCTCTCAGTTCCTGCTG), FOXO3 (Fw: GCGTGCCCTACTTCAAGGAT 
and Rv: GCTCTTGCCAGTTCCCTCAT) and FOXO4 (Fw: TGCCCAGATCTACGAGTGGA and 
Rv: GGGTTCAGCATCCACCAAGA) was determined corrected for the housekeeping 
genes CAPNS1 (Fw: ATGGTTTTGGCATTGACACATG and Rv: GCTTGCCTGTGGTGTCGC), 
RPS11 (Fw: AAGCAGCCGACCATCTTTCA and Rv: CGGGAGCTTCTCCTTGCC) and SRPR 
(Fw: CATTGCTTTTGCACGTAACCAA and Rv: ATTGTCTTGCATGCGGCC). Per cell line the 
average relative expression was determined by setting the untreated at 1.
Statistical analysis
To determine significance of changes between two groups a student’s t-test was used. 



















































































































































































































Supplementary figure 1. Effects of EZH2 inhibition on long-term and in combination with HDAC 
inhibition on BAP1-positive and -negative uveal melanoma cell lines. (A) Extended version of Fig. 
1B, showing all time points at which control reached 80-90% confluency and the relative cell sur-
vival in the corresponding EZH2 inhibitor treated cells was determined. Long-term growth assays 
were stopped when cells no longer proliferate or after 40-45 days. (B) Comparison of EZH2 and 
SUZ12 expression between UM tumors with diploid or a shallow deleted BAP1.[21]
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Supplementary figure 2. Effects of combined EZH2 and HDAC inhibition on BIM, NOXA, Survivin, 
FOXO1, FOXO3 and FOXO4 mRNA levels. Normalized relative expression of BIM and NOXA upon 
48 hours incubation of 4 µM Tazemetostat (Tzms), 40 nM Quisinostat (Q) or combined. Hashtag 
(#) indicates significant differences between vehicle and Tazemetostat or Quisinostat treated 
samples. Asterisk (*) indicates significant differences between the combined treated samples 
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Abstract
Very little to no improvement in overall survival has been seen in patients with 
advanced non-resectable cutaneous melanoma or metastatic uveal melanoma in 
decades, highlighting the need for novel therapeutic options. In this study we inves-
tigated as a potential novel therapeutic intervention for both cutaneous and uveal 
melanoma patients a combination of the broad spectrum HDAC inhibitor quisinostat 
and pan-CDK inhibitor flavopiridol. Both drugs are currently in clinical trials reducing 
time from bench to bedside. Combining quisinostat and flavopiridol shows a syner-
gistic reduction in cell viability of all melanoma cell lines tested, irrespective of their 
driver mutations. This synergism was also observed in BRAFV600E mutant melanoma 
that had acquired resistance to BRAF inhibition. Mechanistically, loss of cell viability 
was, at least partly, due to induction of apoptotic cell death. The combination was 
also effectively inducing tumor regression in a preclinical setting, namely a patient-
derived tumor xenograft (PDX) model of cutaneous melanoma, without increasing 
adverse effects. We propose that the quisinostat/flavopiridol combination is a prom-
ising therapeutic option for both cutaneous and uveal metastatic melanoma patients, 
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Introduction
Melanoma is an aggressive type of cancer which originates from melanocytes, affect-
ing about 132,000 new patients in 2016 in the US alone [1]. Although melanoma is 
found predominantly as a cutaneous disease, melanomas from the uveal tract in the 
eye, uveal melanoma (UM), account for ~5.3% of total melanoma incidence [2]. UM 
is genetically distinct from cutaneous melanoma (CM). CM is most commonly driven 
by oncogenic mutations in NRAS or BRAF [3]; the latter spurred the development of 
mutant-specific BRAF inhibitors. Although most patients with BRAF mutations initially 
respond well to BRAF inhibition, resistance and relapse inevitably occurs within 6 to 
8 months [4]. Besides BRAF inhibitors, immunotherapy has proven to be an effective 
treatment in CM cases [5]. In contrast, UM is in most cases driven by an activating 
mutation in one of the G-proteins GNA11 or GNAQ [6, 7]. It has been shown that the 
continuous activation GNA11 or GNAQ exerts its oncogenic capacity, among others, 
through the activation of the MAPK pathway via protein kinase C (PKC) signaling [8-
10]. This insight has incited the use of PKC inhibitors as treatment for UM, but these 
inhibitors only have limited clinical effects [11]. Despite these ongoing developments 
there still is a lack of curative treatment for metastasized UM and CM, rendering 
metastasized melanoma a lethal disease. Our effort to search for novel therapeutic 
interventions for metastatic melanoma focuses on drugs in clinical development to 
reduce the time from bench to bedside.
A number of studies have shown promising results using histone deacetylase (HDAC) 
inhibitors, both in pre-clinical studies and clinical trials, as potential therapeutic in-
tervention for both CM and UM [12-15]. One of these HDAC inhibitors is quisinostat 
(also known as JNJ-26481585), a second generation broad spectrum HDAC inhibitor. 
Quisinostat has proven its efficacy against several tumor types, including melanoma, 
in pre-clinical studies [16-19] and is currently being tested in phase 2 clinical trials 
[20, 21]. The antitumor-response observed with HDAC inhibitors is often limited to 
induction of a G1 cell cycle arrest. Although this effect can block tumor outgrowth 
[21], finding drug(s) that can synergize with HDAC inhibitors and promote cancer cell 
killing would greatly increase their clinical impact. In breast cancer cells HDAC inhibi-
tion induced the degradation of cyclin D1 protein, which could implicate that HDAC 
inhibition would sensitize cells for CDK inhibition [22]. Indeed, in neuroblastoma cell 
lines HDAC inhibition combined with CDK inhibition induces apoptosis [23]. In this 
study we aimed at potentiating the effect of quisinostat by combining the treatment 
with pan-cyclin-dependent kinase (CDK) inhibition using flavopiridol (also known as 
alvocidib). Flavopiridol is FDA approved and is currently being tested in clinical trials, 
predominantly as therapeutic intervention for lymphoma and acute myeloid leuke-
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mia. Flavopiridol strongly inhibits CDK9 activity, but also affects activities of CDK1, 
CDK2, CDK4, CDK6, CDK7 and CDK12 [24-27]. By inhibiting CDK12, CDK9 and CDK7 
flavopiridol inhibits the phosphorylation of serine 2 and 5 within the RNA pol 2 CTD 
repeats and, thereby, transcription initiation and elongation [26]. Via the inhibition of 
CDK1, CDK2, CDK4 and CDK6 flavopiridol induces cell cycle arrests [24, 25]. Interest-
ingly, flavopiridol has been shown to induce stable disease in 7 out of 16 patients with 
previously untreated metastatic malignant melanoma. Unfortunately, flavopiridol 
failed to achieve significant clinical benefit according to objective response criteria 
[28].
Here we show that single treatment with quisinostat or flavopiridol slows down 
the growth of UM and CM cells, while combined treatment synergistically inhibits 
growth and, importantly, decreases survival. Whereas single treatment only induced 
cell cycle arrest, the combination of quisinostat and flavopiridol induced apoptosis of 
melanoma cells and did so irrespective of their BRAF or NRAS status. Furthermore, 
melanoma cells with acquired resistance to BRAF inhibition remained as sensitive to 
the combination as their BRAF sensitive counterparts. The combination also effec-
tively prevented tumor growth in vivo, in a patient derived xenograft (PDX) model of 
CM. In conclusion, we propose that combining quisinostat with flavopiridol should be 
explored as a first or second line therapeutic option for patients with metastatic UM 
and CM, respectively.
Results
Synergistic reduction of UM cell proliferation by simultaneous CDK and HDAC 
inhibition.
We first evaluated whether quisinostat and flavopiridol were capable of eliciting their 
expected biochemical responses in UM cells (Figure 1A). Consistent with quisinostat 
being an effective inhibitor of HDACs, an increase in acetylation of histone 3 was 
observed in all UM cell lines exposed to this drug. One of the main targets of flavo-
piridol is CDK9, which phosphorylates RNA pol2-CTD at Serine 2. Accordingly, reduced 
phosphorylation of RNA pol2-Ser2 was seen in all but one (MEL202) of the tested UM 
cell lines exposed to flavopiridol. Counterintuitively, it has been reported that treat-
ment of cells with relatively low concentrations of flavopiridol actually increases the 
expression of c-Myc at both the RNA and protein level [29]. Indeed, we also find that 
in all UM cell lines flavopiridol increases c-Myc expression at RNA and protein levels 
(Figure 1A and Supplementary Figure S1). These data are consistent with flavopiridol 
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Figure 1. Simultaneous quisinostat and fl avopiridol treatment synergisti cally inhibits growth of 
UM cell lines. A. UM cell lines OMM1, MM66, OMM2.3, MEL202 and MEL270 were treated with 
20 nM quisinostat and 100 nM fl avopiridol for 24 hours aft er which cells were harvested. Protein 
lysates were analyzed for the expression levels of c-Myc, RNA pol2-CTD Ser2 phosphorylati on and 
acetylated histone 3 by Western blot. Expression of vinculin was analyzed to control for equal 
loading. B. UM cells OMM2.3 and MM66 were treated for 72 hours with indicated concentrati ons 
quisinostat and fl avopiridol, either alone or in combinati on to determine eff ects on cell viability. 
To determine putati ve synergism the combinati on index (CI) values were calculated. Combina-
ti ons with a signifi cant (p: <0.05) lower relati ve survival compared to both single treatments are 
indicated with a *.
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in c-Myc is largely reversed by the addition of quisinostat in most cell lines, as indeed 
quisinostat in most cases reduces c-Myc levels.
We next examined the effect of quisinostat and/or flavopiridol on UM cell prolifera-
tion. In all UM cell lines both quisinostat and flavopiridol reduced relative cell survival 
in a dose-dependent manner at nanomolar concentrations (Figure 1B and Supple-
mentary Figure S2). Furthermore, a combination of these drugs resulted in an additive 
(CI: 1.1-0.9) or synergistic (CI: 0.9>) growth inhibitory effect in all cell lines.
Cell cycle arrest and apoptosis upon CDK and HDAC inhibition in UM cells.
Flow cytometry was used to study the effects of the respective drugs on cell cycle 
progression. In agreement with previous reports, quisinostat induced a G1 cell cycle 
arrest in MM66, OMM1, MEL202 and MEL270 cells (Figure 2A and Supplementary 
Figure S3). The increase in G1 population was approximately 20% in these cell lines, 
concordant with a reduction of both the S- and G2/M- phase populations. However, 
no G1 arrest was observed upon quisinostat treatment in OMM2.3, although a small 
decrease in the number of S-phase cells could be observed (Figure 2A). Flavopiridol, 
due to its ability to inhibit multiple CDKs, has been reported to affect tumor cells 
at distinct stages during the cell cycle [23, 30]. We observed no obvious changes in 
the cell cycle profiles of MM66, OMM1 and MEL202 upon flavopiridol treatment, 
whereas in OMM2.3 cells flavopiridol treatment resulted in a G1 cell cycle arrest and 
in MEL270 cells in a G2/M cell cycle arrest (Figure 2A and Supplementary Figure S3). 
In spite of these partly distinct responses to the single compound treatments, the 
combination of drugs resulted in a significant increase in the subG1 population in all 
tested UM cell lines, indicating that combined treatment induced cell death (Figure 
2 and Supplementary Figure S3). To further explore this increase in subG1, we im-
munoblotted for PARP. PARP is cleaved by activated caspase 3/7 during apoptosis and 
can therefore be used as a marker for apoptosis. An increase in cleaved PARP was 
observed in all cell lines treated with combined quisinostat and flavopiridol (Figure 
2B), but not by single treatments. These data show that combining quisinostat and 
flavopiridol synergistically induce cell death via the induction of apoptosis in UM cell 
lines.
Synergistic effects of CDK and HDAC inhibition in cutaneous melanoma cells.
Since both quisinostat and flavopiridol are indirectly targeting a plethora of biological 
processes instead of specific oncogene-driven growth and -proliferation pathways, 
we explored whether the synergy is uveal specific or could also be observed in CM. 
We investigated whether these drugs elicit their biochemical effects in the following 
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Figure 2. The combinati on of quisinostat and fl avopiridol induces apoptosis in UM cell lines. A. 
OMM2.3 and MM66 cells were treated for 48 hours with 20 nM quisinostat and 100 nM fl avopiri-
dol aft er which cell were harvested to determine the cell cycle profi les by fl ow cytometry aft er PI 
staining. The percentages of each cell cycle phase (G1, S, G2/M and subG1) are the averages of 
three independent experiments. B. UM cell lines MEL270, OMM2.3, MEL202, OMM1 and MM66 
were treated with 20 nM quisinostat and 100 nM fl avopiridol for 48 hours. Protein lysates were 
analyzed by Western blot to investi gate PARP cleavage. Expression of vinculin was analyzed to 
control for equal loading.
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NRASQ61L mutated cell line MM057 and NRAS/BRAF wild-type cell line MM117 were 
also exposed to these drugs. Treatment with quisinostat increased acetylated histone 
3 levels, indicating that quisinostat is efficiently inhibiting HDACs in all cell lines (Fig-
ure 3A). Flavopiridol exposure resulted in reduced abundance of RNA pol2-CTD Ser2 
phosphorylation in most cell lines but not in 634 and SK-MEL28. c-Myc protein levels 
were increased upon treatment with flavopiridol in most cell lines. Similar to UM the 
increase in c-Myc levels was seen at both protein and mRNA levels (Supplementary 
Figure S1). These data indicate that, like in UM, flavopiridol is actively inhibiting CDKs 
in CM cell lines. However, the molecular responses upon quisinostat and flavopiridol 
treatment seemed to vary between cell lines. As observed in UM cell lines, in some CM 
cell lines concurrent HDAC and CDK inhibition could affect the molecular responses; 
reversal of flavopiridol induced c-Myc increase, more pronounced drop of RNA pol2-
S2 and further increase of acetylated histone 3.
We determined the effect of quisinostat and flavopiridol on the growth/survival of 
CM cells using cell proliferation assays (Figure 3B and Supplementary Figure S4). 
The combination of quisinostat and flavopiridol resulted in an additive (CI: 1.1-0.9) 
or synergistic (CI: 0.9>) growth inhibitory effect in all CM cell lines tested. Despite 
the fact that the IC50’s differed per cell line, all IC50’s were in the nanomolar range 
(Table 2). The first line therapy for CM patients carrying the BRAFV600E mutation (~45% 
of all patients) consists of concurrent BRAFV600E/MEK inhibition or immunotherapy, 
to which resistance occurs. Therefore, we investigated whether two cell lines that 
acquired resistance to BRAF inhibition in vitro, MM249-R and SK-MEL28-R were still 
responsive to HDAC/CDK inhibition. Striking responses to both drugs were observed 
in both the BRAFV600E inhibitor resistant and - sensitive parental cell lines (Figure 3A). 
Furthermore, the BRAFV600E inhibitor resistant and - sensitive parental cell lines had 
similar IC50’s for both drugs (Table 2). Importantly, like their parental cell lines, the 
Figure 3. Simultaneous quisinostat and flavopiridol treatment results in synergistic growth in-
hibition of CM cell lines. A. CM cell lines 93.05, A375, 634 (20 nM quisinostat and 100 nM fla-
vopiridol), MM57, SK-MEL28, SK-MEL28R (20 nM quisinostat and 150 nM flavopiridol), MM117, 
M249 and M249-R (40 nM quisinostat and 200 nM flavopiridol) were treated for 24 hours with 
indicated concentrations of compounds. Protein lysates were analyzed by Western blotting to 
investigate levels of c-Myc, RNA pol2-CTD Ser2 phosphorylation and acetylated histone 3. Expres-
sion of vinculin was analyzed to control for equal loading. B. A375 and 93.05 cells were treated 
with quisinostat and/or flavopiridol with indicated concentrations for 72 hours to determine ef-
fect on cell viability. To determine putative synergism the combination index (CI) values were 
calculated. Combinations with a significant (p: <0.05) lower relative survival compared to both 
single treatments are indicated with a *.
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Figure 4. The combinati on of quisinostat and fl avopiridol induces apoptosis in CM cell lines. A. 
A375, 634 and 93.05 were treated with 20 nM quisinostat and 100 nM fl avopiridol for 48 hours 
aft er which cells were harvested to determine the cell cycle profi les by fl ow cytometry upon PI 
staining. The shown percentages of each cell cycle phase (G1, S, G2/M and subG1) are the aver-
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resistant cell lines showed synergistic or additive CI values upon concurrent treatment 
with flavopiridol and quisinostat (Supplementary Figure S4).
Concurrent CDK and HDAC inhibition results in cell cycle arrest and apoptosis 
in CM cells.
To study the mechanism underlying the synergistic growth inhibitory effect ob-
served in response to concurrent inhibition of CDK and HDAC we determined the 
consequences of quisinostat and flavopiridol exposure on the cell cycle progression 
of CM cell lines 93.05, 634 and A375 (Figure 4A). Quisinostat induced a minor G1 
arrest in 93.05 cells, slightly reduced S-phase in 634 but did not affect A375 cells. 
Flavopiridol treatment induced a G2/M arrest in 634, but no clear effect in A375 and 
93.05. These results show again that different cell lines show distinct responses to 
quisinostat or flavopiridol treatment. Interestingly, combining both drugs increased 
the subG1 population in all three cell lines, indicating enhanced cell death (Figure 
4A). To study whether this is, at least partly, a consequence of induction of apoptosis, 
93.05 and A375 cells were stained with Annexin V-FITC and Propidium Iodide (PI) 
upon treatment and analyzed by flow cytometry. The results showed that the ‘early’ 
apoptotic fraction (Annexin V-positive, PI-negative) was increased when quisinostat 
and flavopiridol were combined (Figure 4B and C). To study whether this induction of 
apoptosis is observed in all different CM cell lines upon combined treatment, PARP 
cleavage was investigated by immunoblotting. A marked increase in cleaved PARP was 
evidenced in all cell lines upon quisinostat/flavopiridol exposure (Figure 4D). Given 
that these cell lines carry different driver mutations, these data show that the induc-
tion of apoptosis in response to this combination is independent on the BRAF or NRAS 
mutational status.
Concurrent CDK and HDAC inhibition results in growth inhibition in vivo.
To assess the potential clinical relevance of the quisinostat/flavopiridol combina-
tion, we tested its efficacy in vivo using a PDX preclinical mouse model of melanoma 
(MEL002). We used a BRAF wild type cutaneous melanoma tumor as a model as 
patients with this type of melanoma generally have limited therapeutic options. Once 
100 nM Flavopiridol), MM57, SK-MEL28, SK-MEL28-R (20 nM Quisinostat and 150 nM Flavopiri-
dol), MM117, M249 and M249-R (40 nM Quisinostat and 200 nM Flavopiridol) were treated with 
indicated concentration of drugs for 24 hours. Protein lysates were analyzed by Western blotting 
to investigate PARP cleavage. Expression of vinculin was analyzed to control for equal loading. C. 
The percentage of early apoptotic cells was assessed using Annexin V and PI staining, of which a 
representative experiment is shown using 93.05 cells. D. PI-negative and Annexin V-positive cells 
were considered to be early apoptotic. Percentages shown are averages of three independent 
experiments.
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tumors reached a size of 200mm2, drug injections were given intraperitoneally every 
other day for 28 days. After 28 days, treatment with flavopiridol alone had signifi-
cantly reduced tumor growth (Figure 5A and Supplementary Figure S5). Quisinostat 
monotherapy resulted in stable disease. The combined flavopiridol and quisinostat 
treatment resulted in a decrease in tumor volume significant greater than observed 
with flavopiridol monotherapy. 3/6 tumors from the combined treatment group 
showed a slight tumor regression (0.3, 0.2 and 0.2 fold) compared to day 0 (Figure 
5A). In agreement with the reduced tumor volume, IHC staining for proliferation 
marker Ki-67 showed significantly reduced cell proliferation upon quisinostat treat-
ment (Figure 5B and C). In flavopiridol treated tumors, either alone or in combination 
with quisinostat, a strong variation in numbers of Ki-67 positive cells between tumors 
was observed (Figure 5C), possibly indicating that the tumor growth inhibition is the 
result of a complex mix of arrests at distinct cell cycle phases.
To evaluate whether quisinostat and flavopiridol affected their respective targets 
in vivo the levels of acetylated histone 3, c-Myc and phosphorylated RNA pol2 CTD 
were assessed (Figure 5D). We could detect an increase in acetylated histone 3 upon 
quisinostat treatment, demonstrating the efficacy of quisinostat in vivo. Although 
flavopiridol treatment in vivo did not affect RNA pol2-Ser2 phosphorylation or c-Myc 
protein levels, combination-treated tumors tended to have higher levels of acetylated 
histone 3, a trend also visible in most in vitro treated CM cell lines. Complete his-
topathological examination of two mice per treatment group showed minimal and 
moderate toxicity upon treatment (Supplementary Figure S6). Most severe adverse 
effect found was necrosis of the lymph nodes induced by flavopiridol, which has been 
described before [31]. Importantly, when these two broad spectrum drugs were com-
bined no increase in severity of the adverse events was found. Suggesting these drugs 
can be combined in order to enhance clinical benefits, without enhancing adverse 
effects.
Discussion
Despite recent advancements in the clinic, both metastasized uveal and cutaneous 
melanomas remain difficult to cure. For CM, advances have been made with respect 
to the optimization of mutated BRAF-targeting therapies [4], with or without MEK 
inhibitors, and immunotherapy has made it in some cases to first-line treatment [5]. 
Even so, a large proportion of CM patients does not respond to these therapies or 
eventually develop resistance. For metastasized UM no effective treatment is avail-
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Figure 5. Growth inhibitory and molecular eff ects of HDAC and CDK inhibiti on on cutaneous 
melanoma MEL002 PDX model. A. Animals were transplanted with pieces from a pati ent biopsy. 
When tumors reached 200mm3 mice were injected intraperitoneally with vehicle, fl avopiridol (5 
mg/kg), quisinostat (20 mg/kg) or the combinati on of fl avopiridol and quisinostat. Relati ve tumor 
increase of the vehicle treated group was on average 3.3-fold, whereas treatment with fl avopiri-
dol (5 mg/kg) or quisinostat (20 mg/kg) as single agent resulted in an average tumor increase of 
1.9- and 1.3-fold, respecti vely. Combined therapy resulted in an average tumor increase of 1.1 
fold. Out of the six tumors treated with the combinati on of compounds, three show regression 
compared to day 0 with a tumor growth of 0.7, 0.8 and 0.8 fold. B. Ki-67 staining was performed 
to determine the percentage of proliferati ng cells; representati ve pictures are shown in. C. Quan-
ti fi cati on of Ki-67 staining was performed with ImmunoRati o soft ware. D. Protein lysates were 
analyzed by Western blotti  ng to investi gate levels of RNA pol2-CTD Ser2 phosphorylati on, c-Myc 
and acetylated histone 3. Expression of USP7 was analyzed to control for equal loading.
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To find a novel general therapeutic intervention for most, if not all, melanoma patients, 
we focused on compounds targeting pathways broadly deregulated in most cancer 
cells. This study focusses on the HDAC inhibitor quisinostat and the CDK inhibitor 
flavopiridol, both currently in clinical trials for various types of cancer. This implicates 
that promising pre-clinical results with these compounds can be implemented in the 
clinic relatively quickly, as toxicity of both single agents has already been assessed.
Our results show that, in agreement with previous studies, both the HDAC inhibitor 
quisinostat and the CDK inhibitor flavopiridol exert their respective anticancer func-
tions independent of the type of driver mutations [16, 17, 28, 30, 34]. Quisinostat in-
duces a G1 cell cycle arrest in tested UM cell lines, consistent with previous published 
results from Landreville et al. [12]. Despite the ability of quisinostat to inhibit HDACs 
in both CM and UM cell lines, our results suggest that CM and UM cell lines respond 
partly distinct to this compound. Whereas 80% (4/5) of tested UM cell lines show a 
G1 cell cycle arrest, only 1 out of 3 CM cell lines (BRAF mutant) tested showed only 
a modest increase (10%) in the G1 population. Differences in response to quisinostat 
can be attributed to potential differences in expression of various HDACs or variation 
in other effector protein expression. Regardless of the differences in mechanism of 
action of quisinostat between these different cell lines, it appears that all cell lines are 
growth inhibited by quisinostat with IC50s in the low nanomolar range.
According to previous studies the anticancer effects of flavopiridol are even more 
widespread, due to its ability to inhibit multiple CDK’s, hampering both transcription 
(by inhibition of CDK9, CDK12 and CDK7) and the cell cycle, at multiple phases (via 
the inhibition of CDK1, CDK1, CDK4 and CDK6) [27, 29, 30, 34]. Apart from these well 
described targets, it has been reported recently that flavopiridol inhibits glycogen 
phosphorylase, reducing the available glucose for glycolysis of cancer cells [35]. 
Succeeding this report, it has been demonstrated that flavopiridol reduces various 
components of the glycolytic pathway in glioblastoma cell lines, limiting glycolysis, 
which could be a new perspective to flavopiridol [36]. Despite these broad ranges of 
molecular effects by flavopiridol, the drug is well tolerated in patients while inducing 
tumor regression [37]. Regardless of these wide-spread effects, nearly all melanoma 
cell lines responded similar to flavopiridol treatment at a molecular level, i.e. the 
reduction of RNA pol2 CTD Ser2 phosphorylation and the increase in c-Myc protein 
levels. The increase in c-Myc was mediated by enhanced gene transcription, rather 
than post transcriptional regulation, which is associated with low concentrations of fla-
vopiridol [29]. In combination with quisinostat, these low flavopiridol concentrations 
have synergistic effects via the induction of apoptosis, potentially reducing adverse 
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elusive it could be hypothesized that both drugs influence each other in a positive 
manner; for example, the observed further reduction of RNA pol2 CTD phosphoryla-
tion in the presence of quisinostat. Based upon literature showing that both CDK9 and 
HDAC inhibition decrease expression of the anti-apoptotic protein MCL-1 and thereby 
stimulate apoptosis [18, 38-43] one could propose that the combination treatment 
further reduces MCL-1 levels. It must be noted that concentrations of flavopiridol 
used to achieve these effects on MCL-1 expression tend to be in the micromolar 
range whereas in this study cells were exposed to flavopiridol in a nanomolar range. 
Probably therefore we could not detect consistent changes in MCL-1 levels using our 
experimental design (data not shown). However, it could be that MCL-1 will play an 
important role when high concentrations are used in a more (pre-) clinical setting. 
Similarly, expression levels of other Bcl-2 family members reported to be affected by 
quisinostat and/or flavopiridol were not significantly or consistently affected under 
our experimental settings.
In our study combined flavopiridol and quisinostat treatment significantly reduced 
tumor growth in a cutaneous melanoma PDX model. Quisinostat increased the level 
of acetylated histone 3 concomitant with a strongly reduced tumor cell proliferation. 
Strikingly, in the tumors treated with flavopiridol, either alone or in combination with 
quisinostat, the number of Ki-67 positive cells is highly variable, possibly indicating 
that the growth retardation induced by flavopiridol is a complex mixture of arrests 
at various cell cycle phases as discussed above. At a molecular level we could not 
confirm activity of flavopiridol in the treated tumors, although dose and regimen was 
comparable to previous studies [44, 45]. This could implicate that the molecular ef-
fects of flavopiridol are more transiently in vivo compared to in vitro, possibly caused 
by clearance of flavopiridol from the body, which only takes hours in humans [46]. 
Treatment with flavopiridol did inhibit the tumor growth and resulted in tumor regres-
sion in 50% of the mice treated with both quisinostat and flavopiridol. Interestingly, 
these beneficial effects could be achieved without enhancing adverse effects induced 
by these two broad spectrum drugs. In order to achieve similar synergistic effects in 
vivo compared to in vitro, our data suggest that a different treatment regime and/or 
dosage of flavopiridol should be used. Based on the results presented in this study 
it could be hypothesized that increasing the effect of flavopiridol could potentially 
synergistically enhance the effects of quisinostat, possibly resulting in tumor regres-
sion in vivo.
In conclusion, our data show that the combination of quisinostat and flavopiridol 
treatment inhibits melanoma cell viability synergistically by inducing apoptosis, 
independent of driver mutations and acquired BRAF inhibitor resistance. Simultane-
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ous HDAC and CDK inhibition could be a potential therapeutic intervention for those 
melanoma patients that have relapsed on BRAFi treatment, since BRAFi-sensitive and 
BRAFi-resistant cell lines respond equally effective to this combination of compounds. 
It seems unlikely that one mutation or epigenetic change is able to induce resistance 
to this combination, since quisinostat and flavopiridol inhibits multiple HDACs and 
CDKs. Therefore, we propose this novel therapeutic intervention as treatment op-
tion for patients with metastasized UM. Moreover, combined quisinostat/flavopiridol 
treatment could be used as first-line treatment in CM patients that have a BRAF wild 
type tumor. Lastly, since the combination treatment has shown promising results in 
BRAF inhibitor-resistant cells, also relapsed patients under BRAF inhibitor treatment 
could benefit from our optimized combinatorial treatment regimen. This treatment 
could be implemented in the clinic rather easily since both quisinostat and flavopiri-
dol are already in clinical trials.
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strategy for both cutaneous and uveal metastatic melanoma
Methods
Cell culture
The UM cell lines MEL270, MEL202, OMM2.3 and OMM1 were cultured in a mixture 
of RPMI and DMEM-F12 (1:1 ratio), supplemented with 10% fetal calf serum (FCS) 
and antibiotics. OMM1 was provided by Gré Luyten (LUMC, Leiden, The Netherlands) 
and MEL270, MEL202, OMM2.3 were a kind gift of Bruce Ksander (Schepens Eye 
Research Institute, Boston, MA, USA). Establishment of the UM cell line MM66 has 
been described [47], was kindly provided by Sergio Roman-Roman (Curie Institute, 
Paris, France) and were cultured in IMDM containing 20% FCS and antibiotics. The CM 
cell lines A375, 634 and 93.05 were cultured in DMEM/high glucose supplemented 
with 10% FCS and antibiotics. M117 and M057 CM cell lines were cultured in DMEM-
F10 with 8% FCS. SK-MEL28 was maintained in RPMI plus 10% FCS plus antibiotics. 
DMEM/high glucose containing 5% FCS/antibiotics was used to maintain the M249 
CM cells. Medium for the BRAF inhibition resistant derivatives of SK-MEL28 and M249 
was supplemented with 1µM PLX-4032 (Selleck Chemicals, Houston, TX, USA). All cell 
lines were cultured for no more than 20 passages after thawing and were checked 
regularly for mycoplasma.
Western blot analysis
Cells were rinsed twice with ice-cold PBS and lysed in Giordano buffer (50 mM Tris-
HCl pH7.4, 250 mM NaCl, 0.1% Triton X-100 and 5 mM EDTA; supplemented with 
phosphatase- and protease inhibitors). Equal protein amounts were separated using 
SDS-PAGE and blotted onto polyvinylidene fluoride transfer membranes (Millipore, 
Darmstadt, Germany). After blocking the membranes in TBST (10 mM Tris-HCl pH8.0, 
150 mM NaCl, 0.2% Tween 20) containing 10% milk, membranes were incubated with 
the proper primary antibodies (listed in Table 1) and appropriate HRP-conjugated sec-
ondary antibodies (Jackson Laboratories, Bar Harbor, ME, USA). Bands were visualized 
using chemoluminescence and visualized by exposure to X-ray film.
Cell growth and viability assays and calculation of synergism
Cells were seeded in triplicate, in 96-well format and incubated for 72 hours. Cell sur-
vival was determined via the CellTitre-Blue Cell Viability assay (Promega, Fitchburg, 
WI, USA); the fluorescence was measured in a microplate reader (Victor, Perkin Elmer, 
San Jose, CA, USA). Synergism between flavopiridol and quisinostat was calculated 
using Compusyn software (Paramus, NJ, USA). Combination Index (CI) values below 
0.9 were considered to be synergistic, between 0.9 and 1.1 additive effects and above 
1.1 to be antagonistic. Flavopiridol was obtained from Selleck Chemicals (Houston, TX, 
USA) and Quisinostat was kindly provided by Johnson & Johnson.
144
Combined inhibition of CDK and HDAC as a promising therapeutic 
Flow cytometry
For cell cycle analysis the cells were harvested by trypsinization, washed twice in PBS 
and fixed in ice cold 70% ethanol. After fixation, cells were washed in PBS containing 
2% FCS and resuspended in PBS containing 2% FCS, 50 µg/ml RNAse and 50 µg/ml 
propidium iodide (PI). Flow cytometry analysis was performed using the BD LSR II sys-
tem (BD Biosciences, San Diego, CA, USA). To determine presence of apoptotic cells 
by Annexin V staining, cells were harvested and washed twice in PBS, resuspended 
in Annexin V-binding buffer in presence of FITC-labelled Annexin V (Sigma-Aldrich, 
Saint Louis, MO, USA) and PI, following incubation for 10 minutes at room tempera-
ture. Cells staining negative for PI, but positive for Annexin V were considered to be 
apoptotic. Cells staining positive for both PI and Annexin V were considered to be late 
apoptotic or necrotic and, therefore, excluded from the analysis.
RNA isolation, cDNA synthesis and real-time quantitative PCR
RNA was isolated using the SV total RNA isolation kit (Promega), after which cDNA 
was synthesized using the reverse transcriptase reaction mixture as indicated by Pro-
mega. qPCR was performed using SYBR green mix (Roche Diagnostics, Indianapolis, 
IN, USA) in a C1000 touch Thermal Cycler (Bio-Rad laboratories, Hercules, CA, USA). 
In three independent experiments relative expression of c-Myc (fw: GCCACGTCTC-
CACACATCAG, rev: TGGTGCATTTTCGGTTGTTG), compared to housekeeping genes 
CAPNS1 (fw: ATGGTTTTGGCATTGACACATG, rev: GCTTGCCTGTGGTGTCGC) and SRPR 
(fw: CATTGCTTTTGCACGTAACCAA, rev: ATTGTCTTGCATGCGGCC) was determined. 
Average relative expression per experiment was compared to the untreated set at 1.
Patient derived xenograft mouse model
Tumor pieces of cutaneous melanoma tumor model MEL002 (BRAF wild type) were 
transplanted interscapular in NMRI nude mice as described by M. Dewaele et al. 
[48]. When tumor volume reached 200mm3 6 animals per group were treated intra-
peritoneally, with either vehicle, quisinostat (20mg/kg), flavopiridol (5mg/kg) or the 
combination every other day for 28 days. Bodyweight was measured to monitor the 
animals. During the treatment tumor volume was assessed every other day using a 
caliper and calculated (tumor volume mm3= (width2 x length)/2). At the end of the 
experiment all animals were sacrificed and tumors were removed, general necropsy 
was performed on 2 mice per group. Immunohistochemical (IHC) staining to asses 
tumor cell proliferation were performed as described by Hawinkels et al. [49] using 
primary antibody Ki-67 1:500 diluted (AB9260, Millipore). Three to five representa-
tive pictures were taken per tumor of which an average percentage of Ki-67 positive 
cells was determined per tumor using the ImmunoRatio web application as described 
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Hilden, Germany) according to manufacturer’s protocol in RIPA lysis buffer (150 mM 
NaCl, 1% NP-40, 0.25% deoxycholate, 0.1% SDS, 50 mM Tris-HCl pH 8.0, 2 mM EDTA; 
supplemented with phosphatase- and protease inhibitors) followed by western blot 
analysis, as described above.
Statistical analysis
Differences between two groups were calculated using Student’s t-test. To determine 
the difference in tumor growth over time between groups in the PDX model a two way 
ANOVA was used. P-values of < 0.05 were considered to be significant.
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Table 1. List of antibodies used for Western blot.
Protein Name/Cat# Company
Vinculin hVIN-1/ V9131 Sigma-Aldrich
PARP 9542 Cell Signaling Technology
RNA pol2 p-S2 AB5095 Abcam
c-Myc AB32072 Abcam
Acetylated histone 3 31994 Millipore
Table 2. IC50’s for quisinostat and flavopiridol per cell line.
cell line Quisinostat Flavopiridol
IC50 nM stdev IC50 nM stdev
MEL270 5.9 1.8 82.7 14.4
MEL202 24.8 6.4 68.4 10.3
OMM2.3 16.4 1.9 91.3 14.2
OMM1 18.6 2.8 71.3 3.1
MM66 93.0 21.7 99.8 19.3
634 14.8 2.7 133.6 21.0
93.05 36.2 7.3 66.8 7.0
A375 20.8 8.7 65.9 4.5
MM249 23.8 2.0 143.9 6.3
MM249R 17.5 3.1 128.6 24.5
SK-MEL28 30.7 4.4 113.1 6.1
SK-MEL28-R 28.4 6.2 92.6 10.5
MM117 14.8 1.5 178.2 17.8








































Supplementary Figure S1. Increase in c-Myc mRNA expression upon flavopiridol treatment. CM 
cells MM249 and MM117 and UM cells MEL202 and OMM1 were treated for 8 hours with flavo-
piridol (200, 150, 100 and 100nM, respectively). Cells were harvested, RNA isolated, cDNA was 
synthesized and expression of c-Myc mRNA was determined. Relative expression compared to un-
treated controls is plotted, when the difference was found to be significant (p: <0.05) compared 
to the control this was indicated with a *.
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Supplementary Figure S2. Synergistic growth inhibition of CDK and HDAC inhibition on UM 
cells. UM cells were treated with the indicated concentrations of flavopiridol and quisinostat, 
alone or in combination. After 72h the cell viability was determined. To determine the extent of 
synergism the combination index (CI) was used. Combinations with a significant (p: <0.05) lower 









































































































































Supplementary Figure S3. Effect of CDK and HDAC inhibition on the cell cycle progression of 
uveal melanoma cells. MEL270, MEL202 and OMM1 cells were treated for 48 hours with 20 nM 
quisinostat and 100 nM flavopiridol after which cells were harvested to determine the cell cycle 
profiles by flow cytometry upon PI staining. The shown percentages of each cell cycle phase (G1, 
S, G2/M and subG1) are averages of three independent experiments.
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Supplementary Figure S4. Synergistic growth inhibition of CDK and HDAC inhibition on CM cells. 
CM cells were treated with the indicated concentrations of flavopiridol and quisinostat, alone or 
in combination. After 72h the cell viability was determined. To determine the extent of synergism 
the combination index (CI) was used. Combinations with a significant (p: <0.05) lower relative 










P: 0.0001 P: 0.0001
P: 0.0001 P: 0.61
Supplementary Figure S5. Growth inhibitory effect of HDAC and CDK inhibition on MEL002 PDX 
model in time. Animals were transplanted with tumor pieces. When tumors reached 200 mm3 
mice were injected I.P. every other day for 28 days. A. Mice were treated with flavopiridol (5 
mg/kg), B. quisinostat (20 mg/kg) or C. Mice treated with flavopiridol compared to combination 
treated mice. D. Mice treated with quisinostat compared to combination treated mice. Tumor 
volume was assessed by caliper.
S6
Pathological findings
lung, inflammatory cell infiltrate no change/s
lung, alveolar histiocytosis minimal change/s
forestomach, mucosal hyperplasia/hyperkeratosis mild change/s
pars glandularis, mucosal inflammatory cell infiltrate moderate change/s
liver, inflammatory cell infiltrate severe change/s
kidney, cortical infarct
ovary, atrophy
spleen, white pulp, reactive hyperplastic changes 
spleen, red pulp, increased hematopoiesis
lymph node, reactive hyperplastic changes
lymph node, necrosis
brain, inflammatory cell infiltrate
brain, neurodegeneration
Q F Q+F
Supplementary Figure S6. Lesion heat map of histopathological examination. Complete histo-
pathological examination was performed on two animals treated with either quisinostat (Q), fla-




Oncogenic functions of MDMX in uveal melanoma
Malignant cells often highly express MDMX and/or MDM2 as means to dampen 
p53 activity [1]. MDM2 is an E3 ubiquitin ligase whose activity results in ubiquitin-
dependent p53 degradation, while MDMX shields the transactivation domain of p53. 
However, the oncogenic functions of MDMX are not limited to the inhibition of p53 
activity [2, 3]. Chapter 2 reports which genes are transcriptionally controlled by MDMX 
and to what degree this regulation is p53-dependent. The data presented indicate 
that MDMX regulates cell cycle progression, at least partially via the p53-p21-DREAM 
(DP, RB-like, E2F4 and MubB) axis, and apoptosis via p53 and FOXO’s. It has been 
generally accepted for some time now that p53 promotes the expression of p21 and 
thereby induces transcriptional repression by the DREAM complex [4, 5]. However, 
to what level this particular indirect p53 activity could be inhibited by MDMX had 
not yet been studied. The observation that MDMX depletion, which only minimally 
effects p21 expression, is capable of inducing this transcriptional repression has never 
been reported before. Although possibly not very surprising, since MDMX is known 
to inhibit p53 transcriptional activity [6, 7], it further strengthens the proposition that 
MDMX could serve as alternative therapeutic target, since its inhibition provokes a 
similar downstream effect as inhibition of MDM2. While having a comparable thera-
peutic potential as MDM2 inhibition, MDMX is less commonly expressed and not 
always essential for cell survival in the adult tissue [8-14]. Therefore, it could well be 
that targeting MDMX has less adverse effects in patients compared to inhibition of 
MDM2, potentially making it the preferred way of reactivating p53.
In chapter 2 we established that the downregulated cell cycle controlling genes upon 
MDMX knockdown could indeed be regulated via the p53-p21-DREAM axis. However, 
the transcriptional repression is, at least partly, p53-independent, suggesting the exis-
tence of another transcription factor under the control of MDMX. Not only repressed, 
but also some of the upregulated genes show clear p53 independency. Although 
38% of the upregulated genes were identified as direct p53 target genes the results 
demonstrate that MXD4 (also named MAD4) and PIK3IP1 expression is controlled by 
MDMX in a p53-independent manner. The major DNA binding consensus site identi-
fied in 65% of the up-regulated genes is the Forkhead-Boxes DNA binding site. Indeed, 
FOXO1 levels are slightly increased upon MDMX depletion in a p53-independent 
manner. Inhibition of FOXO1 activity could explain the p53-independent function of 
MDMX. Mechanistically it remains unsolved as yet how MDMX inhibits FOXO1. It is 
known that MDM2 is capable of directly binding and ubiquitinating FOXO1, 3 and 4 
[15, 16]. Preliminary data show that reduced MDMX expression results in increased 
nuclear localization of FOXO1 (data not shown). If the inhibition of FOXO1 is the result 







nizing this interaction could lead to new therapeutic option for tumors overexpressing 
MDMX.
Interestingly, MXD4 affects p53 activity potentially suggesting a novel back-up mecha-
nism (see Figure 1). This back-up mechanism would include that upon MDMX deple-
tion MXD4 is upregulated, mediated by FOXO1, and competes with p53 for SIN3A. By 
forming a complex with SIN3A, which is known to be involved in transcription repres-
sion, MXD4 could be part of a potential pathway leading to the p53-independent gene 
repression mentioned earlier. Interestingly, SIN3A might not only potentially enable 
p53-independent repression, it can also form a transcription repressive complex 
which not only includes E2F4 but also p27 [17, 18]. The latter protein was previously 
described as being stabilized upon MDMX depletion, independently of p53 [2]. Based 
on these earlier studies and the data described in chapter 2 a larger picture is emerg-
ing in which MDMX is controlling a large repressive complex via the regulation of 
SIN3A and E2F4 and inhibition of MXD4 transcription. Furthermore, releasing p53 
from SIN3A allows MDM2 to bind p53 and to target p53 for ubiquitination-mediated 
degradation [19]. This pathway would imply a p53-independent back-up mechanism 
p53 
MDMX 






















Figure 1. Working model of MDMX’s oncogenic functions. In this model MDMX inhibits both p53 
and FOXO1 which prevents target gene transcription. Upon MDMX depletion both transcription 
factors bind DNA and promote transcription resulting in, among other effects, the repression on 
cell cycle regulatory genes. Simultaneously, FOXO mediated upregulation of MXD4 transcription 
could prime p53 for MDM2 mediated degradation by competing with p53 for SIN3A binding.
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in which a cell with high levels of MDMX rewires towards more MDM2 mediated 
p53 inhibition once MDMX is depleted. Not only does this SIN3A/MXD4 mediated 
‘back-up’ mechanism clarify the p53-independent transcription repression upon 
MDMX depletion, it could also provide new therapeutic targets. Depletion of MXD4 
resulted in p53 stabilization, possibly due to an increased SIN3A binding attenuating 
MDM2 binding to p53. MXD4 depletion resulted in a slight, p53-dependent, growth 
inhibition and it synergized with p53 activating and stabilizing drugs, showing that to 
fully unleash p53 and further exploit current p53 activating strategies a way to target 
MXD4 should be elucidated.
In conclusion, the data presented in chapter 2 show that p53-independent oncogenic 
functions of MDMX could be partially explained by the p53-independent effects on 
the transcriptome. In addition to a better understanding of the oncogenic functions 
of MDMX in melanoma, a possible new route to potentiate current anti-cancer strate-
gies in various malignancies was uncovered.
MDMX as enhancer of current therapeutic interventions for metastasised 
uveal melanoma
The feasibility and clinical advantages of p53 reactivation by MDM2 inhibition have 
been established [20]. Unfortunately, clinical studies have shown strong adverse, 
on target, effects in patients upon MDM2 inhibition [21]. Although both MDM2 and 
MDMX are essential for restraining p53 during embryonic development [22-26], in 
adult cells and tissue MDM2 loss is always lethal whereas MDMX loss can be compat-
ible with life [8-13]. The lack of general expression of MDMX compared to MDM2 
would indicate potentially less adverse effects when targeting an MDMX expressing 
cancer. The therapeutic potential of MDMX targeting has been established by our lab 
and others for various cancer types, partly independent of p53 status [2, 3, 27, 28]. 
It has become evident and generally accepted that using a monotherapy on a cancer 
will in general not result in a durative and curative response [29]. Therefore, combina-
tions of drugs are tried in more studies in order to hit a cancer cell from multiple 
angles at the same time, making acquired resistance less likely to occur. Interestingly, 
in melanoma concurrent targeting of MDMX and BRAF has proven to be an effective 
combination [3].
In uveal melanoma an activating mutation in GNAQ or GNA11 is the main driver to-
wards malignancy. Constitutive active GNAQ/GNA11 activates a number of signalling 
pathways, including the proliferation stimulating MAPK pathway. An essential node 







recognized as a valuable therapeutic target for uveal melanoma, e.g. by means of the 
PKC inhibitor Sotrastaurin/AEB071 [30].
In chapter 3 it is described that combined p53 activation and PKC inhibition result 
in synergistic growth inhibition of uveal melanoma cells. In our studies the dual 
MDM2/X inhibitor Nutlin-3 was used, whereas the MDM2 inhibitor CGM097 was 
used in another study describing the beneficial effects of combining p53 reactivation 
with PCK inhibition [31]. Interestingly, in the latter study no synergistic effects upon 
concurrent PKC inhibition and p53 reactivation could be demonstrated in vitro, in con-
trast to our results, suggesting that full release of p53 from both MDM2 and MDMX 
is essential for synergism. Depletion of MDMX, like the pharmacological activation of 
p53 by MDM2 inhibitors, attenuates the proliferation and survival of UM cells, which 
is further enhanced by a combination with PKC inhibition. Thus, MDMX inhibition in 
combination with existing therapeutic interventions for uveal melanoma could serve 
as a promising therapeutic intervention, stressing the need for the development of 
specific MDMX inhibitors, which thus far has been proven very difficult.
Replacing pan-PCK inhibition for PKCδ targeting
Activated protein kinase C (PKC) isoforms is a common feature of UM and has shown 
potential as therapeutic intervention for UM patients [30]. Unfortunately, pan-PKC 
inhibition as single treatment appears to have only limited clinical benefit and elicits 
adverse effects in patients [32]. Combining PKC inhibition with activation of p53, 
which is rarely mutated in UM, by MDM2 inhibitors has shown promising results in 
pre-clinical studies. Therefore, alternative approaches were investigated to achieve 
similar anti-cancer effects, but with potentially less adverse effects. Since the PKC fam-
ily consists of 10 different isoforms it can be hypothesized that targeting a single PKC 
isoform would have less adverse effects compared to a pan-PKC inhibitor. It has been 
demonstrated that, despite the great structural homology between the different PKC 
isoforms, especially within a certain subclass, they appear to have separate and non-
redundant functions. Furthermore, it has been observed that all PKC isoforms tested 
(α, β, θ, ε and δ) are essential for uveal melanoma cell viability [30, 33], emphasising 
that specific targeting of a single PKC isoform could yield an effective treatment. PKCε 
and PKCδ were shown to be responsible for the activation of RASGRP3, a guanine 
nucleotide exchange factor promoting the GTP loading of RAS. So, activation of RAS-
GRP3 serves as a RAS activator driving the RAS/MEK/ERK pathway in uveal melanoma 
[34]. In chapter 3 it is confirmed that uveal melanoma cell viability depends on PKCδ 
expression and, therefore, could be regarded a potential drug target, especially in-
teresting since PKCδ does not seem to be required for development and normal cell 
proliferation [35, 36]. As mentioned above, it is unlikely that the specific targeting 
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of a single signalling molecule will result in a curative response it was investigated 
whether PKCδ depletion would also enhance the effect of MDM2/MDMX inhibition. 
Like pan-PKC inhibition, the specific depletion of PKCδ resulted in synergistic growth 
inhibition of UM cells in combination with p53 reactivation.
In conclusion, the data presented in chapter 3 show that the synergistic effects of 
p53-activation by MDM2/MDMX inhibition and broad spectrum PKC inhibition on 
survival of UM cells can largely be achieved by the presumably less toxic combina-
tion of depletion of MDMX and targeting a specific PKC isoform, PKCδ. Although 
PKCδ appears to be a promising therapeutic target until recently no small molecule 
compound specifically targeting this kinase had been described. The functional non-
redundancy between the various isoforms suggests the opportunity for developing a 
selective inhibitor. Recently, the development of a selective PKCδ inhibitor (B106) has 
been described [35], but our experiments with this inhibitor indicate that the growth 
inhibitory effect is not dependent on PKC activity in uveal melanoma cells (data not 
shown). The approach to develop this inhibitor was to design the structure of B106 on 
the reported Rottlerin’s capability to selectively bind PKCδ compared to PKCα and to 
combine this with parts of the kinase inhibitor Staurosporin. However, it has now been 
widely accepted that Rottlerin does actually not bind PKCs and Staurosporin is con-
sidered to be one of the most a-selective kinase inhibitors commercially available. An 
alternative approach to selectively target PKCδ, or members of the novel-PKC family, 
could very well consist of modifying a known pan-PKC inhibitor such as Sotrastaurin or 
GF109203X. These selective pan-PKC inhibitors have a strong structural overlap with 
the a-selective Staurosporin with regard to the ‘head’ domain of these compounds, 
suggesting that the selectivity of the compounds has to be acquired from the ‘tail’ 
residues. A valid approach for the development of a selective PKCδ inhibitor would be 
to chemically modify the tail region of either GFX or Sotrastaurin and determine the 
specificity using in vitro kinase assays.
Deviating from the hypes
Finding curative therapeutic intervention has been the focus of many decades of 
cancer research. A few success stories, such as Imatinib (targeting the BCR/ABL fu-
sion gene) and Rituximab (targeting CD20), catalysed the targeted therapies hype. 
Although great results were expected based on these successes, the median increase 
in survival was 2.1-2.5 months based on 71 drugs approved to treat cancer by the FDA 
between 2002 and 2014 [37]. According to the ASCO guidelines, regarding improve in 
quality of life and overall survival, only 42% of these drugs had a meaningful clinical 
impact. It should be noted that many of the 71 approved drugs contain an overlap-







profitable therapy, even if only with a modest improvement in overall survival, other 
pharmacological companies will develop compounds with a similar mode of action 
to ensure a piece of the market and the profit. Thereby, they are pushing drug prices 
to incredible height without really improving the quality of the therapy and patient 
survival. This is particularly illustrated by the 50 molecules which entered clinical tri-
als for targeting vascular endothelial growth factor (VEGF) as a means of targeting 
angiogenesis, or the 25 molecules in clinical trials for the targeting of mitosis in solid 
tumours, the latter with an average response rate of just 1% [38]. These duplication 
efforts are even further illustrated by the observation that 9 big pharmaceutical 
companies have a 74% overlap in their molecules with regard to the expected mode 
of action [37].
This focus on targeted therapies, with only limited clinical benefit, has almost blinded 
funding agencies, academia and companies. It is nowadays accepted that targeted 
therapies tend to work efficiently for ‘single cause’ diseases, but not really for more 
complex malignancies such as cancer due to tumor heterogeneity [39]. The most re-
cent big breakthrough in cancer treatment is the development of immune checkpoint 
targeting drugs, discussed in the introduction of this thesis. These developments are 
currently changing the whole cancer research field, like targeted therapies did a few 
decades ago. Although promising in some cancer type, stratification of patients ap-
pears to be crucial for the success of a treatment, like for targeted therapies [40]. 
It appears that immunotherapies are most efficient in tumours with a high muta-
tional load. Cutaneous melanomas have a high mutation load in contrast to uveal 
melanomas. Indeed, uveal melanoma patients did not benefit from immunotherapy 
in the form of Ipilimumab [41, 42]. It appears that with regard to metastasized uveal 
melanoma a therapeutic intervention should not come from current immunotherapy 
nor targeted therapy strategies. Therefore, the remainder of this discussion will be on 
the use of therapeutics not fitting within targeted- nor immunotherapy, but which are 
already in clinical trials, to reduce the time from bench to bedside.
EZH2 and HDAC as therapeutic intervention
In uveal melanoma BAP1 expression is frequently lost due to mutation and loss of 
the second allele [43-45]. In UM 80-90% of the metastases show loss of BAP1 ex-
pression resulting in strong predictive power for BAP1 mutations for the occurrence 
of metastasis [45, 46]. Interestingly, upregulation of Enhancer of Zeste (EZH) 2 ex-
pression in mesothelioma cells upon BAP1 loss has been reported [47]. EZH2 is an 
essential component of the polycomb repressive complex 2 (PRC2), which mediates 
the tri-methylation of histone H3 at lysine 27 [48, 49]. EZH2 controls the expression of 
numerous genes by promoting the repressive tri-methylation of histone H3 thereby 
160
General discussion
reducing transcription [50]. An EZH2 dependency was found in myeloid cells for BAP1 
knockout induced transformation and in vivo it was demonstrated for BAP1-negative 
mesothelioma that EZH2 inhibition is an effective treatment for BAP-1 negative can-
cers [47]. A clinical trial was initiated for patients with BAP1-negative mesothelioma 
using the EZH2-inhibitor Tazemetostat (identifier: NCT02860286). In a later report, 
EZH2 inhibition did not appear to affect both BAP-1 positive and negative UM cell 
proliferation. However, in chapter 4 it is demonstrated that UM cells are responsive 
to long term EZH2 inhibition.
Nevertheless, it appears that for most cell lines tested the time until onset of growth 
inhibition was over a week. Furthermore, only 2 of the cell lines tested completely 
stopped proliferating, meaning that most cell lines tested could be sub-cultured with 
continuous EZH2 inhibition. These relatively slow and mild effects in vitro are far from 
optimal for translation to a clinical setting, in which a patient with metastasised uveal 
melanoma generally only has a few months to live. Therefore, it was investigated 
whether EZH2 inhibition would sensitize UM cells for other compounds, known to be 
effective in uveal melanoma patients. Concurrent inhibition of EZH2 and HDAC has al-
ready been shown to effectively reduced tumor cell survival in various different cancer 
types [51-53]. Therefore this combination could be considered as an interesting novel 
strategy, which should be further studied in clinical trials, for multiple malignancies. 
Importantly, HDAC inhibitors have already been described as a potential therapeutic 
intervention for uveal melanoma [54, 55]. Indeed it was found that also UM cell lines 
are sensitized for HDAC inhibition upon EZH2 inhibition due to the induction of cell 
death. Others have showed that, in KRAS mutated lung cancer cells, EZH2 inhibition 
sensitized for MEK and PI3K/AKT inhibitor [56]. Furthermore, EZH2 is involved in the 
transcriptional repression of various DNA repair-related genes, which result in higher 
sensitivity to chemotherapeutic agents when cells are treated with an EZH2 inhibitor 
[57-59]. These studies indicate that in addition to the dual inhibition of HDACs and 
EZH2, other compounds could well synergize with EZH2 inhibition and be a promising 
therapeutic intervention for metastasised uveal melanoma. Future research has to 
elucidate which combinations are the most potent and feasible.
Combining HDAC and CDK inhibition as therapeutic strategy
As described previously, overall survival has hardly improved for patients with 
advanced unresectable cutaneous melanoma or metastatic uveal melanoma in the 
last decades. This lack of improvement is highlighting the need for novel therapeutic 
options. In chapter 5 the potential of the combination of another compound with 







assessed in this chapter are currently in clinical trials reducing time from bench to 
bedside.
Encouraging results using histone deacetylase (HDAC) inhibitors indicate a potential 
therapeutic intervention for uveal and cutaneous melanoma [12–15]. HDAC inhibition 
often induces of a G1 cell cycle arrest in cancer cells. Although this cell cycle arrest can 
prevent further outgrowth of a tumor [21], finding drug combinations that synergisti-
cally induce cancer cell killing would greatly increase the clinical impact of HDAC in-
hibitors. For example, apoptosis is induced when both CDKs and HDACs are inhibited 
in neuroblastoma cell lines [23]. This study aimed at potentiating the effect of HDAC 
inhibitor Quisinostat by combining the therapy with CDK inhibition using Flavopiridol. 
Flavopiridol is currently tested in clinical trials, mainly as treatment strategy for acute 
myeloid leukaemia and lymphoma. Interestingly, stable disease in 7/16 patients with 
previously untreated metastatic malignant melanoma was induced by Flavopiridol. 
Unfortunately, according to objective response criteria Flavopiridol failed to achieve 
significant clinical benefit [28]. Data presented in chapter 5 show that single treat-
ment with Flavopiridol or Quisinostat slows down the growth of UM and CM cells, 
while concurrent treatment inhibits cell growth synergistically and reduces survival.
Concurrent Flavopiridol and Quisinostat treatment shows a synergistic reduction 
in melanoma cell survival independent of mutations driving the malignancy. These 
synergistic effects were also observed in BRAF mutant melanoma cells that had ac-
quired resistance to BRAF inhibition in vitro. Induction of apoptosis could at least 
partly explain the mechanism behind the observed synergism. However, the molecu-
lar mechanism underlying this induction of cell death remains undetermined. In a 
cutaneous melanoma PDX model combined Flavopiridol and Quisinostat treatment 
induced tumor regression, without enhancing adverse effects. However, the observed 
combinatory effects did not measure up to the expected results based on the in vitro 
assays. This can most likely be attributed to the lack of clear Flavopiridol activity on 
a molecular level. Flavopiridol is known to be cleared from the human body in hours 
[60]. Future research on this drug combination should mainly focus on reaching 
and maintaining proper CDK inhibition by Flavopiridol in order to reach maximum 
synergism and thus clinical benefit. When that can be achieved the Flavopiridol/
Quisinostat combination could be a promising treatment strategy for metastasized 
uveal and cutaneous melanoma patients, regardless of earlier received treatments.
Considerations for drug combinatory studies
When two drugs are combined they can influence each other’s respective outcome 
in either a synergistic, additive or antagonistic manner. When synergy between two 
162
General discussion
drugs occurs this indicates a potential novel therapeutic intervention. However, re-
solving the underlying mechanism driving the observed synergism could be extremely 
difficult, especially when the compounds are targeting a number of related molecules, 
as for instance described in chapter 5. These difficulties arise from the numerous pos-
sibilities on how both drugs might influence each other. This complexity is illustrated 
by a list of basic motives with only 3 theoretical nodes which already results in 21 
possible explanations for synergism, let alone when more general pathways or cel-
lular processes are influenced [61].
The other option upon combining drugs is the occurrence of antagonism. Synergism 
only tends to occur in a minority of drug combinations when systematically tested 
[62]. There appears to be a bias in both published literature and this thesis towards 
synergistic drug combinations rather the antagonistic ones based on a PubMed search 
for ‘antagonism’ or ‘synergism’ in combination with cancer’. This search yielded six 
times more hits for synergism in cancer compared to antagonism in cancer, although 
according to unbiased screening there should be at least ten times more antagonistic 
combinations compared to synergistic ones. Although these combinations clearly do 
not contain a therapeutic benefit, they could reveal potential mechanism of drugs 
resistance. To mechanistically explain antagonism appears to be easier compared 
to synergism as there are far less theoretical explanations for the occurrence of 
antagonism compared to synergism [61]. For example, it has been shown that p53 
reactivation in combination with CDK1/2 inhibition results synergistically in growth 
inhibition of melanoma cells [63]. However, preliminary data from our lab show that 
the pan-CDK inhibitor Flavopiridol has an antagonistic effect on p53 activation (data 
not shown). Which could actually make sense since Flavopiridol’s main target is the 
block of transcription by CDK9 inhibition, which would antagonize p53-induced tran-
scription upon activation. So, despite Flavopiridol’s lack of synergistic capabilities with 
p53 the results could help understanding which drugs or CDK inhibitors could provide 
useful therapeutic enhancers of p53 activation therapies and which will not.
For the studies described in this thesis the ‘educated guess’ methodology was used to 
find novel synergistic combinations to inhibit uveal melanoma cell growth. Illustrated 
by the concurrent targeting of two main hallmarks of uveal melanoma, namely PKC 
activity and high expression of MDMX/2. Furthermore, knowledge of BAP1 and EZH2 
was applied to combine EZH2 and HDAC inhibition, of which the latter had been 
shown to elicit metastasis regression in uveal melanoma patients. The observed 
HDAC inhibition induced cell cycle arrest directed us towards the combination with 







true potential it could easily be doubted whether these combinations are the best 
combinations possible.
An alternative approach consists of performing unbiased synthetic lethal screens to 
find genes and pathways synergising with a particular drug. The question remains 
which drugs to select for these approaches. One might select drugs based on their 
availability in the clinic, proven clinical efficacy, or their ability to induce a growth 
arrest in vitro so the synergism will be clear. However, it could also be considered 
to select a drug for this screening based on the lack of activity. Especially the lack of 
strong adverse effects could be considered a pro due to the reduced likeness of en-
hancing adverse effects in the combination. A prominent downside of this approach 
could well be that the ideal pathway or molecule identified by these screens cannot 
-yet- be targeted by a specific small molecule compound. Another drawback could be 
that no interest exists from the industry to commercialize a certain treatment option.
A last option would be to put all scientific interest aside and, much like the Quisino-
stat/Flavopiridol combination, focus on drugs already in clinical trials and preferably 
FDA approved. Also here it boils down to which drugs to investigate. In such a setting 
it could be wise to test only those compounds the companies are willing to bring for-
ward into clinical trials. Finding a cure for metastasised uveal melanoma following this 
approach has the great advantage of a relatively short time from bench to bedside. 
The obvious downside of this approach is that again the combination with strongest 
effects and with the least adverse side effects could be missed.
Clinical relevance and concluding remarks
When studies, like described in this thesis, are being performed one should always 
wonder what the true question is that needs to be answered. Whether or not there 
is a scientific interest in a certain molecule or pathway or just simply the need to 
find a curative treatment for patients who have none or have run out of treatment 
options. Regardless of the fact that finding a curative treatment for all metastasised 
uveal melanoma patients is most likely impossible due to great inter- and intra-tumor 
variation, the identification of the ‘best possible’ drug (combination) will require the 
‘brains’ of the educated guess approach, the unbiasedness of the second and uncon-
ditional support of pharmacological industries. Concluding that none of the above 
mentioned approaches is either good or wrong as long as they are fitting with the 
question needing to be answered.
To date no effective therapy exists for metastasized uveal melanoma. It is therefore 
that all potential effective or prognosis improving therapeutic strategies need to be 
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evaluated properly in order to obtain an effective therapy for this deadly malignancy. 
Findings in this thesis provide several potential new therapeutic interventions mainly 
based on drugs already in clinical trials in order de reduce time from bench to bedside. 
However, in all cases of suggested drug combinations additional research needs to be 
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1. Innovatieve nieuwe functies van MDMX
1.1. Kanker
Een ziekte waar steeds meer mensen mee geconfronteerd worden is kanker. Dit is een 
ziekte van het ongecontroleerd en ongeremd delen van lichaamscellen. De oorzaak 
hiervan is een opeenstapeling van fouten in het erfelijk materiaal, het DNA, mutaties 
genoemd. Deze mutaties kunnen ervoor zorgen dat bepaalde eiwitten veranderen van 
eigenschappen. Zo kunnen specifieke eiwitten die celgroei en celdeling stimuleren 
door toedoen van mutaties altijd ‘aan’ staan. Op deze manier wordt een cel tot delen 
aangezet, terwijl dit eigenlijk niet de bedoeling is. Hoewel het essentieel is voor het 
ontwikkelen van kanker dat cellen over zo’n ongelimiteerd ‘groeisignaal’ beschikken, 
is dit op zichzelf niet voldoende voor het ontstaan van kanker. Er zijn, voor zover 
bekend, gemiddeld zes mutaties nodig om van een normale cel te veranderen in een 
kwaadaardige cel.
1.2. p53
Cellen beschikken over verschillende mechanismen voor het ontdekken van DNA 
schade en stress, die onder andere ontstaan gedurende het ontsporen van een nor-
male cel tot een kwaadaardige cel. Op het moment dat er te veel schade en of stress 
wordt gedetecteerd, word een proces van geprogrammeerde celdood, genaamd 
apoptose, in werking gezet om het ontstaan van ontspoorde cellen te voorkomen. 
Naast het constante ‘groeisignaal’ moet een kankercel dus ook resistent worden voor 
onder andere apoptose om volledig te ontsporen en ongeremd en ongecontroleerd te 
kunnen blijven delen. Centraal in de herkenning van stresssituaties van een cel staat 
het eiwit p53. P53 is een zogenoemde transcriptie factor die op het moment van de-
tectie van stress zorgt voor de genregulatie van eiwitten die een cel in eerste instantie 
doen stoppen met delen om de geïdentificeerde stressor te verwijderen. Wanneer 
de stresssituatie niet verbetert of de schade onherstelbaar blijkt, treedt apoptose 
in werking. Niet alleen ophoping van DNA schade, maar ook kankercel stimulerende 
mutaties kunnen zorgen voor activatie van p53. Doordat p53 een centrale rol vervult 
in de reactie op stress en groei stimulerende mutaties, is het gen dat codeert voor 
p53 vaak gemuteerd in kanker. Dergelijke inactiverende mutaties worden in ongeveer 
de helft van alle tumoren gevonden, wat p53 het meest frequent gemuteerde eiwit 
in kanker maakt. Kankercellen zonder een p53 mutatie maken gebruik van andere 







Eén zo’n strategie die kankercellen gebruiken voor het onderdrukken van p53 is 
het hoog tot expressie brengen van één of twee p53 remmers, genaamd MDM2 en 
MDMX. Deze twee eiwitten hebben als taak om in een gezonde cel p53 activiteit on-
der controle te houden, zodat het apoptose programma niet wordt geactiveerd en de 
cel onderdeel blijft uitmaken van het lichaam. Hoewel deze twee eiwitten structureel 
veel op elkaar lijken, verschillen ze wel in de manier waarop ze p53 remmen. MDM2 
is een zogeheten ubiquitine ligase, dat ervoor zorgt dat het p53 eiwit snel wordt 
afgebroken. MDMX beschikt niet over deze ubiquitine ligase activiteit, maar kan wel 
zodanig aan p53 binden dat deze niet meer voor de inductie van een groei-stop of 
apoptose kan zorgen. Door MDM2 en/of MDMX hoog tot expressie te brengen kan 
een cel zonder p53 mutaties toch kwaadaardig worden.
1.3. Nieuwe functies van MDMX
In hoofdstuk 2 is getracht om verder de functie van MDMX te bepalen door te onder-
zoeken van welke genen de expressie wordt gecontroleerd door deze p53 remmer. 
De resultaten lieten zien dat MDMX de expressie van celdeling-stimulerende genen 
verhoogt, terwijl het de expressie van genen betrokken bij apoptose juist verlaagt. 
Deze resultaten correleren goed met de eerder beschreven oncogene functies van 
MDMX, waaronder de onderdrukking van p53 activiteit. Uit eerder onderzoek is ech-
ter gebleken dat MDMX ook bijdraagt aan tumorgroei en -ontwikkeling op een manier 
onafhankelijk van p53 remming. Inderdaad, de resultaten beschreven in hoofdstuk 
2 laten zien dat een deel van de waargenomen effecten van MDMX op genregulatie 
onafhankelijk is van p53. Verdere diepgaande analyses van de genexpressie data sug-
gereerden dat MDMX ook de functie van een familie van andere eiwitten beïnvloedt, 
de FOXO eiwitten. Deze eiwitten zijn, net zoals p53, transcriptiefactoren die een 
belangrijke rol spelen bij het aan- of uitzetten van genen. Een belangrijke observatie 
is dat MDMX, naast p53, ook aan FOXO1 kan binden. Dit zou kunnen betekenen dat 
MDMX niet alleen in staat is om de activiteit van p53 te remmen, maar ook van andere 
transcriptiefactoren zoals FOXO1. Met deze hypothese zouden mogelijk een deel van 
de p53-onafhankelijke oncogene effecten van MDMX verklaard kunnen worden, wat 
zou bijdragen aan het beter begrijpen van kanker.
Het steeds beter begrijpen van MDMX, en daarmee kanker, zou op de lange termijn 
kunnen leiden tot nieuwe medicijnen of therapeutische strategieën. Om deze hypo-
these te testen is een p53-onafhankelijk en MDMX/FOXO-gereguleerd gen, coderend 
voor MXD4, in meer detail bestudeerd. Resultaten suggereerden een nog niet eerder 
beschreven ’back-up’ mechanisme waarmee een kankercel MDMX verlies zou kunnen 
compenseren met p53 inhibitie door MDM2. Verdere experimenten toonden aan 
dat MXD4 depletie in kankercellen leidt tot een verhoogde gevoeligheid voor p53-
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activerende medicijnen. Deze resultaten bieden perspectief voor de toekomst van 
p53-activerende medicijnen en mogelijke nieuwe manieren om deze nog effectiever 
te laten zijn.
2. Nieuwe therapeutische strategieën voor uvea melanoom
2.1. Melanoom
Huidmelanoom is een dodelijke variant van huidkanker die ontstaat uit pigment-
producerende cellen genaamd melanocyten. Primaire melanomen kunnen vaak goed 
behandeld worden door middel van chirurgische verwijdering. Patiënten hebben 
daardoor ook een grote overlevingskans. Zodra uitzaaiingen optreden verkleint de 
kans op overleving echter drastisch wegens het gebrek aan effectieve therapieën. Een 
grote stap leek gemaakt met de ontdekking van een zeer specifieke activerende muta-
tie van het gen BRAF, dat in ongeveer de helft van alle melanoom patiënten voorkomt. 
Voor deze gemuteerde vorm van BRAF is vervolgens een medicijn ontwikkeld, wat de 
tumoren erg effectief deed verdwijnen. Echter, zoals vaak bij soortgelijke geperso-
naliseerde medicatie, vindt de tumor na een paar maanden een andere manier om 
overleven en verder te groeien onafhankelijk van het gemuteerde BRAF. Een sprong 
voorwaarts werd gemaakt met de ontdekkingen van verschillen manieren om een 
patiënt zijn of haar eigen immuunsysteem kwaadaardige cellen aan te laten vallen. 
Deze vorm van therapie, ook wel immunotherapie genoemd, lijkt erg effectief en leidt 
zelfs tot genezing van sommige patiënten. Hoewel er gedurende de afgelopen decen-
nia vooruitgang is geboekt in het verbeteren van behandelmethodes, blijft melanoom 
door het ontstaan van resistentie een lethale ziekte waarvoor nieuwe behandelme-
thodes gevonden dienen te worden.
2.2. Uvea melanomen
Een subgroep van melanoom is het uvea melanoom (UM). Deze vorm van melanoom 
beslaat ongeveer 5% van het totaal aantal melanomen en ontstaat uit melanocyten 
uit specifieke structuren in het oog, namelijk het vaatvlies, straallichaam en de iris. 
Net zoals huidmelanomen zijn uvea melanomen goed te behandelen tot het moment 
waarop uitzaaiingen plaatsvinden. Zodra metastases worden gedetecteerd, daalt de 
gemiddelde levensverwachting naar 2 tot 7 maanden. Er is inmiddels veel duidelijk-
heid over verschillende classificaties waarin een tumor kan vallen, die bepalend zijn 
voor het al dan niet ontstaan van metastases. Een cruciale gebeurtenis hiervoor lijkt 
het verlies van één van de twee kopieën van chromosoom 3. Als het andere kopie 
daarnaast een gemuteerd BAP1 gen bevat, resulteert dit in verlies van BAP1 expressie 







beter te voorspellen wordt welke patiënten metastases gaan ontwikkelen, blijft het 
behandelen hiervan nagenoeg onmogelijk. Dit komt omdat deze metastases tot nu 
toe ongevoelig lijken voor alle therapieën, met een korte levensverwachting voor 
de patiënt tot gevolg. Dit proefschrift focust zich daarom verder op het verbeteren 
van bestaande methodes en het vinden van nieuwe strategieën om patiënten met 
uitgezaaide UM te behandelen.
2.3. Verbetering van de huidige behandelmethodes voor gemetastaseerde 
uvea melanomen
2.3.1. Huidige therapieën
Zoals hierboven beschreven heeft iedere kanker mutaties nodig die voor een continue 
‘groeisignaal’ zorgen. De mutaties die verantwoordelijk zijn voor dit signaal in UM 
focussen zich in een specifiek deel van de G-eiwitten GNAq of GNA11. Doordat deze 
eiwitten permanent ‘aan’ staan, wordt er constant een groei-stimulerende signaal-
transductie-cascade geactiveerd. Een onmisbare stap in deze cascade is de activatie 
van zogeheten Protein Kinase C (PKC) eiwitten. Uit eerder onderzoek is gebleken dat 
de remming van de activiteit van deze eiwitten een goede strategie is om de groei van 
UM cellen te stoppen. Het toedienen van deze remmers in de kliniek aan patiënten 
met uitgezaaid UM leidt echter slechts tot een stop van tumorgroei voor gemiddeld 
15 weken in de helft van de patiënten. Hoewel deze resultaten veelbelovend zijn, is 
er in hoofdstuk 3 gezocht naar nieuwe manieren waarop de groei-remmende effecten 
van PKC remmers versterkt kunnen worden.
2.3.2. Combinatie met p53 activatie
Hoewel p53 mutaties zeer frequent zijn, varieert het per kankersoort in welke hoeveel-
heid p53 mutaties aanwezig zijn. In 90% van de eierstoktumoren worden p53 mutaties 
gevonden, terwijl deze nog nooit zijn gevonden in UM. Deze tumoren gebruiken vaak 
MDM2 en/of MDMX om p53 te onderdrukken, wat een interessante therapeutische 
mogelijkheid biedt. Het is namelijk mogelijk om met een ‘drug’ (Nutlin-3) de remming 
van p53 door MDMX/MDM2 te voorkomen en daarmee p53 te reactiveren. Door deze 
MDM2/MDMX inhibitie te combineren met PKC remming werd er een synergistische 
remming van overleving van verschillende UM cellijnen gevonden. Hieraan lag een 
omslag van groei-stop naar apoptose ten grondslag. Deze resultaten impliceren dat 
PKC remming en de bijbehorende positieve effecten in de kliniek versterkt kunnen 
worden door middel van p53 activatie.
2.3.3. MDMX/PKCδ
De combinatie van p53 activatie en PKC remming is erg effectief in het laboratorium, 
maar in de kliniek zouden er problemen kunnen ontstaan. Het is namelijk bekend dat 
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de remming van MDM2 sterke bijwerkingen tot gevolg heeft, die in eerdere klinische 
studies al tot een vroegtijdige stop van deze studies hebben geleid. Deze sterke bij-
werkingen zijn het gevolg van de belangrijke p53-remmende rol die MDM2 heeft in 
gezonde cellen van het volwassen lichaam. MDMX komt in het volwassen lichaam 
beduidend minder hoog tot expressie dan MDM2, waardoor het waarschijnlijk is 
dat specifiek het voorkomen van p53 remming door MDMX in minder bijwerkingen 
resulteert dan de remming van MDM2 functie. In hoofdstuk 3 is daarom onderzocht 
of het specifiek remmen van MDMX dezelfde PKC inhibitie-versterkende effecten 
vertoont als Nutlin-3. Omdat er nog geen specifieke remmer van MDMX bestaat, is 
er gebruik gemaakt van een ‘genetische truc’ die leidt tot afwezigheid van MDMX. 
De resultaten uit hoofdstuk 3 laten zien dat depletie van MDMX de effecten van PKC 
inhibitie inderdaad versterkt.
Omdat ook PKC remmers vervelende bijwerkingen hebben in patiënten, vroegen we 
ons af of PKC remming nader gespecificeerd kon worden. De klinisch gebruikte PKC 
remmers onderdrukken namelijk de activiteit van alle verschillende vormen van deze 
eiwitten. In overeenstemming met eerder gepubliceerde data laten de resultaten in 
hoofdstuk 3 duidelijk zien dat afwezigheid van alleen PKCδ voldoende is om de groei 
van UM cellen te stoppen. Belangrijk in dit hoofdstuk is het bewijs dat p53 activatie 
synergistisch kan worden versterkt met de depletie van specifiek PKCδ. Concluderend, 
p53 activatie gecombineerd met PKC inhibitie is een synergistische werkende com-
binatie in de remming van UM groei, waarvan de potentiële bijwerkingen beperkt 
kunnen worden door de therapieën specifiek te richten op MDMX en PKCδ.
2.4. Nieuwe strategieën voor de behandeling van uitgezaaide uvea 
melanomen
2.4.1. EZH2- en HDAC-remming
Naast het optimaliseren van de bestaande therapieën richt dit proefschrift zich ook op 
het vinden van compleet nieuwe strategieën die gebruik maken van al goedgekeurde 
medicijnen. De nieuwe strategie bestudeerd in hoofdstuk 4 is gebaseerd op literatuur 
waarin beschreven wordt dat tumoren zonder expressie van een bepaald gen (BAP1) 
extra gevoelig zijn voor inhibitie van het eiwit Enhancer of Zeste 2 (EZH2). EZH2 is een 
onderdeel van het Polycomb Repressive Complex 2, een groep eiwitten die samen 
de dichtheid van het DNA bepaalt door modificaties aan te brengen op histonen, de 
eiwitten waarop DNA zit ‘opgerold’. Het ontstaan van UM metastases hangt samen 
met de afwezigheid van expressie van BAP1, met als gevolg dat 80-90% van alle UM 
metastases geen BAP1 expressie hebben. Deze resultaten tezamen suggereerden dat 
EZH2 remming een goede therapie zou zijn voor de behandeling van UM metastases. 







van BAP1 expressie, ongevoelig waren voor EZH2 inhibitie. In deze studie werden de 
effecten van EZH2 remming op UM groei tot maximaal 5 dagen bestudeerd. Omdat 
UM cellen, en zeker die cellen die geen BAP1 meer tot expressie brengen, heel lang-
zaam delen werd het mogelijk geacht dat de effecten van EZH2 remming op langere 
termijn pas meetbaar zouden zijn.
En inderdaad, de data uit hoofdstuk 4 laten duidelijk zien dat UM cellen wel gevoelig 
zijn voor EZH2 remming. Deze groei-remmende effecten van EZH2 inhibitie waren 
echter pas meetbaar na een week of langer. De groeiremming die op lange termijn 
werd geobserveerd leek sterker te zijn in de BAP1-negatieve cellen, wat selectiviteit 
voor de metastase suggereert. Dit kon worden gecorreleerd aan de observatie dat de 
expressie van EZH2 hoger is in BAP1-negatieve tumoren, welke uitzaaiende tumoren 
of al ontstane metastases vertegenwoordigen.
Een opvallende observatie was dat de het moleculaire effect va EZH2 remming, een 
vermindering van een histon modificatie, al zichtbaar was na 24-48 uur, terwijl er dan 
nog geen groeiremming waar te nemen is. De resultaten in hoofdstuk 4 laten zien dat 
de combinatie van EZH2 remming met de inhibitie van andere histon-modificerende 
eiwitten, histon-deacytelases (HDACs), leidt tot een synergistische reductie van de 
overleving van UM cellen. EZH2 remming op korte termijn heeft geen effect op UM 
groei terwijl HDAC inhibitie leidt tot stop van celdeling. Echter, de combinatie resul-
teerde niet alleen in een celdelingstop, maar ook in celdood. Het veroorzaken van 
celdood kan de synergistische afname van de overleving van UM cellen verklaren. De 
belangrijkste conclusies uit hoofdstuk 4 zijn dat EZH2 wel degelijk effect heeft op de 
groei UM cellen en dat deze effecten mogelijk sterker zijn in BAP1-negatieve cellen. 
Het duurt echter lang, dat wil zeggen meerdere celdelingen, voordat EZH2 inhibitie 
in een verminderde groei van deze cellen resulteert, terwijl in combinatie met HDAC 
inhibitie wel op korte termijn celdood geïnduceerd kan worden. Daarom wordt in 
hoofdstuk 4 een combinatie van EZH2 en HDAC-remmers gesuggereerd als potentiële 
nieuwe therapeutische strategie voor het behandelen van gemetastaseerde UM.
2.4.2. Gecombineerde HDAC en CDK inhibitie
Hierboven zijn de experimenten besproken waarin EZH2 inhibitie wordt gecombineerd 
met HDAC remming om de groei en overleving van UM cellen te verminderen. Zoals 
al genoemd leidt HDAC inhibitie tot een celcyclus-stop van UM cellen. Het doel van 
de resultaten beschreven in hoofdstuk 5 was om dit effect van een HDAC remmer te 
versterken. Er is voor dit onderzoek gekozen voor de HDAC inhibitor Quisinostat, een 
experimenteel medicijn dat veelbelovende resultaten liet zien in een fase 1 klinische 
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studie met melanoom patiënten en ook wordt getest op patiënten met ander type 
tumoren.
Er is gekozen om Quisinostat te combineren met een remmer van Cyclin-Dependent 
Kinases (CDKs), genaamd Flavopiridol. CDKs spelen een belangrijke rol in het gecon-
troleerd laten verlopen van de celcyclus, maar zijn ook essentieel voor de regulatie 
van expressie van genen. Een goede progressie van de celcyclus is afhankelijk van 
een strikte volgorde en tijdige activatie en in-activatie van verschillende CDKs. In 
neuroblastoma cellijnen was al aangetoond dat de remming van CDKs de effecten van 
HDAC inhibitie kunnen versterken. Zowel Flavopiridol als Quisinostat kunnen alleen al 
wel een groeistop veroorzaken in UM cellen, maar de combinatie van deze medicijnen 
remt synergistisch de groei en leidt tot celdood.
CDKs en HDACs zijn niet specifiek ontregeld in UM cellen; deze eiwitten dragen in de 
meeste kankers op één of andere manier bij aan tumorprogressie. Omdat deze com-
binatie van medicijnen erg effectief bleek voor UM cellen, werd besloten deze ook 
te testen op huidmelanoom cellen. En inderdaad, ook huidmelanoom cellen bleken 
erg gevoelig voor de combinatie van CDK en HDAC remming. Zoals eerder besproken 
bestaat de huidige behandeling van BRAF-gemuteerde melanoom uit het specifiek 
remmen van dit geactiveerde onco-eiwit. Hoewel dit vaak erg effectief is voor een 
paar maanden, ontwikkelt de kanker bijna zonder uitzondering resistentie. Naast de 
diverse melanoom typen, gedreven door verschillende activerende mutaties, heb-
ben we gekeken of het effect van deze combinatie anders is voor BRAF-gevoelige en 
-resistente cellen. Alle geteste melanoom cellen bleken zeer gevoelig voor de gecom-
bineerde CDK- en HDAC-inhibitie.
Om de effectiviteit van gecombineerde CDK- en HDAC-remming in een meer klinische 
setting te testen is er gebruik gemaakt van een muismodel. In dit model groeit een 
menselijke huidmelanoom subcutaan (onderhuids) in muizen. Deze muizen met 
tumoren werden behandeld met óf alleen Quisinostat, óf alleen met Flavopiridol óf 
met de combinatie óf werden niet behandeld. Flavopiridol remde de groei van de 
tumoren terwijl Quisinostat alleen de groei al bijna volledig kon voorkomen. Daarom 
was er weinig toename in effectiviteit van de combinatie van remmers waar te nemen. 
Bovendien waren de moleculaire effecten van Flavopiridol in de tumorcellen van be-
handelde muizen niet goed detecteerbaar, hetgeen suggereert dat om synergistische 
effecten te zien er een hogere concentratie of toedieningsfrequentie van Flavopiridol 
gekozen dient te worden. Een belangrijk aspect om rekening mee te houden bij het 
bestuderen van synergistische combinaties is de aanwezigheid van negatieve bij-







versterkt worden door een combinatie van medicijnen zoals onderzocht is in het 
laboratorium, maar in een patiënt ook de negatieve effecten synergistisch worden 
versterkt. Echter, een aantal muizen behandeld met Quisinostat, Flavopiridol of de 
combinatie hiervan werden uitgebreid onderzocht door een patholoog en er bleek 
amper verschil te zijn tussen de behandelingen. Dus, de combinatie van CDK en HDAC 
remmers zou een relatief veilige en veelbelovende nieuwe strategie kunnen zijn voor 
de behandeling van verschillende soorten melanoom, ook die met ontwikkelde BRAF 
resistentie.
3. Algemene conclusies en klinische implicaties
De studies beschreven in dit proefschrift dragen bij aan het beter begrijpen van kanker 
en bieden nieuwe perspectieven voor het behandelen van gemetastaseerde UM pa-
tiënten. Het ontrafelen van de functies van MDMX heeft geleidt tot nieuwe inzichten 
en kan in de toekomst leiden tot nieuwe therapeutische strategieën. In het bijzonder 
zal de mogelijke regulatie van FOXO transcriptie factoren door MDMX tot vervolg 
onderzoek leiden, met potentieel interessante klinische mogelijkheden. De huidige 
strategieën om gemetastaseerde UM te behandelen zijn niet effectief en worden 
gekenmerkt door bijwerkingen. Dit proefschrift geeft diverse mogelijkheden om de 
huidige therapieën te verbeteren en compleet nieuwe strategieën die in overweging 
genomen kunnen worden. Echter voor de optimalisatie van de huidige therapieën 
dienen nieuwe medicijnen ontwikkeld te worden, hetgeen nog tijd, geld en vervolg 
studies gaat kosten om te realiseren. Ook de nieuwe strategieën gebaseerd op be-
staande medicijnen dienen nog beter te worden bestudeerd voordat ze als vervanging 
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voor ‘mijn’ studenten Kelly en Manon is op zijn plaats. Jullie vielen onder mijn directe 
begeleiding en hebben altijd vol enthousiasme mijn eindeloze ideeën en suggesties 
verwerkt in jullie projecten. Ik vond het erg leuk en leerzaam om jullie begeleider te 
zijn, bedankt hiervoor.
Graag wil ik ook mijn collega’s van het ‘oude’ MCB bedanken voor een fantastische tijd 
en alle hulp die ik van jullie gehad heb tijdens mijn experimenten. Dat ik hele mooie 
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en bijzondere collega’s had blijkt wel uit de fantastische borrels, LUMC zomerfeesten, 
voetbaltoernooien, hardloopwedstrijden, surfavonden, MCB dagjes uit, housewar-
mings en reizen die we samen hebben gemaakt. Roman, Danielle, Frauke, Maarten T, 
Timo, Vera, Marjolein, Amiet, Tobias, Aleks, Karo, Ivo, Joost, Minnie, Tamara, Jessie, 
Sumit, Fredrik en Matty bedankt voor deze fantastische avonturen! Madelon, jou zou 
ik graag nog in het bijzonder willen bedanken voor alle kopjes koffie door de jaren 
heen, waarbij we alles konden bespreken en relativeren zelfs nu jij in het verre Glas-
gow woont. Op momenten waarop dat nodig was stonden twee collega’s altijd voor 
mij klaar. Edwin en David bedankt dat jullie er altijd voor me waren en dat jullie mijn 
paranimfen willen zijn. Zonder enige twijfel had mijn PhD periode er zonder jullie heel 
anders uitgezien en ik ben jullie erg dankbaar voor de mooie tijd en herinneringen die 
we samen hebben gemaakt.
Om aan het lab te ontsnappen kon ik altijd terecht bij mijn vrienden van het eerste 
uur Maarten W, Tim en Lucas. Hoewel ik er in de laatste periode van mijn PhD niet erg 
meer aan toe kwam wil ik jullie toch graag heel erg bedanken voor de nodige afleiding. 
Ook afspraakjes met ‘de beertjes’ waren voor mij van grote waarde gedurende dit 
traject, Christian, Stefanie, Juna, Martijn, Lisanne, Lizanne, Arjan, Hazal, Roel, Kathy 
en Ishan super bedankt! Daarnaast wil ik ook de familie Cuijpers bedanken voor de 
leuke uitjes en weekenden.
Lieve familie. Papa en Mama, Marike en Peter, Ceciel en Wouter. Wat ben ik jullie 
enorm dankbaar dat jullie er altijd voor mij waren. In goede en in slechte tijden vorm-
den jullie altijd een veilige plek om alles te bespreken. Ook al snapten jullie niet altijd 
het onderwerp, de proef of andere stress situatie, ik kon toch altijd rekenen op jullie 
steun. Dit is voor mij van onschatbare waarde geweest de afgelopen jaren.
En dan als allerlaatste mijn allerliefste Sabine. Ik kan zonder overdrijven stellen dat 
dit hele traject doorlopen zonder jou nooit was gelukt. Wat hebben we samen veel 
meegemaakt tijdens onze PhD en, hoewel het niet altijd zo voelde, zijn we er allebei 
sterker en slimmer uitgekomen. Bedankt dat je er altijd voor mij bent om mijn hart te 









Combined binary ratio fluorescence in situ hybridization  COBRA-FISH
Cutaneous melanoma  CM
Cyclin dependent kinase CDK
Cysteinyl Leukotriene Receptor 2 CYSLTR2
Cytoplasmic FMR1 interacting protein 2  CYFIP2
Cytotoxic T-lymphocyte antigen-4  CTLA-4
Diacylglycerol DAG
DP, RB-like, E2F4 and Muvb  DREAM
Ectodysplasin a2 receptor  EDA2R
Enhancer of zeste homolog 2 EZH2
Excess over bliss EoB
Exonuclease 1 EXO1
EZP011989 EPZ





Histone deacetylase  HDAC
Hyaluronan synthase 2 HAS2
Immunohistochemical IHC
Inositol 1,4,5-trisphosphate IP3
Kinesin family member 23 KIF23
Max dimerizing protein 4 MXD4
MDMX short transcript isoform MDMX-S
Mechanistic target of rampamycin kinase  MTOR
Minichromosome maintenance 10 replication initiation factor MCM10
Mitotic arrest deficient 2 like 1  MAD2L1
Mouse double minute MDM
Myristolated alanine rich protein kinase c substrate MARCKS
p53 reactivation and induction of massive apoptosis PRIMA
p53 upregulated modulator of apoptosis PUMA
Patched domain containing 4 PTCHD4
Patient-derived tumor xenograft PDX




Phosphoinositide-3-kinase interacting protein 1  PIK3IP1
Phospholipase C Beta 4 PLCB4
Poly(ADP-ribose) polymerase 1 PARP
Polycomb repressive complex 2  PRC2
Propidium iodide PI
Protein kinase C PKC
RAS Guanyl Releasing Protein 3 RASGRP3
Receptor tyrosine kinase RTK
Splicing factor 3B subunit 1 SF3B1
Tazemetostat TZMS
Tetraspanin 11 TSPAN11
Tri-methylation histone 3 at lysine 27 H3K27me3
Tumor protein p53 inducible nuclear protein 1 TP53INP1
Ubiquitin specific protease  USP
Uveal melanoma UM
Valine V
Vascular endothelial growth factor  VEGF
Zinc finger matrin-type 3  ZMAT3
